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ABSTRACT OF DISSERTATION

EVALUATION OF THE PHYSICOCHEMICAL PROPERTIES AND STABILITY OF
SOLID LIPID NANOPARTICLES DESIGNED FOR THE DELIVERY OF
DEXAMETHASONE TO TUMORS
Pre-clinical and clinical trials suggest that pre-treatment with dexamethasone
(Dex) may facilitate enhanced uptake of subsequently administered chemotherapeutic
agents. To reduce the side effects associated with systemic administration of Dex, solid
lipid nanoparticles (SLNs) containing dexamethasone palmitate (Dex-P) were prepared as
a means of achieving tumor-targeted drug delivery. These studies were aimed at
evaluating the physicochemical properties and both the physiological and storage stability
of the SLNs.
SLNs were prepared using nanotemplate engineering technology. Stearyl alcohol
(SA) was used as the lipid phase with Brij® 78 and Polysorbate 60 as surfactants and
PEG6000 monostearate as a long-chain PEGylating agent. Both formulations exhibited a
small particle size, ellipsoidal shape, and low polydispersity. 1H-NMR spectroscopy
confirmed that SLNs have the expected solid core and PEGylated surface. Analysis of the
bulk materials indicated that a number of complex interactions are present among the
SLN components, including a eutectic between SA and Brij® 78.
Dex-P could be incorporated in SLNs at 10-30% w/w SA with encapsulation
efficiencies >85%. A preferential interaction with the SA-Brij® 78 eutectic was
identified, indicating a possible interfacial localization. For comparison, SLNs were also
prepared with ascorbyl palmitate (AP) and curcumin. Higher drug loads were achieved
with both palmitate-containing prodrugs than curcumin, though all appeared to align
differently within the SLNs.
SLNs undergo a concentration-dependent particle size growth when incubated at
physiological temperature. However, they appear to remain intact with over 85% of the
added Dex-P retained at 24 h in conditions mimicking human plasma. In the presence of
carboxylesterase, SLNs became turbid and showed a reduction in particle size as
compared to controls. This instability was shown to be a result of the hydrolysis of
PEG6000 monostearate and Polysorbate 60.

To enhance storage stability, a lyophilization protocol designed to minimize
changes in the physicochemical properties of SLNs was developed. During a 3 month
period, lyophilized SLNs stored at 4°C demonstrated the greatest stability, showing a
consistent particle size and an encapsulation efficiency >80%. Overall, these results
indicate that Dex-P loaded SLNs possess the physicochemical properties and stability
desirable for development as a tumor-targeted drug delivery system.
Keywords: solid lipid nanoparticles, crystallinity, drug loading, PEGylation, stability
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Chapter 1
Introduction and Statement of Problem

In spite of the development of an arsenal of highly potent chemotherapeutic agents,
clinical success in treating cancer remains a challenge. Tumors are characterized by a
number of properties (e.g., high interstitial fluid pressure (IFP), irregular vasculature,
efflux pumps) that may act as barriers to drug delivery [1, 2]. As a result, many drugs fail
to perform in vivo as well as would be predicted from in vitro studies due to a failure to
reach the target site in adequate quantities. Correspondingly, a high amount of the
administered drug is left to act on healthy tissues, often to the point of generating doselimiting side effects.

Pre-treatment with Dexamethasone (Dex) is one possible technique for improving the in
vivo success of chemotherapeutic agents. Dex is a synthetic gluococorticoid well known
for its anti-inflammatory properties [3, 4]. However, recent pre-clinical and clinical trials
have indicated that it may also have use as a chemotherapeutic adjuvant. Preadministration of Dex was shown to reduce the toxicity and, in some cases, increase the
efficacy of chemotherapeutic agents. For instance, Dex pre-treatment was shown to
significantly increase the efficacy of carboplatin (DNA alkylating agent), gemcitabine
(antimetabolite), or a combination of both drugs by 2-4 fold in six xenograft models
tested (2 colon, 2 breast, 1 lung, and 1 glioma cancers) [5]. Dex pre-treatment also
reduced the significant decrease in granulocyte counts seen with carboplatin treatment in
CD-1 mice [6]. In clinical trials, Dex pre-treatment has resulted in a reduction in
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hematopoietic toxicity and an improvement in absolute granulocyte count and platelet
count recovery times [7, 8].

The complete mechanism behind Dex‟s beneficial effects remains elusive but is likely a
result of its inhibition of the nuclear factor kappa B (NF-κB) signaling pathway [9, 10].
Disruption of this signaling pathway is thought to be associated with a change in the
tumor cytokine profile [11] that results in decreased IFP [12, 13] and a normalization of
the tumor vasculature [11, 14]. In turn, it is suspected that these effects allow for the
enhanced uptake of chemotherapeutic agents into tumors [5, 11], improving their efficacy
and limiting their toxic side effects [6]. However, there may be some limitations to this
therapy. First, the results do appear to be schedule, dose, and possibly chemotherapeutic
agent-dependent with some literature indicating that Dex may result in a decrease in the
efficacy of chemotherapeutic agents [15-18]. Additionally, there are a number of side
effects associated with systemic administration of Dex that may be undesirable for
patients undergoing chemotherapy, most notably immunosuppression through T-cell
depletion and inhibition [3, 19].

In order to maximize the potential of Dex to serve as a chemotherapeutic adjuvant while
minimizing its toxicities, a localized delivery system would be preferable. Nanoparticles
are one potential means of achieving this goal. Though a number of advantages,
including enhanced solubilization [20], controlled/bioresponsive release capacity [21-24],
evasion of multidrug resistance (MDR) mechanisms [25, 26], and limited drug
degradation [27] have been claimed for these systems over their solution counterparts, the
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most notable is their targeting ability. Due to the enhanced permeability and retention
(EPR) effect of tumors [28, 29], nanoparticles of the appropriate size are able to passively
target tumors [30, 31]. This can enhance drug uptake into the tumor while limiting its
presence throughout the rest of the body.

While a number of nanoparticle drug delivery systems are available, solid lipid
nanoparticles (SLNs) have received considerable attention due to their low toxicity [3234] and amenability to large-scale production methods [33, 34]. Early work from this
laboratory resulted in two SLN formulations encapsulating dexamethasone palmitate
(Dex-P), an ester prodrug of Dex [35]. This prodrug was chosen because the palmitate
moiety was expected to associate with the hydrophobic core of the SLNs and enhance the
drug loading. Additionally, Dex-P has previously been used in humans with a good safety
profile [36]. Interestingly, drug release from the nanoparticles appeared to be dependent
on the carboxylesterase (CE) activity of the surrounding environment [37].

This dissertation will focus on gaining a thorough understanding of the physicochemical
properties of the Dex-P loaded SLN formulations as well as evaluating them for both
physiological and storage stability. Initially, SLNs will be assessed for their size, shape,
core-shell structure, and crystallinity. The extent and mechanism of drug loading will be
evaluated, and comparisons will be made with other drugs of similar structure and
lipophilicity. Secondly, the stability of SLNs will be evaluated under physiological
conditions, both in the absence and presence of CE enzymes. Finally, a lyophilization
protocol designed to minimize changes in the physicochemical properties of the SLNs
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will be developed, and the long-term storage stability of lyophilized SLNs and SLN
suspensions will be compared. These studies may provide valuable information regarding
the structure and stability of not only the drug delivery system under consideration, but
also nanoparticles in general.

Copyright © Melissa Howard 2011
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Chapter 2
Plan of Research

Pre-clinical and clinical trials suggest that delivery of Dex to tumors can lower the IFP
[13], thereby reducing this physiological barrier to the uptake of administered
chemotherapeutic agents. However, Dex exhibits toxicities such as immunosuppression
that can adversely affect patients undergoing chemotherapy. Targeting the delivery of
Dex specifically to tumors would minimize the undesirable side effects associated with
systemic administration of the drug. Nanotemplate engineered SLNs containing Dex-P
were prepared as a means of achieving tumor-targeted drug delivery. The overall
hypothesis of this dissertation is that the interactions among the components of SLNs
decrease the crystallinity of nanoparticle lipids resulting in enhanced drug loading and
limited stability of the nanoparticles under both physiological and storage conditions. The
following specific aims will be pursued in order to test this hypothesis:

Specific Aim 1: To fully characterize the physicochemical properties of nanotemplate
engineered SLNs, including particle size, shape, structure, and changes
in the extent or type of crystallinity from the starting materials due to
interactions among the nanoparticle components.
Specific Aim 2: To assess the degree of loading of Dex-P into nanotemplate engineered
SLNs as compared to other compounds of similar structure or
lipophilicity.
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Specific Aim 3: To evaluate the stability of nanotemplate engineered SLNs in
conditions mimicking those of human plasma as a function of time.
Specific Aim 4: To determine if the PEGylating agents incorporated into SLNs are
affected by the CE activity of the surrounding environment.
Specific Aim 5: To determine if the storage stability of drug loaded SLNs is enhanced
when using lyophilization protocols that minimize changes in the
physicochemical properties of the nanoparticles.

To achieve these Specific Aims, the research plan described in sections 2.1 through 2.5
was carried out.

2.1.

Preparation and Characterization of Blank SLNs

The objective of this section was to compare the physicochemical properties of two SLN
formulations previously developed for Dex-P loading. SLNs were prepared using
nanotemplate engineering technology (NET). Stearyl alcohol (SA) was used as the lipid
phase with Brij® 78 and Polysorbate 60 (PS60) as surfactants in both formulations; the
second formulation differed by the inclusion of a long-chain PEGylating agent, PEG6000
monostearate (PEG6000MS).

Nanoparticle size and shape were assessed using a

combination of dynamic light scattering (DLS) and transmission electron microscopy
(TEM) techniques. SLN structure was determined through a comparison of the 1H-NMR
spectra of solubilized and intact SLNs accompanied by relaxation time measurements.
Powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) were used
to analyze the crystallinity of the SLNs.
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2.2.

Preparation and Characterization of Drug Loaded SLNs

The use of Dex-P has been shown to enhance drug loading in the SLNs. The goals of this
section were 1) to prepare and characterize SLNs loaded with Dex-P and 2) to make
comparisons with other drugs of similar structure or lipophilicity. In addition to the
properties described above (size, shape, structure, and crystallinity), SLNs will be
assessed for the extent of drug loading and encapsulation efficiency. Ultrafiltration will
be used for separation of free and encapsulated drug; quantification will be performed
using an HPLC-UV assay. Curcumin and ascorbyl palmitate (AP) will be used for the
comparison studies. Both drugs are lipophilic, but curcumin lacks the palmitate moiety
that may align with the SLN lipids.

2.3.

Stability of Drug Loaded SLNs in Human Plasma-mimicking Conditions

Release of Dex from the SLNs appeared to be dependent on the presence of CE activity.
The aims of this section were 1) to confirm the stability of SLNs and 2) to confirm the
retention of Dex-P with the SLNs under conditions mimicking those found in human
plasma (specifically the absence of CE activity). Initial studies were focused on
monitoring the size and shape of SLNs incubated at 37°C. To further elucidate the
mechanism of particle size growth, the effect of SLN concentration on particle size
growth was evaluated, and SLNs returned to 4°C following incubation at 37°C were
tested for size recovery. SLNs were then exposed to human serum albumin (HSA) as a
representative protein and monitored for size and turbidity changes. Size exclusion
chromatography (SEC) was used as a secondary technique to confirm the intact state of
the SLNs in the presence of HSA. To determine the retention of Dex-P with the SLNs in
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the presence of human plasma, a multi-step filtration process was employed, consisting of
an initial filtration through a 0.2 μm membrane followed by ultrafiltration. By accounting
for the known protein binding, the amount of drug retained with the SLNs was calculated.

2.4.

Stability of PEGylating Agents in the Presence of CE Activity

The objective of this section was to determine if the accelerated drug release observed in
the presence of CE enzymes may be partially attributable to hydrolysis of the estercontaining materials, PS60 and PEG6000MS, leading to increased accessibility of the
prodrug to enzymes. Hydrolysis of PEG6000MS was monitored using SEC, and
hydrolysis of PS60 was monitored using a pH-stat assay. Comparisons were made
between the materials in SLNs and in micelles, and controls were run using bis(4nitrophenyl) phosphate (BNPP) as a CE inhibitor. In parallel, the effects of hydrolysis on
the stability of SLNs were evaluated through monitoring changes in turbidity, particle
size, and particle shape.

2.5.

Storage Stability of Drug Loaded SLNs

The goals of this section were 1) to optimize a protocol for lyophilizing SLNs and 2) to
compare the long-term stability of aqueous and lyophilized SLNs. In optimizing the
lyophilization protocol, the following aspects were considered: lyoprotectant (LP) type
and concentration, SLN concentration, freezing temperature, rate of freezing, and drying
time. SLNs were assessed for changes in the particle size, shape, monodispersity, and
drug loading. For the long-term stability study, lyophilized SLNs and SLN suspensions
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were stored at 4°C and 25°C/60% RH. Samples were removed at days 0, 1, 3, 7, 14, and
months 1, 2, and 3 for measurement of the particle size and drug loading.

Copyright © Melissa Howard 2011
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Chapter 3
Background and Significance

3.1.

CANCER AND CHEMOTHERAPY

Cancer can be defined as the uncontrolled growth and spreading of abnormal cells [38].
As of 2010, it remained one of the leading causes of death in the United States of
America, second only to cardiovascular disease [39]. Although the final numbers are not
in, it is estimated that nearly 600,000 Americans died from cancer in 2010 and another
1.5 million people were diagnosed with new cases [39]. Due to the staggering numbers
associated with this disease, a variety of treatment options are currently being utilized,
and a number of others are under development [38, 40, 41].

Surgical resection is typically employed with early-stage disease [38, 41]. Unfortunately,
it cannot be utilized in all cases, such as when the cancer is undetectable, has
metastasized, or is not confined to a solid tumor (e.g., leukemia). Further, it may be
difficult to completely remove the affected cells, and surgery may trigger a faster
metastatic process for any remaining cells [38]. For this reason, chemotherapy, radiation
therapy, hormone therapy, immunotherapy, or a combination of these may be employed,
either in lieu of or following surgery [38]. Of these, chemotherapy is the most
mainstream.
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3.2.

BARRIERS TO CHEMOTHERAPY

Chemotherapy refers to the use of drugs directed at killing or controlling the growth of
cancer cells. Despite extensive research on the development of highly potent
chemotherapeutic agents, clinical success in treating cancer remains limited. Although
many of these drugs demonstrate in vitro potency, they are often less successful than
anticipated in vivo because of drug delivery limitations. Following injection, a drug must
be distributed throughout the vascular space, transported across the vascular wall,
transported through the interstitial space, and finally transported across the cell
membrane [42]. Unfortunately, many obstacles exist on this path that may prevent drug
from reaching the site of action in sufficient quantity. As a result, drug distributes into
healthy tissues, potentially inducing dose-limiting toxicities [38].

The irregular vasculature of tumors is the first barrier to tumor drug delivery (Figure 3.1)
[1]. Tumor vasculature consists of blood vessels co-opted from the host vasculature as
well as vessels that result from the angiogenic response of host vessels to cancer cells [1,
43]. As a result, tumor vasculature may display different fractal dimensions and
minimum path lengths from normal blood vessels. Some regions of a tumor may be wellvascularized, while others may be necrotic regions based on a lack of blood flow. This
may prohibit drug from reaching all regions of the tumor. Unfortunately, this issue is
further complicated by the fact that the characteristics of the vasculature may be
dependent on the tumor type, growth rate, location, and disease stage.
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Figure 3.1. Differences in the stroma of normal tissue (a) and tumo(u)r tissue (b).
Adapted from [44]. Reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews Cancer, 4(10), 806-813 (2004), copyright © 2004.
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High IFP is a second barrier that may be encountered during the extravasation step [1,
44]. The IFP of tumors is controlled by a combination of the hydrostatic pressure
(pressure exerted by a fluid due to the force of gravity) and colloid osmotic pressure
(pressure built up by the tendency of water to diffuse through a semipermeable
membrane into a compartment with higher concentration of high molecular weight
molecules, such as proteins that are unable to pass through the membrane) (Figure 3.2).
While normal blood vessels display a net outward pressure of 1-3 mm Hg, tumor blood
vessels may exhibit a net inward pressure of up to 18 mm Hg. This may limit the
transport of molecules out of the vasculature into the interstitial space.

Figure 3.2. Schematic showing the hydrostatic and colloid osmotic pressures in
capillaries (PCAP and COPCAP, respectively) and the surrounding interstitium (PIF
and COPIF, respectively) in normal tissues (a) and tumo(u)r tissues (b). It should be
noted that values are approximate. Adapted from [44]. Reprinted by permission
from Macmillan Publishers Ltd: Nature Reviews Cancer, 4(10), 806-813 (2004),
copyright © 2004.
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It is thought that there may be several contributors to this high IFP (Figure 3.1) [44].
First, as mentioned above, tumor vasculature is highly irregular with numerous
convolutions and defects. It is also characterized by enhanced “leakiness” as a result of
larger inter-endothelial pores than are present in healthy blood vessels. This may lead to
larger numbers of proteins exiting the vasculature. Secondly, tumor lymphatic vessels
may be underdeveloped or defective, preventing adequate drainage of fluid and proteins
from the tumor tissue. Finally, the interstitial matrix may be contracted based on the work
of tumor fibroblasts. While higher concentrations of proteins in the tumor interstitium
may result in higher colloid osmotic pressures, increased fluid may lead to elevated
hydrostatic pressures. Depending on their balance, the net pressure may oppose flow of
molecules into the interstitial space.

If molecules successfully extravasate from the blood vessels into the tumor interstitium,
they must then traverse the interstitial space in order to reach tumor cells. Unfortunately,
numerous impediments may again exist. First, tumors are characterized by a large
interstitial space [42], and drug transport by diffusion may be slow [1]. This can be
exacerbated by non-specific binding of the drug to various proteins. Secondly, the IFP is
higher in the center of the tumors than it is in the periphery, forcing materials to
overcome this outward convection to diffuse into the tumor center [1]. Thirdly, the tumor
stroma itself may be prohibitive of drug transport (Figure 3.1). Tumors are characterized
by elevated collagen concentrations, resulting in a dense network that may impede drug
movement [42]. Macrophages and other inflammatory cells are also known to infiltrate
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tumors, releasing cytokines and growth factors that may act on cells of the blood vessels
and stroma fibroblasts to further increase interstitial fluid pressure [45].

Finally, drugs may face obstacles in achieving high intracellular drug concentrations. In
order to protect themselves, many cancer cells overexpress transporters that serve to
pump drugs out; these are also known as efflux pumps [2, 46]. The most well-known
efflux pump is P-glycoprotein (P-gp/MDR1), an ATP-dependent transporter encoded for
by the ABCB1 gene. Others that have received attention include the multidrug resistance
associated proteins (MRP1, MRP2, and probably MRP3, MRP4, and MRP5) and the
ABCG2 protein. Thus, although the drugs may pass readily through the cellular
membrane, they are rapidly effluxed from the cell and are unable to achieve therapeutic
efficacy. This is termed MDR and can be apparent from an initial treatment (intrinsic
MDR) or can be developed following treatment (acquired MDR).

3.3.

DEXAMETHASONE (Dex)

In order to reduce or eliminate these barriers to chemotherapy, additional drugs may be
administered either prior to or concurrently with the chemotherapeutic agents. These
drugs may or may not have therapeutic properties of their own but are primarily used as
adjuvants in order to improve the efficacy and/or decrease the toxicity of the
chemotherapeutic agents. One example of such a drug is Dex (Figure 3.3). Dex is a
synthetic

glucocorticoid

most

well

known

for

its

anti-inflammatory

and

immunosuppressive properties [3, 4]. It has shown effectiveness against certain types of
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cancers, such as leukemia [47, 48], and it has been extensively used in conjunction with
chemotherapeutic agents as an anti-emetic [49, 50].

Figure 3.3. Structures of Dexamethasone (Dex, top) and Dexamethasone palmitate
(Dex-P, bottom)

However, recent pre-clinical and clinical trials have focused on its use as a
chemotherapeutic adjuvant. Studies have shown that Dex pre-treatment can reduce the
toxicity and, in some cases, increase the efficacy of chemotherapeutic agents. For
instance, both prednisolone and Dex effectively protected progenitor cells in four strains
of mice against 5-fluorouracil, a cell-cycle-specific antimetabolic chemotherapeutic agent
[51]. Bone marrow progenitors and blood cell numbers were shown to return to normal
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from 3-5 days and from 1-2 days earlier, respectively, than without glucocorticoid
treatment. The same level of efficacy could be achieved with Dex at an approximately
16.5-fold lower dose than with prednisolone. A synergistic growth inhibition was also
observed in six B-cell non-Hodgkin lymphoma cell lines when tumor cells were pretreated with Dex prior to treatment with rituximab, a chimeric human immunoglobulin
G1 (IgG1) anti-CD20 monoclonal antibody known to induce cytotoxicity in malignant B
cells [52]. Wang et al demonstrated that pre-administration of Dex was able to
significantly increase the efficacy of carboplatin, a DNA alkylating agent; gemcitabine,
an antimetabolite; or a combination of both drugs by 2-4 fold in six xenograft models
tested (2 colon, 2 breast, 1 lung, and 1 glioma cancers) [5]. Correspondingly, Dex pretreatment was effective in reducing the decrease in granulocyte counts shown to occur
with carboplatin treatment in CD-1 mice [6]. The same group also examined the effects
of Dex on adriamycin (an anthracycline antibiotic capable of intercalating DNA, also
known as doxorubicin) therapy with similar results. Pre-administration of Dex resulted in
almost complete inhibition of tumor growth in a syngeneic model of breast cancer [11].
In clinical trials, Dex pre-treatment has resulted in a reduction in hematopoietic toxicity
and an improvement in absolute granulocyte count and platelet count recovery times [7,
8].

The complete mechanism (Figure 3.4) behind Dex‟s beneficial effects remains elusive,
but it is assumed to be rooted in Dex‟s inhibition of the NF-κB signaling pathway [9, 10].
Dex administration induces production of the inhibitory protein IκBα, which can bind to
activated NF-κB and prevent its entrance into the nucleus [9, 10]. As the NF-κB signaling
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pathway is known for its role in the production of a number of pro-inflammatory
cytokines [53, 54], its inhibition would be expected to have major repercussions. This is
in alignment with the significant change in the tumor cytokine expression profile that has
been reported upon administration of Dex [11]. For example, Dex treatment was shown
to upregulate tumor necrosis factor-α (TNF-α), a cytokine known to enhance tumor
development and metastasis at low concentrations but to induce necrosis and apoptosis of
tumor cells at high concentrations. Administration of Dex also resulted in the
downregulation of vascular endothelial growth factor (VEGF), a marker for angiogenesis,
and interleukin 1β (IL-1β), a pro-inflammatory cytokine. It is thought that this change in
cytokine expression plays a role in the reported ability of Dex to decrease the interstitial
fluid pressure of tumors [12, 13] and normalize the vasculature [11, 14]. With these
barriers to drug delivery reduced, subsequently administered chemotherapeutic agents
may be taken up into tumors to a greater extent [5, 11], improving their efficacy. Also, as
more drug is delivered to tumors, less is delivered to healthy tissues, and side effects may
be reduced or eliminated [6].

Inhibition of NF-κB
signaling pathway

Change in tumor
cytokine expression
profile

Decreased
interstitial fluid
pressure/normalized
vasculature

Increased
efficacy/decreased
toxicity of
chemotherapeutic
agents

Enhanced uptake of
chemotherapeutic
agents

Figure 3.4. Proposed mechanism of action for Dex’s chemotherapeutic adjuvant
properties
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Yet, despite the potential for this therapy, there may be some limitations. Some studies
have shown antagonistic results with pre- or co-administration of Dex actually resulting
in a decrease in the therapeutic efficacy of chemotherapeutic agents. For example, Herr at
al demonstrated that co-administration of Dex negated some of the effects of cisplatin.
This was traced to a down-regulation of some pro-apoptotic elements of the death
receptor and mitochondrial apoptosis pathways resulting in decreased activity of various
caspases [55]. Meyer et al also found a reduction in the therapeutic efficacy of cisplatin
with pre-administration of Dex [18]. Through an upregulation of the survival factor Akt
and an attenuation of the activation of the mitochondrial apoptotic pathway, Dex reduced
the high dose cisplatin induced apoptosis by 10-25% in human osteosarcoma cells.
Studies by Sui et al showed that pre-treatment with Dex reduced the therapeutic efficacy
of paclitaxel against human breast and ovarian xenografts tumors by 20-25% [17]. These
results, however, are in contrast with clinical observations [8].

A second potential limitation of this therapy is that Dex is capable of inducing a number
of side effects when administered systemically [56]. The most notable of these is
immunosuppression through T-cell depletion and inhibition [3, 19].

For patients

undergoing chemotherapy with already weakened immune systems, this can be a limiting
factor. In order to maximize the therapeutic potential of Dex while minimizing its side
effects, a localized delivery system is desirable.
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3.4.

NANOPARTICLES

3.4.1. Definition and Advantages
Nanoparticles are increasingly being used as drug delivery systems. In strictest terms, the
word nanoparticle refers to a structure in the 1-100 nm size range in at least one
dimension [57]. However, more commonly the term is applied to any particle within the
nanometer size range. Possibly of more importance is the fact that materials at this scale
frequently display different properties than those of the bulk material.

A number of nanoparticle drug delivery systems have been developed, including solid
lipid nanoparticles (SLNs, dispersions of solid lipids), liposomes (self-assembled lipid
bilayers), micelles (self-assembled amphiphilic molecules) and dendrimers (repeatedly
branched spherical polymers) (Figure 3.5). These systems display a number of
advantages over conventional drug delivery systems. First, nanoparticles are capable of
achieving enhanced solubility [20]. This is critical in an age of increasingly hydrophobic
drugs, where new methods are continually required for solubility enhancement.
Depending on the type and composition, nanoparticles may also be able to provide this
enhancement with considerably decreased toxicity as compared to earlier methods (e.g.,
Cremophor) [58]. Secondly, nanoparticles have the capacity for controlled and/or
bioresponsive drug release. Systems can be designed so that drug is released slowly over
an extended period of time, generally by a diffusion process [59, 60]. Alternatively,
systems can be developed that achieve a rapid release of drug upon the addition of a
biological stimulus, such as a change in pH, redox potential, temperature or the presence
of a relevant enzyme [21-24]. Thirdly, nanoparticles have been reported to evade MDR
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mechanisms. This can be a result of their cellular internalization pathway [61, 62] or P-gp
inhibition [26]. Fourthly, nanoparticles have been shown to protect loaded molecules
from enzymatic degradation [27]. This advantage is particularly relevant for proteins and
other enzymatically-labile compounds that would quickly become inactivated in the
absence of a protective drug carrier.

Figure 3.5. Representative nanoparticle drug delivery systems: solid lipid
nanoparticles (top left), dendrimers (top right), micelles (bottom left), and liposomes
(bottom right). Adapted from [63]*

However, of the most relevance in terms of drug delivery for chemotherapeutic purposes
is the ability of nanoparticles to target drug to tumors. As described above for Dex as
well as for many chemotherapeutic agents, there is a desire to localize drug delivery to
tumors as much as possible in an attempt to maximize the efficacy of the drug while
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minimizing its toxic side effects. Nanoparticles have two potential means of achieving
this.

The first and most widely-applied targeting approach is passive targeting, which is based
on the well-known EPR effect [29, 64]. The permeability portion of the EPR effect
results from the fact that tumor vasculature is irregular and “leaky”, or characterized by
larger inter-endothelial junctions than are present in healthy tissue, as mentioned above
(Figure 3.6). Therefore, by incorporating a drug into a nanoparticle of an appropriate size,
the drug should be targeted to the tumor simply based on the size effect. Studies have
shown that tumors have a characteristic pore size of 200 nm to 1.2 μm [29]. However, the
average size varies based on the type of tumor and its location within the body.
Therefore, the generally recommended size limit for nanoparticles designed for tumortargeted drug delivery is <200 nm. Coupled with the leaky vasculature, the poorly
developed lymphatic system of tumors may lead to enhanced retention of materials
within the tumor tissue. Notably, based on similar conditions found at sites of
inflammation, nanoparticles may also be used to provide targeted drug delivery for
diseases such as arthritis [65-67].
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Normal Vasculature

Leaky Tumor Vasculature

Particles<Pore Cutoff size

Particles>Pore Cutoff size

Figure 3.6. Schematic depicting nanoparticle extravasation into tumor tissue via the
enhanced permeability and retention (EPR) effect

Active targeting is the second targeting approach that can be employed [57]. Using this
technique, ligands that can interact with cell surface receptors are attached to the
nanoparticle surface. Receptors upregulated on either tumor cells or on tumor-associated
endothelial cells can be chosen for targeting. Because tumor cell receptors are
inaccessible from the blood, extravasation into the tumor tissues remains primarily a
product of the EPR effect. However, following extravasation, higher intracellular drug
concentrations can be obtained through receptor-mediated endocytosis of the
nanoparticles [68]. Because endothelial cell receptors are accessible from the vasculature
and transport mechanisms are available that ferry materials across the endothelial cell
barrier, vascular targeting may potentially be used to increase extravasation into the
tumor tissue [69]. Vascular targeting may also be used for therapies targeted at
endothelial cells (e.g., anti-angiogenic drugs).
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3.4.2. Nanoparticle PEGylation*
3.4.2.1. Theory
In order for nanoparticles to serve as successful tumor-targeted drug delivery systems,
they must first remain in circulation long enough to reach the tumor site. Before this can
happen, many colloidal carriers are cleared from the circulation as a result of
opsonization of the particles and subsequent uptake by cells of the reticuloendothelial
system (RES) [70-72]. Though some studies have shown an opsonin-independent uptake
of liposomes by macrophages in mice [73-76], the macrophage uptake of nanocarriers in
most species appears to be dependent on interaction with proteins adsorbed on the
nanoparticle surface [77-80]. Opsonin proteins, such as the complement protein C3b,
immunoglobulins G and M, fibronectin, C-reactive protein, β2-glycoprotein, and
apolipoproteins [71, 76, 81, 82] may recognize nanoparticles based on their size, charge,
rigidity, or hydrophobicity, instigating removal of the foreign particles by the RES.
Complement proteins, immunoglobulins, and fibronectin were found to be the major
opsonin proteins, but which protein serves as the dominant opsonin appears to depend on
the specific characteristics of the nanocarrier with most showing high levels of adsorption
of at least several different proteins [81, 82]. Thus, in order for nanoparticles to become
viable alternatives to traditional delivery systems, they must be made less susceptible to
recognition by these opsonins.

The neutrality, hydrophilicity, molecular flexibility, and non-immunogenicity of
poly(ethylene glycol) (PEG) made it a natural initial choice for surface modification of
nanoparticles, and today, PEGylation (the coating of a surface with PEG via adsorption,
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grafting, or entrapment methods) is considered the means of choice for decreasing protein
adsorption and imparting „stealthiness‟ (the ability of avoid RES uptake) to nanocarriers.
Several theories have been proposed to explain why PEG increases the stealthiness of
nanocarriers (Figure 3.7). Simple explanations include the reduction in surface charge
[71] and/or hydrophobicity [83, 84] and, hence, a decrease in the attractive forces
between the nanoparticle and opsonin proteins. However, numerous other hydrophilic
molecules have been used as coatings and failed to produce similar results [85]. Nagaoka
et al discuss the possibility that the high mobility of the longer PEG chains simply
prevents proteins from interacting with a surface for a time sufficiently long enough to
bind [86]. Coupled with the hydrophilicity and mobility of PEG is its wettability [87].
Highly flexible PEG chains are able to squeeze water molecules out of the polymer layer,
creating a large water cloud impermeable to proteins [88, 89]. Others have posited that
PEG creates a minimum interfacial free energy and decreases the necessity of protein
binding in order to reduce the interfacial energy. However, based on protein adsorption
studies performed by Jansen et al, this theory appears to hold only in limited situations
[90]. In fact, in several other cases, it has been shown that minimizing interfacial free
energy results in additional protein binding [90, 91]. The most widely accepted
explanation, put forth by Jeon et al, relies on a description of the interactions between
proteins and PEGylated surfaces [70, 92]. PEG chains are hydrophilic and flexible,
leading to an extended conformation when free in solution. When proteins encroach on
the nanoparticle surface, the PEG chains are compressed. This change to a higher energy
conformation in turn creates a repulsive force that can inhibit protein binding.
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O-Opsonin
D-Dysopsonin

Figure 3.7. Mechanisms by which PEG prevents opsonin adsorption when grafted in
an optimal configuration. Adapted from [63]*

As an alternative theory, some investigators have proposed that long-circulating
characteristics are not a matter of avoiding protein adsorption, but of attracting the
appropriate proteins. While it is thought that PEG causes a nonspecific decrease in
protein adsorption [81], some have proposed that it instead alters the profile of adsorbed
proteins. Moghimi and Patel have performed several studies that support the idea of the
existence of liver- and spleen-specific opsonins [93-96], which may cause an altered
distribution profile. Additionally, there appear to be some proteins that behave as
dysopsonins, suppressing phagocytic uptake [72, 97] (Figure 3.7).

Early studies

identified two serum components, one with a molecular weight < 30,000 Da and one with
a molecular weight > 100,000 Da, that remained bound to poloxamine 908 (four PEG
polymers attached to four poly(propylene glycol) (PPG) polymers all connected by an
ethylene diamine moiety, MW ~ 25,000 Da) coated polystyrene particles and decreased
uptake by liver cells beyond that seen with poloxamine 908 alone [98, 99]. More recent
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studies by Dunn et al and Mosqueira et al also support the concept of dysopsonic activity
but fail to show such promising results with their covalently PEGylated nanostructures
[100, 101]. Dunn et al utilized similar polystyrene particles and saw decreased uptake by
liver non-parenchymal cells for both polystyrene particles and poloxamine 908 coated
polystyrene particles. Additionally, those particles with a low surface coating of
covalently attached 2,000 Da PEG (PEG2000) showed a significant decrease in uptake
after incubation with serum. However, as the PEG2000 surface concentration was
increased from a PS:PEG2000 ratio of 1:0.025 (~15% C-O surface coverage) to a ratio of
1:1.053 (~41% C-O surface coverage), the significant reduction in liver uptake was no
longer observed, possibly because the PEG coating was too dense to allow dysopsonin
binding.

3.4.2.2. Optimization of Surface Coverage
Despite the apparent value of PEGylation, guidelines remain elusive for achieving
optimum surface coverage. If one accepts the Jeon theory, adequate surface coverage of
the particle with PEG must be achieved in order to block adsorption of proteins. The ideal
coverage has been described as intermediate between the “mushroom” and “brush”
configurations [70, 102]. The “mushroom” configuration is characterized by very low
surface coverage, leading to large areas available for protein binding. The “brush”
configuration is characterized by a very high surface coverage, which could theoretically
lead to a restriction of PEG flexibility and a potential decrease in its steric repulsion
properties. However, most experimental data indicate that a predominantly brush
configuration provides the most effective opsonin repulsion [103, 104]. This might be
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attributable to an inability to attain a sufficiently high density such that PEG flexibility is
restricted.

Coverage of the surface can be controlled through chain molecular weight, surface chain
density, and chain conformation. Although each individual system requires optimization,
several trends in surface coverage have emerged: (i) the surface density is more important
than the molecular weight of the PEG chain [92, 100, 105], (ii) there is a threshold
molecular weight for PEG chains to be effective because of a loss of flexibility and
hydration with shorter PEG chains [70, 106, 107], (iii) linear PEG chains of molecular
weight greater than 5,000 Da rarely provide improved results and may show an increase
in protein adsorption because of an inability to obtain high surface density [82, 108, 109],
and (iv) branched PEG chains are less effective at preventing adsorption than linear PEG
chains [106, 110]. Generally, linear PEG chains of molecular weight 1,500-5,000 Da
have been shown to provide efficient stealthiness [82, 106, 111]. The exact length
necessary likely depends on the curvature of the surface and other attractive forces. As an
overarching rule, it has been recommended that a minimum effective hydrodynamic layer
thickness of approximately 5-10% of the particle‟s diameter should be sought for
sufficient coverage [102, 112].

This list is by no means exhaustive, and there have been several exceptions noted. For
example, Mosqueira et al found that when PEG chains of 20,000 Da and 5,000 Da were
both grafted at a distance of 4.5 nm between PEG chains, PEG20000 was better able to
prevent cell uptake of nanocapsules. A grafting distance of only 2.2 nm was required for
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PEG5000 to achieve the same results as PEG20000 at a distance of 7.8 nm, and
PEG20000 continued to decrease cell uptake at higher grafting densities. They proposed
that the PEG chains could have different conformations at the surface resulting in
different efficiencies in preventing interaction between the nanocapsule and a cell, or that
since there is a low surface coverage, the chain length became the limiting factor [101].
Gref et al also found improved circulation times as well as reduced liver uptake with
PEG20000 over PEG with 0, 5, and 12 kDa chains [113].

3.4.2.3. Attachment Methods
One common method for attaching PEG to the surface of nanoparticles is surface
adsorption. This can be done through the use of linear PEG polymers or through the use
of poloxamers (nonionic block copolymers composed of a central hydrophobic chain of
poly(propylene glycol) (PPG) flanked by two hydrophilic chains of PEG) and
poloxamines where the hydrophobic PPG chains insert into the hydrophobic particle and
the PEG chains orient themselves toward the aqueous environment [102]. Alternatively,
1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-PEG (DSPE-PEG) is commonly used
in the preparation of liposomes. These methods have been used since the early 1980s and
are thoroughly reviewed elsewhere [102, 107]. Though many particles exhibited
improved stealth capacities, some results were less than satisfactory.

The major hypothesis to explain these less than optimal results was the desorption of
PEG or displacement by proteins when in the bloodstream [114, 115]. Thus, there was a
move towards ensuring more stable linkages. Harper et al was one of the first groups to
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attach PEG via a covalent linkage. They showed an average reduction in macrophage
uptake of approximately 40% by preparing polystyrene-poly(ethylene glycol) (PS-PEG)
particles as opposed to adsorbing PEG onto the surface of PS particles. An even greater
decrease was seen when poloxamer 238 was adsorbed onto the surface of the PS-PEG
particles [116]. Bazile et al found improved results with polymeric nanoparticles made
from poly(d,l-lactic acid)-poly(ethylene glycol) (PLA-PEG) diblock copolymers. The in
vivo plasma half-life of the PLA-PEG nanoparticles was increased by a factor of 180 as
compared to the poloxamer-stabilized PLA nanoparticles [117]. Later, in vitro assays
revealed that, in the presence of serum, PLA nanocapsules coated with a poloxamer
showed higher levels of protein adsorption [109] and cell uptake [101] than nanocapsules
with covalently attached PEG.

Today, many polymeric micelles and nanoparticles are made from PEG-based diblock
copolymers, which ensure a stable coating. Liposomes are also being further developed
into polymersomes, composed entirely of PEG-based block copolymer amphiphiles.
Those systems not composed of block copolymers rely on the inclusion of a certain
percentage of pre-formed PEG-lipids or PEG-phospholipids in addition to their nonPEGylated counterpart. By using a compound already integral to the particle, a stable
linkage may be obtained. What follows is a sampling of recent reports. Nanoparticles
prepared with PEG-lipids were capable of delivering 70-80% of injected siRNA to
tumors by four hours [118]. SLNs prepared with dipalmitoylphosphatidylethanolaminePEG2000 or stearic acid-PEG2000 showed 30-40% less uptake by murine macrophages
than non-stealth SLNs [119]. Doxorubicin-loaded SLNs containing stearic acid-PEG2000
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exhibited reduced clearance as well as an improved biodistribution over non-stealth SLNs
[120]. Lidocaine-loaded poly(lactic-co-glycolic acid)(80kD)-PEG(20kD) nanoparticles
showed less than 30% uptake by the liver Küpffer cells at five hours compared to 66%
uptake in five minutes for uncoated particles [113]. Doxorubicin-loaded poly(β-benzyl-Laspartate)-PEG copolymer micelles showed a sustained drug release and increased
antitumor activity over free drug [60]. Sustained release of salvicine over 28 days was
obtained with poly(n-hexadecyl cyanoacrylate)-poly(ethylene glycol) (PHDCA-PEG)
nanoparticles [121]. Phagocytosis of poly(hydroxyethylaspartamide methacrylated)PEGylated nanoparticles was reduced based on the degree of PEGylation [122].
Poly(methoxy-polyethyleneglycol5000

cyanoacrylate-co-n-hexadecyl

cyanoacrylate)

(PHDCA-PEG5000) niosomes were prepared that exhibited a half-life of 11.46 hours and
that reduced tumor weight by 89.3% at half the dose given via a normal injection of
solution [108]. Camptothecin-loaded nanocapsules prepared with PLA-PEG showed an
increase of approximately 30% in the reduction of metastatic nodules over uncoated
nanocapsules [123].

3.4.2.4. Current State of the Art
Currently, there are several PEGylated nanocarriers approved for therapeutic use or
undergoing testing [124]. Of these, Doxil is probably the most well-known as it was the
first liposomal drug formulation approved by the Food and Drug Administration (FDA).
In this formulation, doxorubicin HCl is encapsulated (>90%) in a liposome composed of
cholesterol, hydrogenated soy phosphatidylcholine (HSPC), and DSPE-mPEG. Doxil was
originally approved for the treatment of AIDS associated with Kaposi‟s sarcoma in 1995
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[125] but is now also used for the treatment of metastatic breast and ovarian cancers and
multiple myeloma. Compared to the non-liposomal drug, Doxil achieves up to 10-fold
higher levels in tumors. It is also noted for its long-circulating characteristics and
reduction in toxicity, especially cardiotoxicity. Beyond these PEGylated nanocarriers,
there are a variety of PEGylated protein products on the market, including PEGylated
arginine deaminase, PEGylated interferon, and PEGylated L-asparaginase. As evidenced
by these products and the wide variety of other products in which PEG is used as an
excipient, PEG has repeatedly been deemed safe by the FDA.

3.5.

SOLID LIPID NANOPARTICLES

3.5.1. Definition and Advantages
Several reports exist of Dex being loaded into nanoparticle systems, including polymeric
nanoparticles [59, 126, 127], polymer-drug conjugates [67], and liposomes [128, 129].
Unfortunately, these systems may be limited by a number of disadvantages, including
toxicity, low drug encapsulation efficiency, unknown or unproven safety of some of the
materials used in their preparation, and rigorous or high-cost production methods [130,
131]. For this reason, solid lipid nanoparticles (SLNs) were proposed as an alternative
nanoparticle system.

SLNs are characterized by a solid lipid core with stabilizing surfactants and/or polymers
on the particle surface [132]. They have gained increasing attention since their
development in the early 1990s based on their reported ability to combine the advantages
of several nanoparticle systems while negating some of their disadvantages [33, 34].
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First, they can be prepared from inexpensive, readily available materials. A wide variety
of both lipids (e.g., triglycerides, partial glycerides, waxes, PEGylated lipids, fatty
acids/alcohols, steroids) and surfactants/polymers (e.g., polysorbates, brijs®, lecithin, bile
acids) have been used in their preparation. Secondly, because the lipid matrix can be
prepared from biocompatible lipids and the surfactants and/or polymers used can be
chosen based on FDA approval status, these drug delivery systems typically exhibit very
low toxicity. Coupled with the low toxicity of the materials used in SLN preparation is
the fact that most SLN preparation methods do not rely on the use of organic solvents,
eliminating that as a possible toxicity concern. Thirdly, and possibly of most importance,
is the fact that SLNs can be prepared using simple, scalable production methods, a
requirement for translation from academic labs to industrial labs.

3.5.2. Production Methods
The two most commonly used SLN production methods are the high pressure
homogenization (HPH) and microemulsion techniques [34]. HPH was the earliest method
used for SLN preparation. This technique arose from its use in the preparation of o/w
emulsions for parenteral nutrition. Although a liquid lipid is replaced with a solid lipid
for SLN preparation, a similar procedure can be employed if conducted at temperatures
above the melting point of the lipid. This is referred to as hot homogenization. Basically,
the drug is added to the lipid at 5-10°C above the lipid melting point, and then the melt is
dispersed with stirring in an aqueous surfactant solution at the same temperature. The
pre-emulsion is then homogenized, and the resulting hot o/w microemulsion is cooled to
room temperature (or lower). SLNs are produced as the lipid solidifies.

33

The cold homogenization technique can be applied when 1) drugs exhibit temperature
sensitivity, 2) hydrophilic compounds partition into the aqueous phase at elevated
temperatures, and 3) lipid crystallization is complex leading to multiple polymorphic
forms of the lipid and/or supercooled melts [33, 34]. The first step of this process is the
same as that in the hot homogenization. Drug is added to the melted lipid. However,
following this step, the melt is cooled, and the solid lipid is ground to lipid
microparticles. The lipid microparticles are then dispersed in a cold surfactant solution.
Homogenization is conducted at room temperature or below, producing SLNs.

SLNs can also be produced from o/w microemulsions using scalable methods [34, 131].
Microemulsions can be defined as stable biphasic mixtures of two immiscible liquids
stabilized by a surfactant and usually a co-surfactant [131]. It may be necessary to add the
co-surfactant in order to generate the low interfacial surface tensions (γ) between the
dispersed and continuous phases required for the preparation of stable microemulsions.
Because microemulsions are characterized by a large surface area, the interfacial surface
tension must be low enough so that the positive interfacial energy (γA, where A is the
interfacial area) can be balanced by the negative free energy of mixing (ΔGm).

Microemulsions can be prepared using solid lipids by employing a preparation
temperature above their melting point. The lipid will solidify upon cooling, generating
SLNs. Initially, the cooling procedure was performed through dilution in cold water
[133]. More recently, a process known as nanotemplate engineering technology (NET)
was developed in which “direct cooling” is utilized [131, 134]. A schematic of the
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preparation procedure is shown in Figure 3.8. Basically, the process consists of three
steps: 1) melting a pharmaceutically acceptable matrix comprised of lipid(s),
surfactant(s), polymer(s), and drug at 55-70°C, 2) adding pre-heated water with stirring to
form the o/w microemulsion, and 3) cooling to room temperature with stirring to generate
the SLNs.

Figure 3.8. Nanotemplate engineering technology (NET)

In comparison to the dilution method, NET has the advantage of being a single vessel
preparation method. By utilizing a direct cooling approach, it becomes unnecessary to
optimize the rate and ratio of mixing, which have been reported to have a significant
impact on the properties of the resulting SLNs [34]. Further, much higher concentrations
may be obtainable using NET than using the dilution method as microemulsion:water
dilution ratios of 1:10 v/v up to 1:100 v/v have been reported in the literature [131]. This
represents a major improvement in microemulsion technology as low concentrations were
previously considered a significant disadvantage of the microemulsion technique as
compared to the HPH technique [34].
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3.5.3. Limitations
As described above, SLNs have the potential to overcome many of the disadvantages
associated with other nanoparticle drug delivery systems. However, they too may have
limitations, most of which are associated with the lipid crystallinity of the particles. On
one end of the spectrum, SLNs that exhibit high crystallinity may be limited by low drug
loading [135]. There may simply be little room for the drug to be inserted among the
tightly packed lipid molecules. On the other end of the spectrum, working with less
crystalline lipids (or reducing the crystallinity of the lipid through the addition of other
lipids and/or surfactants) may lead to stability issues. If the lipid crystallizes over time, it
may lead to drug expulsion [136-138], particle size growth [138, 139], or gelation [140143]. However, by characterizing the physicochemical properties of the SLNs, these
issues may be anticipated and avoided through changes to the composition (e.g., lipids,
surfactants) [144, 145], preparation procedure [33], or storage conditions [146].

3.6.

PRELIMINARY WORK**

3.6.1. Formulation Optimization
In preliminary work from this laboratory designed to develop Dex loaded SLNs using
NET, approximately 160 formulations containing various combinations of cetyl alcohol,
stearyl alcohol, polysorbates (20, 40, 60 or 80), and Brij® 78 were prepared. Cremophor,
lecithin, and various PEGylating agents were added to some formulations. An optimized
formulation that yielded clear nanoparticle suspensions and a small particle size
distribution was obtained. The formulation was comprised of SA (1.6 mg/mL), PS60 (0.4
mg/mL), and Brij® 78 (3.5 mg/mL) (structures are shown in figure 3.9). To potentially
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improve the stealthiness of the nanocarriers, the formulation was adjusted for the
inclusion of a long-chain PEGylating agent, PEG6000MS. This is essentially a
PEGylated analog of a stearyl (C16) function and is expected to be more compatible with
the primary component of the lipid matrix, SA, than other commonly used PEGylating
agents, such as DSPE-PEG. Because the PEGylating agent is able to function as a
surfactant, the Brij® 78 concentration could be reduced to 2.8 mg/mL when PEG6000MS
was included.

Stearyl alcohol (SA)

Polysorbate 60 (PS60)
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Brij® 78

PEG6000 monostearate (PEG6000MS)

Figure 3.9. Structures of SLN components

3.6.2.

Drug Loading

Dex could be loaded into SLNs (without PEG6000MS) at a drug load of 3.5% w/w SA
(e.g., 0.056 mg/mL Dex in comparison to 1.6 mg/mL SA) while maintaining a small
particle size (~70 nm). Following incubation in PBS at 37°C, a burst release of drug was
observed, accounting for 45–55% of the original amount of Dex loaded into the SLNs. In
considering the time required for SLNs to distribute throughout the circulation and
extravasate into tumors, it was decided that these SLNs would not deliver Dex to tumors
in sufficient quantities.
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For this reason, Dex-P (Figure 3.3) was chosen as an alternative drug for loading. Dex-P
is a lipophilic ester of Dex that has been used in marketed products, such as Limethason®,
an intravenously administered lipid emulsion [36]. A liposome formulation containing
Dex-P has also been described, and a conformational analysis showed that the palmitate
chain was aligned with the acyl chains of the phospholipids while Dex was oriented
towards the aqueous phase [129]. It was expected that Dex-P would align similarly when
incorporated into SA-based SLNs. Early studies indicated that Dex-P could be loaded in
SLNs with or without PEG6000MS at 10-30% w/w SA with high encapsulation
efficiencies. This was confirmed at a later time; results are discussed in chapter 5.

3.6.3.

Evaluation of Stealth Properties

The stealth properties of the nanoparticles were evaluated by determining the adsorption
of a model opsonin,
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I-IgG. 10% Dex-P loaded SLNs with and without 2.5 mg/mL

PEG6000MS were compared. Latex particles (90 nm) were used as a positive control
because they are hydrophobic and readily adsorb IgG. Nanoparticle-adsorbed IgG was
separated from free IgG by SEC using a Sepharose CL-4B column. Representative
elution profiles are shown in Figure 3.10. Expressed in quantitative terms as the mean ±
standard deviation (SD) of 3 measurements, this equates to an adsorption of the following
(all values in μg IgG/mg nanoparticle): latex, 185.0±9.5; non-PEGylated SLNs, 20.8±1.6;
PEGylated SLNs, 6.7±0.7. Both SLNs with and without PEG6000MS exhibited
considerably lower protein adsorption as compared to latex particles. In the absence of
PEG6000MS, this could be attributed to the presence of the polyether portion of Brij® 78
and PS60. Although not as long as suggested based on most PEG research as described
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above, these surfactants apparently exhibit some protective capacity. However, the SLNs
containing PEG6000MS exhibited a statistically lower amount of protein adsorption as
compared to SLNs without PEG6000MS (P<0.05).

16000
14000
Latex

12000

SLNs-PEG6000MS

CPM

10000

SLNs+PEG6000MS

8000
6000
4000
2000
0
0

2

4

6

8

Fraction
Figure 3.10. Adsorption of IgG (as measured by radioactive CPM) on SLNs.
Nanoparticle-adsorbed protein was separated from free protein using a Sepharose
CL-4B column; nanoparticles eluted in fractions 5-7. Adapted from [35]**

As a second test of the stealth properties, SLNs that had been radiolabeled with

14

C-SA

were evaluated for uptake by murine macrophages. The initial study was conducted using
SLN prepared with 2.5 mg/mL PEG6000MS as in the IgG adsorption studies. While
there was a difference in the SLNs taken up by these cells after a 90 min incubation as
compared to SLNs without PEG6000MS, the difference at earlier time points was
minimal. Additional studies were performed to evaluate the effect of including higher
concentrations of PEG6000MS in the SLN formulation. The results are shown in Figure
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3.11. Two-way ANOVA revealed that the effect of different formulations depends on
what time uptake was evaluated. There was a statistically signiﬁcant interaction between
formulation and time (P<0.001). Multiple comparisons versus control group (SLNs with
0 mg/mL PEG6000MS) were done using the Holm–Sidak method. The addition of
PEG6000MS signiﬁcantly decreased the macrophage uptake at the 30, 60, and 90 min
time points as compared to the control group (P<0.05). At the 90 min time point, each of
the two groups was signiﬁcantly different (P<0.05). As more PEG6000MS was used in
the preparation of SLNs, the macrophage uptake decreased. The uptake of SLNs with 0
mg/mL PEG6000MS was 36.6%/mg cell protein. As the amount of PEG6000MS in the
formulation increased, the uptake of the
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C-labeled nanoparticles was observed to

decrease, reaching a low of 14.7%/mg cell protein for SLNs formulated with 4 mg/mL of
PEG6000MS. These results indicated that as the concentration of PEG6000MS was

SLN uptake/mg Protein

increased, there was a corresponding increase in the stealth properties.
45.00%
40.00%
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

0.0 mg/mL PEG6000MS
2.5 mg/mL PEG6000MS
3.0 mg/mL PEG6000MS
4.0 mg/mL PEG6000MS

0
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Incubation Time (min)
Figure 3.11. Uptake of 14C-labeled Dex-P loaded SLNs with varying amounts of
PEG6000MS by murine macrophages as a function of time. All data represents the
mean ± SD of 5 measurements. Adapted from [35]**
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Based on the above studies, two formulations were chosen for evaluation in this project
(Table 3.1). Formulation 1 did not include PEG6000MS. Although the addition of the
molecule appeared to increase the stealthiness of the nanoparticles, it was considered
worthwhile to compare formulations with and without this molecule to determine if the
increased complexity was warranted. PEG6000MS was included in formulation 2 at a
concentration of 3 mg/mL. This was considered to provide the optimal combination of
particle size, drug loading, and stealth capacity.

Table 3.1. SLN formulations
Formulation 1
1.6 mg/mL
0.4 mg/mL
3.5 mg/mL
0.0 mg/mL
0.16-0.48 mg/mL

Stearyl alcohol (SA)
Polysorbate 60 (PS60)
Brij® 78
PEG6000 monostearate (PEG6000MS)
Dexamethasone Palmitate (Dex-P)

Formulation 2
1.6 mg/mL
0.4 mg/mL
2.8 mg/mL
3.0 mg/mL
0.16-0.48 mg/mL

*The text from the Nanoparticle PEGylation section as well as Figures 3.5 and 3.7 were
previously published in [63]. Reproduced with minor modifications from American
Scientific Publishers: Journal of Biomedical Nanotechnology, PEGylation of Nanocarrier
Drug Delivery Systems: State of the Art, 4, 2008, 133-148, M.D. Howard, M. Jay, T.D.
Dziubla, X. Lu. Copyright © American Scientific Publishers 2008.
**Portions of the text from the preliminary work section, Figure 3.10 (originally
presented in table format), and Figure 3.11 were previously published in [35].
Reproduced with kind permission from Springer Science+Business Media: The AAPS
Journal, Nanoparticles containing Anti-inflammatory Agents as Chemotherapy
Adjuvants: Optimization and In Vitro Characterization, 10(1), 2008, 133-140, X. Lu,
M.D. Howard, M. Mazik, J. Eldridge, J. Rinehart, M. Jay, M. Leggas. Copyright ©
Springer Science+Business Media 2008.

Copyright © Melissa Howard 2011
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Chapter 4
Physicochemical Characterization of Nanotemplate Engineered Solid Lipid
Nanoparticles*

4.1.

INTRODUCTION

Due to their simplicity of formulation and basic biocompatibility of the constituent
materials, SLNs have become an exciting area for nanomedicine research. As with other
systems, they have the potential for targeted drug delivery [147, 148], controlled or
triggered drug release [149-151], enhanced drug solubility [152, 153], and improved drug
stability [154, 155]. Yet, SLNs also possess low inherent toxicity due to the use of
physiological lipids and non-organic solvents during preparation [33, 34, 130] and are
amenable to large-scale production methods [33, 34]. Of course, SLNs possess some
limitations, including low drug loading [135], drug expulsion [136-138], particle size
growth [138, 139], and a tendency to form gels [140-143]. These issues are linked to the
fundamental physicochemical properties that are predominately controlled by the
material of composition (e.g., lipids, surfactants) and preparation procedure [33]. For
example, SLNs prepared from highly crystalline triglycerides have lower drug loading
capacity than SLNs prepared from complex glycerides [138]. Lipids with multiple
polymorphic forms can lead to drug expulsion upon form transitions [138], which are
kinetically modulated by surfactant choice [145, 156]. The choice of lipid(s) and
surfactant(s) and their concentrations have been found to affect SLN aggregation and
gelation [139, 157]. Even the choice of formulation parameters has been shown to affect
drug loading, release profiles, and long-term physical stability [158, 159].
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The SLNs under consideration in this study are prepared using NET. While in vitro and
in vivo results have been promising [160, 161], there exists relatively little
physicochemical characterization of nanotemplate engineered SLNs beyond particle size
and zeta potential measurements [162, 163].

Indeed, the complex interplay of the

multicomponent systems used in SLN preparations make a priori predictions of the
overall stability and phase behavior of the SLN difficult, necessitating a more thorough
understanding of the SLN physiochemical properties. As such, the objective of this study
was to perform a thorough characterization of the two SLN formulations being
considered for development as a Dex-P delivery system, providing comparisons and
possible advantages/disadvantages of the two.

4.2.

MATERIALS AND METHODS

4.2.1. Materials. PS60 and Brij® 78 were obtained from Uniqema (Chicago, IL).
PEG6000MS was a gift from Stepan (Northfield, IL). SA was purchased from Spectrum
Chemicals and Laboratory Products (Gardena, CA). Water was obtained from a Milli-Q
Synthesis ultrapure water system (Millipore; Billerica, MA). Chloroform-d (CDCl3) and
deuterium oxide (D2O) were products of Acros Organics; the deuteration of both NMR
solvents was at least 99.8%.

4.2.2. SLN Preparation. SLNs were prepared using NET as previously described [131].
Briefly, the process consists of three steps: 1) melting an appropriate mixture of lipids,
surfactants, and (optionally) long-chain PEGylating agents; 2) adding pre-heated water
with stirring to generate an o/w microemulsion; and 3) cooling the microemulsion to
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form a suspension of SLNs. For this study, microemulsions were prepared at 70°C in
order to facilitate the melting of all components. SLNs were cooled in a room
temperature water bath. Formulation 1 composition was 1.6 mg/mL SA, 0.4 mg/mL
PS60, and 3.5 mg/mL Brij® 78. Formulation 2 composition was 1.6 mg/mL SA, 0.4
mg/mL PS60, 2.8 mg/mL Brij® 78, and 3.0 mg/ml PEG6000MS. Batch size ranged from
2-10 mL. SLNs were filtered using a 0.2 μm polyethersulfone membrane prior to
analysis. SLNs for DSC and PXRD analysis were freeze-dried using a Virtis Advantage
benchtop freeze-dryer following freezing at -40°C. Freeze-dried SLNs were tested for
water content using a Karl Fischer coulometric assay.

4.2.3. DLS and TEM. DLS particle size measurements were performed in triplicate at
25°C on a Delsa™ Nano Zeta Potential and Submicron Particle Size Analyzer (Beckman
Coulter Inc., Brea, CA) following a 1:30 dilution with Milli-Q water. TEM images were
obtained using a Philips Tecnai Biotwin 12 equipped with a Gatan ES 1000W CCD
digital camera (FEI, Hillsboro, OR). A drop of sample (7 µl) was incubated for 1.5 min
on a carbon coated TEM grid. The grid was then dried and stained (0.2 μm filtered 2%
uranyl acetate) for an additional 1.5 min. For each formulation, three samples were
analyzed with a minimum of five images taken per sample at different locations on the
grid. Analysis of the images was performed using ImageJ [164]. The lengths of both the
major and minor axes were obtained using the manual analytical tools. Assuming a
prolate spheroid shape for the ellipsoid where the minor axis is the same in the x and y
directions, the volume of an ellipsoid with these dimensions was calculated according to
the following:
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where r is the radius of the relevant axis. Using this value as the volume of an equivalent
sphere allowed for the calculation of an approximate particle diameter according to the
following equation:

In order to apply a quantitative measurement to the particle shape analysis, the aspect
ratio for the particles was calculated by dividing the length of the major axis by that of
the minor axis. These calculations were performed for 20 particles per image, giving a
total of 100 measurements per sample. The average measurement for each sample was
used in calculating the average and standard deviation for particles in each formulation.
As a measurement of the homogeneity of the size distribution (comparable to the PI
values obtained by DLS), a pooled standard deviation (PSD) was also calculated using
the following equation:

where si represents the standard deviations obtained from each individual sample of 100
particles, ni represents the sample size (i.e., 100 for all 3 samples), and k represents the
number of samples (i.e., 3). This differs from the standard deviation calculated above
which represents the variability in the average size obtained from the three samples.
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4.2.4. NMR Spectroscopy. NMR experiments were performed on a Varian 500 MHz
NMR (Varian Inc., Palo Alto, CA). 1H-NMR spectra were obtained for the individual
SLN components and SLNs dissolved in CDCl3 and for intact SLNs in D2O. Peaks were
assigned to their associated structures based on available NMR tables. Benzenesulfonic
acid sodium salt was added in a known concentration to the D2O samples as an internal
standard. Molecular relaxation times were calculated for the three main signals (0.9, 1.3,
and 3.6 ppm) in the intact SLN spectra and in spectra obtained from the surfactant
micelles in D2O. Spin-lattice (T1) relaxation times were analyzed using an inversion
recovery experiment, and spin-spin (T2) relaxation times were analyzed using a Carr
Purcell Meiboom Gill (CPMG) sequence.

4.2.5. DSC. DSC analysis was performed on a TA Instruments DSC 2920 (TA
Instruments, New Castle, DE) using a 1°C/min heating rate from 25°C-75°C in triplicate.
The corresponding TA Instruments Universal Analysis software was used to identify
peak maxima temperatures and peak enthalpies; in the case of mixtures, the enthalpy
associated with a peak was corrected for the proportion of its associated material in the
mixture. Where appropriate, samples were cooled to 0°C at a 5°C/min rate and subjected
to a second heating cycle. SA, Brij® 78, and PEG6000MS were analyzed initially in their
original state; PS60 exhibited no thermal events in this range. These components were
then analyzed following exposure to the thermal treatments used in the preparation
method described above but without forming an aqueous dispersion (referred to as
“processed”). Basically, samples were melted at 70°C with stirring followed by cooling
in a room temperature water bath. This same technique was used to evaluate mixtures of
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the SLN components (prepared in the same ratios found in SLNs). All combinations are
denoted as Component X-Component Y. These are differentiated from SLNs, which are
prepared using the NET method and freeze-dried prior to DSC analysis. Phase diagrams
covering the full range of molar ratios were prepared for SA-Brij® 78, SA-PEG6000MS,
and Brij® 78-PEG6000MS. Following preparation, all samples were stored at room
temperature for 24 hours prior to analysis. Hermetically sealed aluminum pans were used
with loadings of 5-6 mg for all single component and mixture samples and 1-2 mg for
freeze-dried SLNs.

4.2.6.

PXRD. A MultiFlex X-ray powder diffractometer (Rigaku, The Woodlands, TX)

and Jade XRD pattern processing software (Materials Data Inc., Livermore, CA) were
used to obtain the x-ray diffraction patterns of SA, Brij® 78, PEG6000MS, and freezedried SLNs. The scan parameters were set at a range of 5-60° 2θ, step size of 0.02° 2θ,
and scan speed of 2° 2θ.

4.2.7.

SLN Temperature-Dependent Stability Study. Particle size measurements

were performed on SLNs as described above at temperatures ranging from 20-65°C for
formulation 1 SLNs and from 25-70°C for formulation 2 SLNs, both in 5°C intervals.
Samples were incubated in the DLS chamber, and measurements were automatically
recorded every 30 min for 6 h. In determining particle size, the solution viscosity was
adjusted as a function of temperature. As the change in particle size was observed to be
linear for the duration of the experiments, growth rates were obtained through a linear
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least squares fit. Growth rate was then plotted as a function of temperature, and a double
tangent approach was applied to determine a critical point.

4.2.8. Statistical Analysis. All data is presented as the mean ± SD of three independent
measurements unless otherwise noted. Comparisons were made using a t-test (paired two
sample for means). Results are considered statistically significant at a level of p<0.05.

4.3.

RESULTS

4.3.1. DLS and TEM Analysis. Particle size measurements were taken by DLS. Both
formulations produced nanoparticles of a small size (<100 nm) and low polydispersity
(Table 4.1). No differences were observed for particles before and after filtration (Table
4.2) or among batches ranging from 2-10 mL (Table 4.3). SLNs were also analyzed by
TEM (Figure 4.1). As the particles appeared to have a slightly ellipsoidal shape, particle
size was calculated by determining the volume of the ellipsoid and back-calculating the
particle size of a sphere with the equivalent volume. For purposes of analysis, it was
assumed that the particles were prolate spheroids and not oblate spheroids. The data from
these two techniques is in reasonable agreement. The size obtained for formulation 1
SLNs by TEM was larger than that obtained by DLS, whereas no significant difference
(P>0.05) was found for the particle size of formulation 2 SLNs determined by the two
techniques. The aspect ratio of the particles was also calculated as a quantifiable marker
for particle shape differences. Formulation 1 appeared slightly more spherical than
formulation 2.

49

Table 4.1. Particle size and shape data (n=3)
DLS
Formulation
1
2

Particle size
(nm)
53.2±1.4
89.4±1.9

PI
0.119±0.041
0.111±0.023

Particle size
(nm)
69.8±5.3
92.9±3.7

TEM
PSD
(nm)
15.2
16.4

Aspect
Ratio
1.24±0.02
1.30±0.02

Table 4.2. Effect of filtration (0.2 μm polyethersulfone membrane) on SLN
properties (n=2)
Property
Particle size (nm)
PI
Intensity
Density (mg/mL)

Formulation 1
Unfiltered
Filtered
56.4±1.4
56.7±0.6
0.094±0.021 0.048±0.001
11468±223
10575±723
1015.8±4.2
1017.9±2.7

Formulation 2
Unfiltered
Filtered
91.4±0.8
90.7±0.7
0.058±0.020 0.048±0.011
11416±136
11995±761
1012.7±0.6
1013.9±2.5

Table 4.3. Effect of batch volume on SLN properties (n=3)
Batch
Volume
2 ml
5 ml
10 ml

Formulation 1
Size (nm)
PI
54.9±1.0 0.094±0.011
55.1±2.3 0.097±0.016
55.1±1.3 0.114±0.052
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Formulation 2
Size (nm)
PI
89.6±3.4 0.114±0.033
90.1±2.3 0.085±0.049
87.7±0.8 0.051±0.033

Figure 4.1. TEM images of formulation 1 (left) and 2 (right) SLNs. Images were
taken at a magnification of 98000x (formulation 1) and 68000x (formulation 2).

4.3.2. NMR Analysis. SLN components were dissolved in CDCl3, and 1H-NMR spectra
were obtained for each. The following 1H-NMR signals were detected - 0.9 ppm (RCH3): SA, PS60, Brij® 78, PEG6000MS; 1.3 ppm (R-CH2CH3): SA, PS60, Brij® 78,
PEG6000MS; 1.6 ppm (R-CH2-CH2-OR): SA, PS60, Brij® 78, PEG6000MS; 2.3 ppm
(R-CH2-COOR): PS60, PEG6000MS; 3.6 ppm (R-CH2-OR): SA, PS60, Brij® 78,
PEG6000MS; 4.2 ppm (CH2-COO-CH2CH2OR): PS60. Of these signals, the most
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important to consider are the ether signal at 3.6 ppm generated from the PEG portions of
PS60, Brij® 78, and in formulation 2, PEG6000MS, as well as the prominent aliphatic
signal seen at 1.3 ppm in all four components.

1

H-NMR spectroscopy was further applied to SLNs to gain structural information on the

nanoparticles. There is a significant reduction in the size and number of aliphatic peaks
present in the intact SLNs in D2O as compared to solubilized SLNs in CDCl3 (Figure
4.2). This is likely attributable to the peak broadening that occurs due to solid phase
intermolecular interactions, rendering the peaks associated with the solid lipid core
undetectable. To quantify the reduction, benzenesulfonic acid sodium salt was added to
the D2O samples as a reference standard. There was essentially no loss in the PEG peak
at 3.6 ppm moving from the solubilized to intact SLNs. Approximately 100% (97.8% in
formulation 1 and 106.7% in formulation 2) of the added PEG (from Brij® 78, PS60, and
PEG6000MS) remained in a detectable liquid state in the intact SLN sample, presumably
on the surface of SLNs but also potentially in micellar form. This allowed us to use the
3.6 ppm peak as a reference to determine the reduction in size of the aliphatic peaks in
the intact SLNs as compared to the solubilized SLNs. The signal at 1.3 ppm was reduced
by 79.4% in formulation 1 and 90.5% in formulation 2.
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Figure 4.2. 1H-NMR spectra of formulation 1 (left) and formulation 2 (right)
solubilized SLNs in CDCl3 (top) and intact SLNs in D2O (bottom). Integrations are
given for the PEG peak (3.6 ppm) and the main aliphatic peak (1.3 ppm).
Percentages are calculated using the CDCl3 spectra as the control.

Additional complementary information on the structure of SLNs was gained by
determining the relaxation times for the remaining signals [165]. Similar spin-lattice (T1)
and spin-spin (T2) relaxation times are indicative of a group with high molecular
mobility, whereas a T1 value significantly larger than the corresponding T2 value is
indicative of a group with limited molecular mobility. Table 4.4 shows the data obtained
for the three major peaks seen in all D2O samples. It can be seen that the T1/T2 ratios for
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the 3.6 ppm PEG peak are in the range of 1.1-1.3 for the SLNs, indicating a high degree
of molecular mobility. This corresponds well with the expected localization of PEG on
the surface of the particles. Alternatively, the T1/T2 ratios for the aliphatic peaks at 0.9
ppm and 1.3 ppm are significantly larger, indicating that the remaining lipid molecules
(not in the solid state) have limited molecular mobility. These signals may be attributed
to the aliphatic chains of the surfactants that adsorb to the surface and form a loose shell
around the solid core, or to the presence of micelles. In order to investigate these
possibilities, the individual micellar suspensions were also analyzed (Table 4.4). At the
concentrations used in this study (the same as in SLNs), less than 10% of each
component would be expected to exist free in solution based on previously determined
CMC values (appendix C). Thus, the T1/T2 ratios for the micellar suspensions should
primarily reflect the signals of the molecules in micelle form. The T1/T2 ratio for the SLN
1.3 ppm peaks is approximately 7.5-9.0 whereas that for the micelles is only in the range
of 1.2-3.4, indicating that the aliphatic chains of micelles are not the primary contributors
to the aliphatic peak signals in the SLN samples. Interestingly, the 0.9 ppm peaks showed
similar T1/T2 ratios across both SLN and micelle samples. As this peak arises from the –
CH3 portion of the aliphatic chains, it is likely that this signal is reflective of a very small
proportion of molecules in the loose shell orientation or in micelles.
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Table 4.4. T1 and T2 relaxation times determined for SLNs and SLN components
prepared using SLN preparation conditions

Formulation 1
Formulation 2
PS60
Brij® 78
PEG6000MS

ppm
0.9
1.3
3.6
0.9
1.3
3.6
0.9
1.3
3.6
0.9
1.3
3.6
0.9
1.3
3.6

T1(s)
0.9229
0.6045
0.6662
0.8967
0.6391
0.7401
0.9343
0.4454
0.6990
0.9822
0.5865
0.6888
0.8770
0.5687
0.6936

T2 (s)
0.2876
0.0796
0.5749
0.2745
0.0720
0.6046
0.4371
0.3669
0.6099
0.3097
0.1752
0.5219
0.1969
0.2291
0.5782

T1/T2
3.2085
7.5976
1.1589
3.2667
8.8764
1.2241
2.1375
1.2140
1.1460
3.1711
3.3484
1.3199
4.4540
2.4820
1.1996

4.3.3. DSC and PXRD Analysis. DSC was used to evaluate a series of samples,
including the SLN starting materials, mixtures of the SLN components, and the SLNs
themselves, for melting point and enthalpy changes. Samples were stored at room
temperature for 24 hours prior to analysis, but no differences were observed for samples
run immediately following preparation versus those stored for up to one month at room
temperature. Freeze-dried SLNs were shown to have low water content (1.17±0.91% H2O
for Formulation 1 and 0.69±0.22% H2O for Formulation 2). The observed melting point
reductions of the SLNs were primarily attributable to interactions among the SLN
components with the SLN preparation procedure having a minimal effect, as evidenced
by the data obtained with the “processed” materials (Table 4.5). Phase diagrams were
constructed for three of the analyzed mixtures: SA-Brij® 78 and SA-PEG6000MS
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because of the large reductions in the SA melting point and Brij ® 78-PEG6000MS
because of the development of an intermediate peak (Figures 4.3-4.5).

Table 4.5. Melting points (Tfus) determined from DSC peak maxima temperatures
(Data is represented as the mean ± SD of 3 independent measurements of the Tfus
value)
SA:PS60:Brij
78:PEG6000MS
weight ratio
-

Brij 78

SA

PEG6000MS

-

58.16±0.46

-

Brij 78
PEG6000MS

-

44.39±0.14

-

-

-

-

-

63.09±0.78

SA (processed)

-

-

57.98±0.32

-

Brij 78 (processed)
PEG6000MS (processed)

-

42.93±0.27

-

-

-

-

-

61.20±0.70

SA-PS60

1.6 : 0.4 : 0.0 : 0.0

-

56.30±0.22

-

1.6 : 0.0 : 2.8 : 0.0

41.61±0.56

51.48±0.25

-

1.6 : 0.0 : 0.0 : 3.0

-

47.09±0.66

58.79±0.25

0.0 : 0.4 : 2.8 : 0.0

42.55±0.39

-

-

0.0 : 0.0 : 2.8 : 3.0

41.50±0.29

-

59.15±0.20

SA-Brij 78-PS60
®
SA-Brij 78-PS60PEG6000MS
Formulation 1 SLNs

1.6 : 0.4 : 3.5 : 0.0

40.42±0.22

50.13±0.35

-

1.6 : 0.4 : 2.8 : 3.0

38.70±0.09

51.20±0.11

58.01±0.14

1.6 : 0.4 : 3.5 : 0.0

48.50±0.23

-

Formulation 2 SLNs

1.6 : 0.4 : 2.8 : 3.0

40.24±0.33
36.40±0.18/
39.87±0.59

49.86±0.35

57.73±0.11

Sample1
SA
®

®

®

SA-Brij 78
SA-PEG6000MS3
®

PS60-Brij 78
®

Brij 78-PEG6000MS
®

4

Tfus (°C)
®

2

1

Combinations prepared by subjecting materials to the NET procedure but without the
addition of water are represented as component X-component Y. SLNs were freeze-dried
prior to analysis.
2

Brij® 78 or SA-Brij® 78 eutectic

3

An additional small peak was present at 50.40±0.26°C.

4

An additional small peak was present at 50.38±0.21°C.
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The SA-Brij® 78 phase diagram (Figure 4.3) revealed that at low SA concentrations (<15
mole %), a solid solution with SA dissolved in Brij® 78 was apparent. At the
concentrations of interest (Formulation 1, 66.06 mole % SA; Formulation 2, 70.97 mole
% SA), the sample was characterized by the presence of both an SA phase and a eutectic
phase. The eutectic composition was observed at approximately 30-40 mole %. The
solid-liquid equilibrium line was modeled with good agreement using the van‟t Hoff
freezing point relationship [166] as follows:

where x is the mole fraction of the major component at the temperature T, R is the gas
constant, ΔHfus is the molar enthalpy of fusion of the pure component, and Tfus is the
melting temperature of the pure component. Residuals [experimental value (y) – model
value (m)] were calculated and used in the determination of the sum of squares due to
error [
[

], giving a low value of SSE = 10.26. Goodness of fit
, where SST = y – yavg] was calculated to be 0.9997.
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Figure 4.3. Top: SA-Brij® 78 phase diagram obtained from DSC peak maxima
temperatures. Samples of different molar proportions were heated from 25-75°C;
each symbol represents a peak seen in the thermograms. SA appears to dissolve in
Brij® 78 up to 15 mole %. A eutectic appears at 30-40 mole % SA. Data is modeled
using the van’t Hoff freezing point relationship equation with good agreement (solid
line). Dashed lines indicate assumed phase boundaries. α = Brij® 78-rich solid phase;
β = SA-rich solid phase; L = liquid phase. Bottom: Representative SA-Brij® 78
thermogram at the ratio of interest (70.87 mole % SA, formulation 2)
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The second mixture chosen for study was SA-PEG6000MS (92.21 mole % SA). The
thermogram of the original mixture showed two peaks with melting temperatures
significantly reduced below that of SA, and a major endotherm associated with
PEG6000MS. Throughout the entire range of compositions, the same major endotherm
was observed with the shoulder becoming more prominent at higher and lower
concentrations (Figure 4.4). The cause for the shoulder is unknown, giving rise to the
label, γ, for the intermediate region of the phase diagram. Correction of the enthalpy
associated with this peak for the proportion of PEG6000MS present in the mixture (SLN
concentration) produced a larger value than was seen with PEG6000MS alone (234.8±1.9
J/g>170.9±13.0 J/g), indicating that this peak was likely not attributable to a single phase.
This agrees with the region of the phase diagram below this endotherm being bound by
two solid forms, indicating the possible presence of both a PEG6000MS and an SAPEG6000MS mixed phase.
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Figure 4.4. Top: SA-PEG6000MS phase diagram obtained from DSC peak maxima
temperatures. Samples of different molar proportions were heated from 25-75°C;
each symbol represents a peak seen in the thermograms. Dashed lines indicate
assumed phase boundaries. A shoulder was observed on the PEG6000MS peak,
becoming more apparent at higher and lower mole percentages (intermediate region
labeled γ). The area below this region is bounded by two solid phases, indicating the
likely presence of both PEG6000MS and SA-PEG6000MS phases. Assumed phases
are labeled as an aide. A more complete analysis is required to verify their exact
nature. S, S’= Solid phase of unknown structure; L= Liquid phase; γ = unknown.
Bottom: Representative SA-PEG6000MS thermogram at the ratio of interest (92.21
mole % SA)
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Brij® 78-PEG6000MS (16.44 mole % PEG6000MS) was the final mixture chosen for
further analysis. The original sample displayed three endotherms: one each from Brij 78
and PEG6000MS and a smaller peak intermediate between these two. The phase diagram
(Figure 4.5) showed that below 30 mole %, no crystalline Brij® 78 was detectable,
indicating possible dispersion in PEG6000MS. A separate Brij® 78 phase is present
above 30 mole % that upon melting leaves a PEG6000MS-rich solid phase and a liquid.
At PEG6000MS mole percentages of 10-30%, the small intermediate peak was present
but disappeared above these levels. Above the melting temperatures associated with this
peak, a modified PEG6000MS-rich solid phase is present along with a liquid phase. The
PEG6000MS peak was again characterized by a left-hand shoulder (intermediate region
labeled γ in the phase diagram).
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Figure 4.5. Top: Brij® 78-PEG6000MS phase diagram obtained from DSC peak
maxima temperatures. Samples of different molar proportions were heated from 2575°C; each symbol represents a peak seen in the thermograms. Dashed lines indicate
assumed phase boundaries. A shoulder was again observed on the PEG6000MS
peak. Brij® 78 appears to dissolve in PEG6000MS up to approximately 30 mole %.
A small intermediate peak was seen at low PEG6000MS mole percentages. Overall,
the materials remain as two separate phases with minimal interaction. Assumed
phases are labeled as an aide. A more complete analysis is required to verify their
exact nature. S, S’, S’’= Solid phase of unknown structure; L= Liquid phase; γ =
unknown. Bottom: Representative Brij® 78-PEG6000MS thermogram at the ratio of
interest (16.44 mole % PEG6000MS)
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DSC and PXRD were used to evaluate the crystalline polymorph(s) present in SLNs.
Since it is known that rapid cooling of melted SA can induce the formation of the
metastable β-form [167], a DSC assay including a cooling cycle and a second heating
cycle was developed. The generation of the β-form was confirmed with pure SA.
Thermograms were then obtained for the mixtures (SA-PS60-Brij® 78 and SA-PS60Brij® 78-PEG6000MS) using this protocol to determine where the β- and γ-forms would
appear if present. These were compared to the SLN thermograms (Figure 4.6). The major
SLN peaks were shown to overlap with the known γ-peaks in the mixtures. Overlayed
powder X-ray diffractograms of the SLNs and their starting components are shown in
Figure 4.7. Although SA peak intensity was significantly reduced in the SLNs as
compared to the pure component materials, no obvious transition to the metastable form
was observed. The SA peak in the SLNs was shifted slightly to the left as would be
expected with the β-form [167], but as only one peak is visible, it is likely that this can be
attributed to the γ-form. Neither technique was sensitive enough to conclude that the βform was absent.
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Figure 4.6. DSC thermograms comparing formulation 1 (left) and formulation 2
(right) SLNs with a second heating of their respective mixtures (SA-PS60-Brij® 78
and SA-PS60-Brij® 78-PEG6000MS) *SA β-form

Figure 4.7. Powder X-ray diffractograms of freeze-dried SLNs in comparison to the
starting materials. Formulation 1 in comparison with SA and Brij® 78 (left);
Formulation 2 in comparison with SA, Brij® 78, and PEG6000MS (right).
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4.3.4. SLN Temperature-Dependent Stability Study. The growth rate of SLNs
increased with increasing temperature (Figure 4.8). Formulation 1 SLNs were observed
to become fully destabilized at temperatures exceeding 65°C, preventing analysis at
higher temperatures. The same phenomenon was not apparent in formulation 2 SLNs
until 70°C. When the growth rates were plotted against temperature, a break point was
observed for each formulation: 35.2°C and 43.0°C for formulation 1 and formulation 2,
respectively.
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Figure 4.8. Particle size growth rates of SLNs at different temperatures. Application
of the double tangent method indicated a critical temperature of 35.2°C for
formulation 1 SLNs (left) and 43.0°C for formulation 2 SLNs (right).

4.4.

DISCUSSION

In order to ensure the utility of SLNs as a clinically applicable drug delivery system, it is
important to have a thorough understanding of their physicochemical characteristics.
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These properties have been shown to have a significant effect on particle stability,
including size growth [138, 139], gelation tendency [140-143], and drug retention [136138].

DLS and TEM indicated that both NET formulations studied had a particle size of less
than 100 nm, similar to SLNs produced using other methods [168-170]. Data from the
two measurement techniques were in reasonable agreement though the particle sizes
observed from TEM images were slightly larger than those obtained from DLS
measurements. As the two techniques are based on different principles, this was an
unexpected result. Measurements obtained from light scattering are based on the
hydrodynamic diameter of the particle and provide an intensity-weighted average particle
size, whereas measurements obtained using microscopic techniques are based on the
diameter of the dry particle and give a number-weighted average particle size. As a result,
particle sizes from DLS tend to be larger than those obtained by TEM [171]. The
different result seen here may be attributed to the assumption of spherical particles
inherent in the DLS calculations. However, the possibility of particle size and shape
changes due to TEM grid preparation cannot be excluded. Non-spherical shapes have
been reported for a number of SLN systems [172-174]. Anisometric particles may be a
result of a crystal modification present [140] or a result of crystallization occurring nonuniformly in three dimensions [173]. Overall, it was determined that particles were within
a size range appropriate to take advantage of the enhanced permeability and retention
effect for tumor targeting [29]. The effect of morphology is unclear but may be expected
to play a role in drug release, transport, and internalization [175].
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Other groups have reported the existence of supercooled melts within a SLN formulation
[136, 137]. To determine if this was present in the NET SLNs, 1H-NMR spectroscopy
was performed. Although supercooling of 5-10°C was observed in the two formulations
under study, it was not significant enough to prohibit the formation of SLNs. Only a
small proportion of the lipid remained in solution, which high T1/T2 ratios indicated was
likely attributed to the aliphatic chains adsorbed to the particle surface.

Further structural information on the SLNs was obtained by evaluating the PEG signal
arising from PS60, Brij® 78, and for formulation 2, PEG6000MS. PEG surface coverage
is critical for the prevention of particle aggregation and gelation [139] and inhibiting
protein adsorption [63]. Although it is presumed that PEG is present on the surface of
nanoparticles in a flexible conformation, it is important to confirm this as other structures
are feasible. Reverse micelles have been detected in SLNs [176], although not those
possessing PEGylated surfactants. The addition of an internal standard confirmed that
~100% of the added PEG remains in solution in intact SLNs, and the low T1/T2 ratio
found for the 3.6 ppm NMR peak indicated that it had high molecular mobility,
correlating well with the expected surface localization of PEG.

To determine the physical state (e.g., crystalline vs. amorphous) of the solid phase, DSC
and PXRD were performed. Changes in the crystalline nature of the SLNs were analyzed
by DSC by monitoring for shifts in melting point and enthalpy from the raw materials.
The crystallinity index can be determined by dividing the peak enthalpy of a processed
material by that of the raw material in order to quantify the extent of crystallinity.
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However, this calculation is not appropriate if the material forms a new phase not seen in
the pure components (i.e., if it has formed a eutectic with another material or if it has
undergone a polymorphic conversion).

DSC indicated that SLNs had reduced melting points as compared to the starting
materials. A series of samples were used to evaluate the effects of the preparation
procedure and the interactions among the SLN components in the bulk state. While the
preparation procedure was shown to play some role in reducing the SLN melting points,
the interactions among the formulation components appeared to be the primary
contributors. The three samples showing the most complex thermograms (SA-Brij® 78,
SA-PEG6000MS, and Brij® 78-PEG6000MS) were chosen for further study to confirm
that no changes were occurring that would prohibit calculation of the crystallinity index.
Specifically, phase diagrams covering the entire range of molar combinations were
constructed for each mixture. It should be noted that the phase diagrams were obtained by
observing phase transitions with measurable enthalpy changes, and are unlikely to
identify all phase transitions that may exist in these mixtures.

The Brij® 78-PEG6000MS mixture was chosen for further study because of the additional
peak observed intermediate between those of the individual components. This was
assumed to be attributable to a new phase developed based on the interactions between
the two materials. Based on their similar structures, it might be expected that these
interactions would be significant. However, the peak was relatively small in comparison
to the other two peaks (10-20% of the enthalpy of the Brij® peak), and it was of interest
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to see how this would change with other proportions. The phase diagram indicated that
this peak remains small and is only present at 10-30 mole % PEG6000MS. At most
concentrations, the materials exist as two separate phases. The lack of interaction may be
of some concern if it leads to the presence of multiple nanoparticle populations. Based on
the above DLS and TEM data, this does not appear to be the case, but the possibility
cannot be eliminated.

The other two mixtures chosen for study were those of SA with Brij® 78 and SA with
PEG6000MS. The SA-Brij® 78 mixture was chosen because of the large reduction in the
SA melting point observed as compared to the starting material. The phase diagram for
this mixture revealed that a eutectic was formed at 30-40 mole % SA. This prevents the
calculation of crystallinity indices from the peak enthalpies because the peaks no longer
represent a single component that can be compared to the starting materials. The SAPEG6000MS (92.21 mole% SA) mixture was chosen because of the presence of multiple
peaks and the large reduction in the SA melting point. The phase diagram indicated that
at most temperature and concentration combinations, both PEG6000MS and an SAPEG6000MS mixed phase exist. Thus, while the initial analysis indicated that SA
crystallinity was reduced in the SLNs, the in-depth study revealed that SA is actually
present in several different forms within the SLNs.

An additional drop in the melting point was observed on going from the complete
mixtures to the SLNs (50.13°C to 48.50°C for formulation 1 and 51.20°C to 49.86°C for
formulation 2). Three possible explanations were considered for this. The first was the
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presence of water in the freeze-dried SLNs. The water content was shown to be ~1%
based on a Karl Fischer titration. Using this value, it was calculated that there could be up
to 1 molecule of water per 6 molecules of SA if the water was present in the lipid core of
the particles. This would potentially decrease the lipid melting temperature. However, it
seems more likely that most of the remaining water would be associated with the
hydrophilic PEG shell of the particles and would only minimally impact the lipid melting.

The second possible explanation was the Kelvin Effect, which describes why smaller
particle sizes result in lower melting temperatures [177]. Numerous studies exist that
have demonstrated this to play a role in the melting of SLNs [178-180]. This effect can be
approximated using the Gibbs-Thomson equation [177]:

Assuming an interfacial surface tension, γsl, in the range of 10-2 – 10-3 mN/m (common
for microemulsions, [131]), a specific volume, Vs, of the solid of 1.23 cm3/g, a radius, r,
of 45 nm (for formulation 2 SLNs), and a ΔHfus of 210 J/g (bulk SA value from DSC), a
T/T0 ratio of ~0.999 was calculated. Multiplying this by the SA melting temperature
found in the SA-Brij® 78-PS60-PEG6000MS combination, a reduced temperature of
51.15°C would be expected, which is higher than the experimental value obtained.
However, as this is only an approximation, the actual effect may be larger.

The presence of a different polymorph represented a third possible explanation for the
observed results. The β-form of SA is known to have a lower melting point than the γform [167]. In order to elucidate whether the third explanation was a possibility, two
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additional studies were performed. SLNs were compared to DSC thermograms of the
mixtures that had undergone a cooling phase designed to introduce the metastable β-form
of SA. Additionally, powder X-ray diffractograms of the freeze-dried SLNs were
compared to those of the starting materials. Although it was difficult to conclude that the
β-form of SA was absent, it did not appear to be the primary crystalline polymorph of SA
present. As such, it seems likely that the small particle size of SA in the SLNs and the
presence of water in the samples are the main contributors to the reduction in the SLN
melting point.

Based on these results, it appeared that the SLNs under consideration have promise as a
drug delivery system. The interactions among the components may lead to the decreased
crystallinity desirable for high drug loading capacities [35], a goal of SLN research. For
instance, liquid lipids have been added to solid lipids to generate lipid matrices with
multiple defects. These so-called nanostructured lipid carriers have shown enhanced drug
loading [143, 181, 182]. Nanotemplate engineered SLNs with an appropriate formulation
may be able to attain a similar result. On the other hand, there may be cause for concern
in terms of the stability of the SLNs. The proximity of the low melting point of the SABrij® 78 eutectic (38-40°C) to physiological temperatures may lead to a disruption of the
particle structure under in vivo conditions. Enhanced mobility of the SLN components
may allow for crystallization, causing changes in particle size or drug release profiles.
Alternatively, it may decrease protection for biologically sensitive compounds (e.g., by
making them susceptible to enzymatic attack). This was of particular concern with
formulation 1 SLNs in which there is a higher concentration of Brij® 78 than in

71

formulation 2, possibly leading to a higher proportion of SA present in this low melting
form. Analysis of the SLN DSC thermograms (Figure 4.6) furthered this concern, as the
SA-Brij® 78 eutectic peak was considerably more prominent in the formulation 1 SLNs
than in the formulation 2 SLNs.

However, the question remained as to whether the bulk properties adequately represent
the situation observed in nanoparticles. In order to determine this, growth curves were
constructed for the SLNs at a variety of temperatures. At the temperature where the SLNs
melt or partially melt, it might be expected that there would be a transition in their growth
curves if growth is due to Ostwald ripening as has been proposed [34]. Particle size
increased with time at all temperatures; higher temperatures led to higher growth rates. At
65°C and 70°C, formulation 1 and formulation 2 SLNs, respectively, became completely
destabilized, preventing determination of a growth curve. In plotting the growth rates for
the formulation 1 SLNs at lower temperatures, a break point was observed at the critical
temperature of 35.2°C. If figure 4.6 is referenced, it can be observed that this corresponds
approximately with the onset of melting of the SA-Brij® 78 eutectic, indicating that a
portion of SA is present in this form even if the composition is different from that
observed in the bulk state. While the low critical temperature (below 37°C) observed with
these SLNs confirms that physiological stability may, in fact, be a problem for these
particles, it also provides an important result in that it validates the assessment of the bulk
properties of materials used in SLN preparation as a means of anticipating and/or
understanding the interactions occurring within nanoparticles.
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The critical temperature for the formulation 2 SLNs was higher, at 43.0°C. This
corresponds approximately with the onset of melting of SA alone, indicating that little to
no SA is present in the low melting eutectic form in these SLNs. As such, these SLNs are
expected to exhibit considerably higher stability than formulation 1 SLNs under
physiological conditions.

4.5.

CONCLUSIONS

Nanotemplate engineered SLNs were shown to exhibit desirable properties for a drug
delivery system. Both formulations were of a small particle size (<100 nm), ellipsoidal
shape, and low polydispersity. 1H-NMR spectroscopy confirmed that the SLNs have the
expected solid core structure and PEGylated surface. Analysis of the bulk materials
indicated that a number of complex interactions are present among the SLN components,
including the formation of a SA-Brij® 78 eutectic and a mixed SA-PEG6000MS phase.
The decreased crystallinity resulting from these interactions may allow for enhanced drug
loading. However, physiological stability was identified and confirmed as a potential
problem due to the low melting point of the eutectic. For this reason, formulation 2, in
which PEG6000MS is present and the amount of Brij® 78 in the formulation is reduced,
was chosen as the primary formulation for future studies.

*Reprinted with permission from Howard, M. D.; Lu, X.; Rinehart, J. J.; Jay, M.;
Dziubla, T. D., Physicochemical Characterization of Nanotemplate Engineered Solid
Lipid Nanoparticles. Langmuir 2011, 27, (5), 1964-1971. Copyright © 2011 American
Chemical Society.
Copyright © Melissa Howard 2011
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Chapter 5
A Comparative Study of the Extent and Mechanism of Drug Loading in Solid Lipid
Nanoparticles

5.1.

INTRODUCTION

SLNs are a versatile drug delivery system capable of carrying both hydrophobic and
hydrophilic small molecule drugs [131] as well as proteins [183], DNA [184], and
contrast agents [185, 186]. Of these, hydrophobic small molecules have been studied
most extensively. Numerous drugs, including doxorubicin [161], cyclosporine [187], and
coenzyme Q10 [163, 188] have been successfully loaded into SLNs. Three main models
are typically used to describe drug incorporation: 1) a solid solution model, 2) a coreshell model with a drug-enriched shell, and 3) a core-shell model with a drug-enriched
core [34]. While these are useful for explaining obtained results (e.g., drug release), it can
be difficult to predict and/or optimize how drug will be incorporated into the particles and
to what extent.

Systematic studies considering the effects of lipid and surfactant composition have shed
some light on how these parameters affect drug loading. For instance, the use of complex
glycerides in lieu of pure glycerides can allow for higher drug loading due to their lower
crystallinity [138]. An increase in the monoglyceride content of the lipid phase was
shown to accelerate drug release; this was attributed to the ability of the monoglycerides
to act as a surfactant and allow more drug to reside at the particle surface [153, 189].
High surfactant concentrations have also led to a burst release of drugs for a similar
reason [190]. Our current understanding of how the physicochemical properties of the
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drug itself influence drug loading is more limited. Most reports on drug loading into
SLNs have focused on the optimization of a system for a specific drug [149, 168].
Although a number of drugs have been reported to be loaded into SLNs, it can be
difficult to compare them across different formulations and preparation methods.

Only recently has SLN research been directed toward gaining a better understanding of
how the physicochemical properties of drugs are a determinant of how and to what extent
they are loaded into nanoparticles. Advancements in technologies like electron
paramagnetic resonance (EPR) [191] and paraelectric spectroscopy [192] have allowed
for the determination of the location of probe structures within SLNs. Other studies have
attempted to systematically vary drug lipophilicity and determine the effect on drug
loading [153, 193]. In general, drug loading has been shown to increase with
lipophilicity. Further, enhanced lipophilicity tends to slow drug release as a result of
better incorporation in the lipid matrix of the nanoparticles. However, as the lipophilicity
is typically increased through the addition of hydrophobic side chains that may align with
SLN lipids, it may be difficult to discern whether changes are primarily associated with
the change in drug lipophilicity or structure.

In our own studies, we found that the use of Dex-P , a lipophilic ester prodrug of Dex, in
SLNs was able to enhance drug loading and slow drug release as compared to Dex itself
[35]. As with other nanoparticle systems, it was difficult to discern whether this was
primarily associated with the increased lipophilicity of the compound or whether it was
due to the palmitate side chain aligning with the SLN lipids. A conformational analysis of
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the packing of Dex-P into liposomes showed that Dex was likely oriented toward the
aqueous phase, interacting with the phospholipid head groups, while the palmitate chain
was aligned with the acyl chains of phospholipids [194]. It was expected that Dex-P may
align similarly in SLNs composed of a SA lipid phase and stabilized by PS60, Brij® 78,
and PEG6000MS. This theory was supported by the apparent cleavage of Dex from the
SLNs by the action of CE enzymes [37].

This section was focused on further evaluating the extent and mechanism of loading of
Dex-P into the SLNs as well as on determining how drug loading affects the
physicochemical properties of the SLNs. For comparison, two additional drugs, AP and
curcumin, were chosen for study. Structures and relevant physicochemical properties of
these compounds are given in Figure 5.1. Both have previously been loaded into SLNs by
other groups [195, 196]. AP was chosen because it is a prodrug with the same palmitate
side chain present in Dex-P. However, as ascorbic acid (AA) is considerably more
hydrophilic than Dex, loading of AP should be primarily dependent on the palmitate
moiety. Curcumin was chosen for study because it is lipophilic but characterized by a
different structure with no hydrophobic side chains. SLNs were prepared with the three
drugs of interest at loadings of 10-30% w/w SA (0.16-0.48 mg/ml drug in comparison to
1.6 mg/ml SA). Encapsulation efficiency (amount of drug associated with particles/added
drug) was determined, and drug loaded particles were assessed for their size, shape, and
core-shell structure. Interactions between the drugs and the nanoparticle components
were analyzed in order to better understand how the drugs were loaded into the SLNs.
Finally, drug release from the SLNs was monitored.
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Figure 5.1. Structures of Dex-P, AP, and curcumin. MW was calculated by
ChemDraw. LogP and aqueous solubility values were taken from the literature
(References: Dex-P [197], AP [198-201], Curcumin [202-205]). Melting temperatures
(Tfus) were determined by DSC.

5.2.

MATERIALS AND METHODS

5.2.1. Materials. SA and polysorbate 80 were obtained from Spectrum Chemicals and
Laboratory Products (Gardena, CA). PS60 and Brij® 78 were purchased from Uniqema
(Chicago, IL). PEG6000MS was a gift from Stepan (Northfield, IL). AP, curcumin,
deuterium

oxide (D2O), acetonitrile

(ACN), methanol

(MeOH),

and

D-Salt

Polyacrylamide 6000 desalting columns were purchased from Fisher Scientific
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(Pittsburgh, PA). Dex (USP) was a gift from Pﬁzer (Kalamazoo, MI). Palmitoyl chloride
and Float-A-Lyzer G2 dialysis tubes (1 mL, 100 kD) were from Sigma-Aldrich (St.
Louis, MO). Phosphate buffered saline (PBS) was purchased from Invitrogen (San Diego,
CA). Water was from a Milli-Q Synthesis ultrapure water system (Millipore; Billerica,
MA). Centrifugal ﬁlter devices (Microcon YM-10) were purchased from Millipore.

5.2.2. Synthesis of Dex-P. The procedure to prepare Dex-P has previously been
reported [35]. In brief, 300 mg Dex was dissolved in 12 mL pyridine followed by a
dropwise addition of 578 mg palmitoyl chloride. The mixture was stirred in the dark
under nitrogen for 24 h. Nitrogen was used to evaporate the solvent, and the product was
dissolved in dichloromethane prior to loading onto a 30 mL silica gel column. Elution of
the column with a dichloromethane to dichloromethane:ethyl acetate (6:4 v/v) gradient
was used to isolate the puriﬁed product. The reaction progress was monitored using silica
gel thin layer chromatography (TLC) with a chloroform:ethyl acetate (7:3) mobile phase.
Retention factor values were 0.10 and 0.69, for Dex and Dex-P, respectively.

5.2.3. SLN Preparation. SLNs were prepared using the nanotemplate engineering
method [131]. The process used in this study consisted of 1) melting an appropriate
mixture of lipids, surfactants, and drug at 70°C, 2) adding an aqueous phase to generate
an oil-in-water microemulsion, and 3) cooling the microemulsion to room temperature to
form a suspension of SLNs. PBS was used as the aqueous phase of the microemulsion
for all studies except the NMR studies, in which D2O was substituted. Blank SLNs (with
no added drug) consisted of 1.6 mg/mL SA, 0.4 mg/mL PS60, 2.8 mg/mL Brij® 78, and
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3.0 mg/mL PEG6000MS. For drug loaded SLNs, Dex-P and curcumin were added to the
original mixture at 10, 20, or 30% w/w SA. As AP was degraded in a concentrationdependent manner during the preparation process, presumably largely as a result of
oxidative reactions [206], the amount added initially was adjusted in order to give final
drug loads of 10, 20, or 30% w/w SA (correction equation: actual load = 1.18*expected
load - 10.4).

5.2.4. Drug Loading and Encapsulation Efficiency. HPLC was used to determine the
concentration of drug loaded in the SLNs. The following conditions were used for Dex-P
analysis: Alltech C18 column (5 μm, 250 mm×4.6 mm), 95:5 ACN:H2O mobile phase
run at 2 ml/min, and UV detection at λ=240 nm. AP was analyzed using the following
parameters: Alltech Nucleosil C18 column (5 μm, 150 mm×4.6 mm), 75:10:15:0.1
MeOH:ACN:20 mM PBS:TFA mobile phase run at 1 ml/min, and UV detection at
λ=254 nm. Analysis conditions for curcumin were as follows: Supelco Discovery C18
column (5 μm, 250 mm×4.6 mm), 50:50 ACN:H20 mobile phase run at 1 ml/min, and
UV detection at λ=420 nm. Standard curves for each drug were developed. Samples were
prepared at 1 mg/ml and diluted with the respective mobile phase to concentrations in the
range of 10-200 μg/ml. Five concentrations were chosen for each drug, and three separate
samples were analyzed at each concentration.

Following preparation, each SLN suspension was passed through a 0.2 μm filter: Dex-P
and AP through nylon membranes and curcumin through polytetrafluoroethylene (PTFE)
membranes due to its extensive adsorption to nylon membranes. For analysis of the drug
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concentration in these initial and filtered SLN suspensions, 100 μl of each sample was
diluted 5x with methanol, and 10 μl were injected on the HPLC column. Filtered Dex-P
and AP SLNs (300 μL) were then ultrafiltered (Microcon YM-10, 10K MWCO) to
remove free drug followed by three washes with PBS. Filtrates were directly injected to
the HPLC column. The amount of free drug present in the filtrates was subtracted from
the amount present in the filtered SLN suspension; this was compared to the initial
preparation in order to calculate the encapsulation efficiency.

Due to binding of curcumin to the ultrafiltration membrane, free drug was instead
removed from these SLNs using a D-salt polyacrylamide 6000 desalting column. Three
hundred microliters of the filtered curcumin SLN suspensions were loaded to the column;
PBS was used as the eluent. A strong yellow band was observed to travel through the
column, allowing for easy collection. This band came off in the void volume of the
column (as confirmed by blue dextran), providing evidence that it was associated with
SLNs and not free drug. Further, particle size of the collected sample was analyzed and
shown to coincide with intact SLNs. Drug concentration of the collected sample was
determined following a 5x dilution with methanol. After correction for the sample
dilution that occurs with running the sample through the column, the encapsulation
efficiency was calculated by comparing this concentration with the concentration present
in the initial preparation.
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5.2.5. DLS and TEM. DLS was used to measure particle size. Samples were diluted
1:30 with Milli-Q water and analyzed in triplicate at 25°C on a Delsa™ Nano Zeta
Potential and Submicrometer Particle Size Analyzer (Beckman Coulter Inc., Brea, CA).
TEM images were used to provide information on the shape of SLNs. One drop (~7 μL)
of a SLN suspension was incubated for 1.5 min on a carbon-coated TEM grid. The grid
was then dried and stained (0.2 μm filtered 2% uranyl acetate) for an additional 1.5 min.
Following 5 min of drying, the grid was imaged using a Philips Tecnai Biotwin 12
equipped with a Gatan ES 1000W CCD digital camera (FEI, Hillsboro, OR).

5.2.6. NMR Spectroscopy. 1H-NMR spectra were obtained for drug loaded SLNs in
D2O using a Varian 500 MHz NMR (Varian Inc., Palo Alto, CA). Comparisons were
made with images of blank SLNs previously analyzed [207]. To provide a quantifiable
means of comparing the different samples, the ratios between the integrals of the main
aliphatic peak at 1.3 ppm and the PEG peak at 3.6 ppm were calculated.

5.2.7. DSC. DSC analysis was performed on a TA Instruments DSC 2920 (TA
Instruments, New Castle, DE). The corresponding TA Instruments Universal Analysis
software was used to identify peak maxima temperatures. Mixtures of the drugs with the
SLN components were prepared at the ratios found in SLNs. Dex-P and AP were used at
10, 20, or 30% w/w SA; curcumin was used at either 10 or 20% w/w SA. Materials were
melted and mixed at 70°C as in the SLN preparation but without forming an aqueous
dispersion and then cooled to room temperature. Following preparation, samples were
allowed to sit for 24 h prior to loading of 5-7 mg in hermetically sealed aluminum pans.
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Dex-P containing mixtures were run from 25-75°C at a 1°C/min heating rate. AP and
curcumin containing mixtures were run using the same protocol followed by a 10°C/min
ramp to 150°C and 250°C, respectively. Comparisons were made with drugs analyzed
individually as well as with blank mixtures previously analyzed [207]. All measurements
were performed in triplicate.

5.2.8. Drug Release. SLNs were prepared in PBS with 0.02% Polysorbate 80; the drug
loading was 10% for all drugs. Following filtration using an appropriate 0.2 μm
membrane, 1 mL SLNs were loaded into 100 kD Float-A-Lyzer G2 dialysis tubes
preconditioned in Milli-Q water for 15 min and in PBS with 0.02% Polysorbate 80 for 30
min and dialyzed against 1 L of the same buffer at 37°C with shaking at 50 rpm. At
various time points (0, 1, 3, 6, 24, and 48 h), 100 μL were withdrawn from inside the
dialysis tube and immediately diluted 5x with MeOH. HPLC assay conditions were as
described above. To determine if diffusion of the drug across the dialysis membrane was
a rate-limiting factor, studies were repeated with free drug. Excess drug was added to
solutions of PBS with 0.02% Polysorbate 80 and allowed to shake for 1 h. Following
filtration (0.2 μm), samples were loaded into dialysis tubes, and the experiment was
conducted in the same manner as that used for analyzing release of drug from SLNs.
GraphPad Prism was used for fitting of the data; single or double phase exponential
decay profiles were chosen as appropriate. The initial value was fixed at 100% drug
remaining, and complete drug release was required.
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5.3.

RESULTS

5.3.1. Drug Loading and Encapsulation Efficiency. Linear calibration curves were
obtained for all three drugs in the range of 10-200 μg/mL (Figure 5.2). Comparison with
these showed that SLNs could be loaded with Dex-P or AP at 10-30% w/w SA with
encapsulation efficiencies >85% (Tables 5.1-5.3). Higher drug concentrations did not
result in decreased encapsulation efficiencies. Drug loss was predominantly associated
with removal during the 0.2 μm filtration step. In general, only 1-2% of the drug was
removed during the ultrafiltration step. In contrast, the encapsulation efficiency for SLNs
containing 10% curcumin was reduced to approximately 75%, with around 10% being
removed during the 0.2 μm filtration step and the other 15% removed during the column
filtration step. Column filtration was required due to adsorption of curcumin to the
ultrafiltration membrane.
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Figure 5.2. Calibration curves developed for Dex-P, AP, and curcumin using the
appropriate HPLC assay (n=3)

Table 5.1. Particle size and encapsulation efficiency data for SLNs loaded with DexP at 10-30% w/w SA. Blank information is taken from [207].
Dex-P
Drug
Loading
EE (%)
Size (nm)
PI
Blank
89.4±1.9 0.111±0.023
10%
91.56±4.48 97.7±0.1 0.069±0.027
20%
86.63±7.54 114.4±10.4 0.096±0.010
30%
91.77±6.02 132.1±3.1 0.096±0.003
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Table 5.2. Particle size and encapsulation efficiency data for SLNs loaded with AP
at 10-30% w/w SA. Blank information is taken from [207].
Drug
Loading
Blank
10%
20%
30%

EE (%)
91.84±3.86
94.28±0.78
85.88±8.25

AP
Size (nm)
89.4±1.9
88.5±3.0
84.4±2.8
84.8±1.2

PI
0.111±0.023
0.069±0.013
0.071±.029
0.032±0.23

Table 5.3. Particle size and encapsulation efficiency data for SLNs loaded with
curcumin at 10-30% w/w SA. Blank information is taken from [207].
Curcumin
Drug
Loading
Blank
10%
20%
30%

EE (%)

Size (nm)

PI

74.62±5.05

89.4±1.9
79.4±0.5

0.111±0.023
0.078±0.051

SLNs not formed

5.3.2. DLS and TEM. The particle size of Dex-P loaded SLNs was shown to increase
with higher drug loads as determined by DLS (Table 5.1). Analysis of the particle shape
by TEM indicated that, at 10 and 20% loadings, SLNs retained a similar ellipsoidal shape
to that observed with blank SLNs (Figure 5.3). However, both rod- and ellipsoidalshaped particles were apparent in the SLNs with 30% Dex-P. The number and length of
the rod-shaped particles differed from sample to sample.

SLNs loaded with 10% AP were similar in particle size to blank SLNs where loadings of
20 or 30% AP led to a slight reduction in particle size (Table 5.2). All drug loaded
particles appeared similar in shape to blank SLNs (Figure 5.3). Inclusion of 10%
curcumin led to a reduction in the particle size of SLNs by approximately 10 nm (Table
5.3). Particles also appeared slightly more spherical than blank SLNs (Figure 5.3).
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Figure 5.3. TEM images of SLNs loaded with Dex-P, AP, or curcumin in
comparison with blank SLNs

5.3.3. NMR Spectroscopy. 1H-NMR spectroscopy was previously used to confirm the
core-shell structure of blank SLNs [207]. Comparison of the spectra of solubilized SLNs
in CDCl3 and intact SLNs in D2O indicated that approximately 90.5% of the aliphatic
chains of SLNs exist in the solid state with the remaining tightly adsorbed to the
nanoparticle surface. Further, it was shown that essentially 100% of the added PEG is on
the surface of SLNs in a flexible conformation. The 1H-NMR spectra of all drug loaded
SLNs in D2O appeared similar; spectra for the Dex-P loaded SLNs are shown in Figure
5.4. For a quantifiable comparison, the ratio between the integral of the major aliphatic
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peak at 1.3 ppm and the PEG peak at 3.6 ppm was calculated for all samples. Results are

shown in Table 5.4. Changes were minimal in comparison to blank SLNs. A slight
increase was observed in AP loaded SLNs with increasing drug loading. Loading of 10 or
20% Dex-P also resulted in an increase, but 30% Dex-P resulted in a decrease. Since the
PEG peak is expected to remain the same as blank SLNs, the ratio differences are likely a
result of changes in the 1.3 ppm aliphatic peak. Drug-associated peaks were absent in all
spectra, but this was primarily attributable to the low drug concentrations present.

Blank

10%

20%

30%

Figure 5.4. 1H-NMR spectra of Dex-P loaded SLNs in D2O in comparison with that
of blank SLNs. Spectra for AP and curcumin-loaded SLNs appeared similar.

Table 5.4. Comparison of the 1H-NMR spectra of drug loaded SLNs with blank
SLNs in D2O. The 1.3 ppm aliphatic signal and 3.6 ppm PEG signal were integrated,
and the 1.3 ppm/3.6 ppm ratio was calculated.
Sample
Blank
10% Dex-P
20% Dex-P
30% Dex-P
10% AP
20% AP
30% AP
10% Curcumin

1.3 ppm/3.6 ppm
0.0868
0.1038
0.1012
0.0832
0.0917
0.1034
0.1102
0.0823
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5.3.4. DSC. In order to better understand the interactions occurring between the drugs
and the SLN components, mixtures of each drug with the SLN matrix were prepared and
thermal analysis was conducted using DSC. The blank SLN mixture exhibits three peaks
in the DSC thermogram which were previously shown to be attributable to an SA-Brij®
78 eutectic (38.70±0.09°C), a separate SA phase (51.20±0.11°C), and a SA-PEG6000MS
mixed phase (58.01±0.14°C) [207]. The thermograms for the mixtures containing drug
were characterized by similar profiles, although transition temperatures were shifted in
some cases (Figure 5.5). All three drugs caused a downward shift of the SA-Brij® 78
eutectic peak. However, whereas higher Dex-P and curcumin concentrations resulted in
greater reductions in the melting temperature, the peak shift was relatively insensitive to
AP concentration. The SA peak was shown to shift to lower temperatures with increasing
Dex-P or AP concentrations; the change resulting from the addition of AP was larger than
that of Dex-P. The addition of curcumin led to an increase in the melting temperature.
The SA-PEG6000MS peak also showed a downward shift with all three drugs. The
change was concentration-dependent with AP and curcumin but concentrationindependent with Dex-P. A small left-hand shoulder was also present on the SA peak in
all cases that was not present in the blank mixtures. This was likely a result of a certain
proportion of the SA existing in the metastable β-form. Drug-associated peaks were
difficult to discern in the Dex-P and AP samples. A very broad peak around 200°C was
present in the mixtures containing curcumin.
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Figure 5.5. Analysis of drug containing mixtures by DSC. Results are separated by
the three main peaks observed in the thermograms: SA-Brij® 78 eutectic, SA, and
SA-PEG6000MS mixed phase. The peak maxima are given as the melting
temperatures (Tfus), and the value associated with the blank mixtures is indicated by
the dotted line.

5.3.5. Drug Release. Drug release profiles for Dex-P and curcumin loaded SLNs are
shown in Figure 5.6. AP was shown to be unstable under the conditions of the study, and
as such, drug release profiles for AP loaded SLNS could not be obtained. In both cases,
release was characterized by a rapid initial phase followed by a slower secondary phase.
The data could be fit using two-phase exponential decay curves: Dex-P, y=0.1838e-0.3793x
+ 0.8162e-0.003024x ; Curcumin, y=0.3918e-0.5349x + 0.6082e-0.0234x . However, the release of
curcumin was considerably faster than that of Dex-P in both phases. At 48 h, drug release
of Dex-P was <30%, whereas with curcumin it was approximately 80%.
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To determine the role diffusion of the drug across the dialysis membrane plays in limiting
the analysis of drug release, studies were conducted using free drug. With both Dex-P
and curcumin, drug was completely eliminated from within the dialysis tube by the 6 h
time point. Single exponential decay curves could be used for fitting the data with the
following results: Dex-P, y=e-0.7832x; curcumin, y=e-0.9510x (Figure 5.6).
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Figure 5.6. Drug release profiles for SLNs loaded with either 10% Dex-P or
curcumin in comparison with diffusion of free drug across the dialysis membrane.
The dotted lines represent the fit obtained using either one- or two-phase
exponential decay equations: SLN-encapsulated Dex-P, y=0.1838e-0.3793x + 0.8162e0.003024x
; SLN-encapsulated Curcumin, y=0.3918e-0.5349x + 0.6082e-0.0234x; free Dex-P,
y=e-0.7832x; free curcumin, y=e-0.9510x.
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5.4.

DISCUSSION

As SLNs have gained popularity as drug delivery systems, there has been increasing
interest in understanding the parameters that control drug loading. While systematic
studies have provided information on how the choice of lipids and surfactants as well as
their concentrations may play a role in determining the extent and localization of drug
loading, information on how the properties of the drug itself may affect loading remain
limited. In this study, loading of Dex-P, the drug of interest, was compared with AP and
curcumin. AP has a structure similar to Dex-P, but the ascorbate functionality is more
hydrophilic than Dex. Curcumin is lipophilic but has no aliphatic chains that might be
expected to align with the SLN lipids. In order to better understand how the drugs were
loaded, the physicochemical properties of drug loaded SLNs (size, shape, and structure)
and the interactions between the drugs and the SLN components were studied. Drug
release from the SLNs was also monitored.

Dex-P could be loaded at 10-30% w/w SA with encapsulation efficiencies of >85%;
precipitation was observed above this concentration. AP could be loaded at even higher
concentrations; however, for comparative purposes, only the 10-30% drug loading data is
presented. Encapsulation efficiencies for AP were also >85%. SLNs could not be
prepared with curcumin loadings greater than 10%. The encapsulation efficiency was also
lower (~75%) at this concentration.

Interestingly, though both Dex-P and AP exhibit high encapsulation efficiencies, SLNs
loaded with these two drugs exhibit different properties. While AP loaded SLNs exhibit a
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particle size similar to or just smaller than blank SLNs, Dex-P loaded SLNs exhibit a
concentration dependent increase in the particle size, though remaining in the size range
appropriate for taking advantage of the EPR effect [29]. Particle shape appears similar to
blank SLNs at all AP concentrations and at low Dex-P concentrations, but at the highest
Dex-P loading (30%), a transition from ellipsoidal- to rod-shaped particles was observed.
Based on the NMR studies, the overall solid core and PEGylated surface structure of the
SLNs appeared to be maintained upon loading of either drug. Increases in the 1.3
ppm/3.6 ppm ratio are likely indicative of the drug inhibiting recrystallization of the lipid
to the same extent as observed with blank SLNs and are to be expected. However,
whereas this ratio increases in a concentration-dependent manner across the entire range
of AP loadings, the addition of Dex-P increases the ratio only up to the 20% loading.
Above this, the ratio is actually shifted lower than that observed with blank SLNs,
echoing the transition in particle shape.

It was assumed that these differences may be attributable to how the drugs pack within
the SLNs. By studying how the loading of drug affects the melting temperature of SLN
component mixtures, information can be gained on drug-matrix interactions. Based on
the previous modeling studies with Dex-P [129], it seems likely that this drug along with
AP may reside at the interface of the solid core and PEG shell with the hydrophobic
palmitate moiety anchoring the drug within the lipid phase. Evidence for this was
provided in the DSC studies where the addition of Dex-P or AP was shown to decrease
not only the melting temperature of the SA phase but also one of the SA-surfactant
phases.
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On the other hand, the fact that the two drugs predominantly impact the melting of
different SA-surfactant phases may explain why the drug loaded SLNs exhibit such
different properties. In the case of AP, there is a concentration-dependent decrease in the
melting temperature of the SA-PEG6000MS mixed phase with little effect on the melting
temperature of the SA-Brij® 78 eutectic. In contrast, the addition of Dex-P results in a
concentration-dependent decrease in the melting temperature of the SA-Brij® 78 eutectic
while only minimally affecting the SA-PEG6000MS phase. It is unknown why the drugs
associate with the SLNs in such distinctly different manners but is likely attributable to
the hydrophilicity and/or size of the parent drugs.

In contrast to both Dex-P and AP, SLNs could not be formed with curcumin loadings
>10%, and encapsulation efficiency was lower at this concentration. Though 1H-NMR
spectroscopy indicated that the core-shell structure was maintained, the particle size was
reduced by approximately 10 nm as compared to blank SLNs. Further, the particles took
on a more spherical shape than blank SLNs, indicating a possible third drug packing
mechanism.

In analyzing the DSC results, it appears that curcumin‟s interactions with SA are
negligible. There was actually a slight increase in the SA melting point instead of the
decrease observed with Dex-P and AP. Instead, large downward shifts in the melting
temperatures of both SA-surfactant phases were observed. Based on the apparent
interactions with both SA-surfactant phases, it may be tempting to conclude that
curcumin resides within the PEG shell. However, caution must be used in making this
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conclusion. It is possible that curcumin resides within the interfacial region similarly to
the Dex and ascorbic acid functionalities but lacks the aliphatic chain that extends into
the lipid core of the particle.

As a final comparison, drug release from the Dex-P and curcumin loaded SLNs was
evaluated; AP was unstable under the conditions of the study. Both drug release profiles
appeared biphasic, demonstrating a burst release within the first 3-6 h of the study
followed by a slower release over the remaining time period. The burst release may be
due to an initial rapid diffusion of surface-associated drug from the SLNs, while the
sustained release may be attributable to drug lost through a particle erosion mechanism.
This corresponds with the assumed growth due to Ostwald ripening, which relies on the
exchange of nanoparticle components. Yet, notably, release of curcumin was faster than
Dex-P in both phases. Whereas nearly 80% of the encapsulated Dex-P remains associated
with the nanoparticles following the 48 h time period, approximately 80% of the
curcumin was found to be released. This difference was not associated with the time
necessary for the drug to diffuse out of the dialysis membrane, as both drugs were
eliminated from the internal compartment within 6 h. This data is in line with curcumin
residing within the PEG interfacial region but not being anchored within the solid particle
core as is assumed to be the case with Dex-P (and AP).

5.5.

CONCLUSIONS

Overall, it appears that Dex-P loaded SLNs can be prepared with high drug loading and
encapsulation efficiency while maintaining a suitable particle size, shape, and structure.
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However, due to the presence of multiple particle populations with higher drug
concentrations, a loading of 10% w/w SA will be used for further studies. Interestingly,
comparison with AP and curcumin indicated that all three drugs showed different loading
capacities and mechanisms. Release of Dex-P was shown to be slower than that of
curcumin, and higher encapsulation efficiencies were achieved for both palmitate
prodrugs than curcumin despite the fact that all three drugs likely reside at the core-shell
interface. This was attributed to the ability of the hydrophobic side chains of Dex-P and
AP to anchor the drugs within solid lipid core of the particles. Yet, even with Dex-P and
AP, differences in the mechanism of drug packing were observed with corresponding
changes in the properties of the SLNs.

Copyright © Melissa Howard 2011
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Chapter 6
Solid Lipid Nanoparticle Stability in Human Plasma

6.1.

INTRODUCTION*

Preliminary results with Dex-P loaded SLNs indicated a dependence of drug release on
the CE activity of the surrounding media (Figure 6.1) [37]. In this study, nanoparticles
were diluted 1:14 with 10% media in PBS and incubated at 37°C. At certain time points,
samples were subjected to ultrafiltration, and filtrates were assayed for drug
concentration (in the form of either Dex-P or Dex). In mouse plasma with high CE
activity [208], drug release was rapid, reaching nearly 100% within 24 h. All drug
assayed in the filtrates was found to be in the form of Dex, indicating that cleavage had
occurred. Alternatively, in media with negligible CE activity (human plasma [208],
denatured mouse plasma, mouse plasma treated with BNPP), nearly all drug was retained
in the retentate and found to be in the form of Dex-P. Drug release was intermediate
between these two in rat plasma, corresponding well with reported values for CE activity
in rat plasma as compared to mouse or human plasma [208].
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Figure 6.1. Dependence of drug release on CE activity of the surrounding
environment over a 24 h incubation at 37°C (n=3). Adapted from [37]*

If drug release was in fact triggered by CE, it presented both some interesting challenges
and possibilities. Because of the difference in CE activity between human plasma and
plasma of typical small animal models (mice and rats), testing this drug delivery system
in vivo may be problematic as results obtained would likely not be representative of what
would be observed in humans. Carboxylesterase-deficient Es1e(-/-)/SCID mice were
considered as a potential alternative. Although drug release remained higher than that
seen with human plasma (Figure 6.1), it was closer than that observed with mice or rats,
indicating that these animals may serve as a model more closely representative of the
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human situation. On the other hand, this enzymatically-triggered drug release may
provide a mechanism for controlling drug release at the tumor site based on the higher
CE activity levels found in human tumors than in human plasma [209, 210]. Drug may
remain stably entrapped in SLNs while in circulation and then be triggered to rapidly
release upon extravasation into tumors. To test this, drug release was tested in A549
human tumor xenografts that were removed from mice and homogenized (Figure 6.1).
Approximately 78% of the drug was released within 24 h, and again, nearly all was in the
form of Dex. To determine if any of this release was attributable to mouse plasma
remaining in the homogenate, an additional study was performed using an A549 cell
lysate. Release was similar at 24 h (Figure 6.2), confirming that drug release may be
accelerated in human tumors over human plasma.
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Figure 6.2. Accelerated drug release from SLNs incubated at 37°C for 24 h in
homogenized human tumor xenografts or human tumor cell lysates as compared to
human plasma (n=3). Adapted from [37]*
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However, the caveat to this study was that it was difficult to differentiate between drug
retained in SLNs and drug associated with plasma proteins. It was considered possible
that Dex-P was “released” from the SLNs (either due to partitioning out of the SLNs or to
general SLN instability) but remained associated with plasma proteins that would prevent
its filtration. Enzymatic cleavage may then take place at the protein surface, generating
free Dex that may be filtered. This is shown schematically in Figure 6.3. As such, it was
important to show 1) that the SLNs remained intact and 2) that Dex-P remained stably
associated with the SLNs in conditions mimicking human plasma in order to confirm the
CE-dependent drug release.
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Dex-P
Palmitic Acid
Dex
Protein

Figure 6.3. Potential mechanisms of drug release from SLNs. Top: Dex is
enzymatically cleaved from surface of SLNs. Middle: Dex-P partitions out of intact
SLNs onto plasma proteins prior to enzymatic cleavage. Bottom: SLNs are unstable
in the presence of plasma proteins, leading to adsorption of Dex-P onto the surface
of plasma proteins prior to enzymatic cleavage.
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6.2.

MATERIALS AND METHODS

6.2.1. Materials. SA was from Spectrum Chemicals and Laboratory Products (Gardena,
CA). PS and Brij® 78 were products of Uniqema (Chicago, IL). PEG6000MS was a gift
from Stepan (Northfield, IL). Tritiated dexamethasone [6,7-3H(N)] (specific activity =
35-50 Ci/mmol) was purchased from American Radiolabeled Chemicals (Saint Louis,
MO). PBS was obtained from Invitrogen (San Diego, CA). Centrifugal ﬁlter devices
(Microcon YM-10) were purchased from Millipore (Billerica, MA). Human plasma
containing sodium heparin as the anticoagulant was purchased from Innovative Research,
Inc. (Novi, MI). HSA (96-99%) was a product of Sigma-Aldrich (St. Louis, MO). Liquid
scintillation cocktail (Optiphase HiSafe3) was purchased from PerkinElmer (Waltham,
MA).

6.2.2. Synthesis of Dex-P. Dex-P was prepared as previously described [35]. Briefly,
300 mg Dex was dissolved in 12 mL pyridine. Palmitoyl chloride (578 mg) was added
dropwise to this solution. The mixture was stirred in the dark under nitrogen for 24 h. The
solvent was removed by nitrogen, and the product was dissolved in dichloromethane for
loading onto a 30 mL silica gel column. A dichloromethane to dichloromethane:ethyl
acetate (6:4 v/v) gradient was used to elute the puriﬁed product. The reaction progress
was monitored using silica gel TLC with a chloroform:ethyl acetate (7:3) mobile phase.
Retention factor values were 0.10 and 0.69, for Dex and Dex-P, respectively. For the
preparation of radiolabeled Dex-P, 3H-Dex was used in place of Dex.
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6.2.3. SLN Preparation. SLNs were prepared using the nanotemplate engineering
technique as reported previously [131]. Basically, the process consisted of three steps: 1)
melting an appropriate mixture of lipids and surfactants (and drug in the case of drugloaded SLNs), 2) adding PBS to generate an oil-in-water microemulsion, and 3) cooling
the microemulsion to room temperature in order to generate the SLNs. Blank SLNs with
a formulation of 1.6 mg/mL SA, 0.4 mg/mL PS60, 2.8 mg/mL Brij® 78, and 3.0 mg/mL
PEG6000MS were used for particle size, shape, and turbidity analyses. A second
formulation (2.0 mg/mL SA, 0.5 mg/mL PS60, 3.5 mg/mL Brij® 78, 3.5 mg/mL
PEG6000MS, and 0.2 mg/mL Dex-P/3H-Dex-P) was used for the SEC studies and for the
evaluation of the stability of the Dex-P association with SLNs.

6.2.4. SLN Stability – Physiological Temperature and pH
6.2.4.1. Temperature Effect. Samples were incubated at either 4°C or 37°C. At each
time point (0, 1, 3, 6, and 24 h), 30 μL were removed and diluted to 1 mL with 0.2 μm
filtered water. Particle size analysis was performed in triplicate at 25°C on a Delsa™
Nano Zeta Potential and Submicrometer Particle Size Analyzer (Beckman Coulter Inc.,
Brea, CA). Following the final time point, samples were collected for TEM imaging. One
drop (~7 μL) of a SLN suspension was incubated for 1.5 min on a carbon-coated TEM
grid. The grid was then dried and stained (0.2 μm filtered 2% uranyl acetate) for an
additional 1.5 min. Excess stain was removed, and the grid was allowed to dry for 5 min.
Images were obtained using a Philips Tecnai Biotwin 12 equipped with a Gatan ES
1000W CCD digital camera (FEI, Hillsboro, OR).
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Three samples were analyzed per temperature, and a minimum of five images were taken
per sample at different locations on the grid. Images were analyzed using ImageJ [164].
The lengths of both the major and minor axes were obtained using the manual analytical
tools. Assuming a prolate spheroid shape for the ellipsoid where the minor axis is the
same in the x and y directions, the volume of an ellipsoid with these dimensions was
calculated using the following equation:

where r is the radius of the relevant axis. Using this value as the volume of an equivalent
sphere, the approximate particle diameter was calculated:

In order to apply a quantitative measurement to the particle shape analysis, the aspect
ratio for the particles was calculated by dividing the length of the major axis by that of
the minor axis. These calculations were performed for 20 particles per image, giving a
total of 100 measurements per sample. The average measurement for each sample was
used in calculating the average and standard deviation for particles stored at each
temperature. The PSD was also calculated using the following equation:

where si represents the standard deviations obtained from each individual sample of 100
particles, ni represents the sample size (i.e., 100 for all 3 samples), and k represents the
number of samples (i.e., 3). This differs from the standard deviation calculated above
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which represents the variability in the average size obtained from the three samples and is
used primarily as a measurement of the homogeneity of the size distribution (comparable
to the PI values obtained by DLS).

6.2.4.2. Size Recovery. SLNs were incubated at 37°C for 24 h. Following a return to
refrigerated (4°C) conditions, samples were removed for measurement of the particle size
at 0, 1, 3, 6, 25, 50, and 168 h. DLS analysis was performed as described above (n=3).

6.2.4.3. Concentration Effect. SLNs were diluted 10-fold or 30-fold with PBS. These
SLNs along with SLNs at the original prepared concentration were incubated at 37°C for
24 h. DLS particle size measurements were performed at 0, 1, 3, 6, and 24 h (n=3). For
consistency among the samples, all samples were diluted with PBS as necessary to
achieve a 30-fold dilution from the original concentration prior to analysis.

6.2.5. SLN Stability – Human Plasma Proteins
6.2.5.1. Size and Shape of SLNs in Human Plasma. SLNs were diluted 1:14 (v/v) with
a 10% human plasma solution in PBS. Following incubation at 37°C, 30 μL were
removed and diluted to 1 mL with 0.2 μm filtered water for particle size analysis by DLS.
TEM images were obtained after a 24 h incubation, using similar methods to those
described above with the exception of an additional 5-fold dilution with water prior to
grid preparation.

105

6.2.5.2. Size and Turbidity of SLNs with HSA. To replicate a 10% human plasma
solution, HSA was dissolved in PBS at a concentration of 5 mg/mL. SLNs with and
without HSA were incubated at 37°C with shaking at 100 rpm. At each time point (0, 1,
3, 6, and 24 h), 500 μL aliquots were removed. Four hundred and seventy microliters
were used in assessing the turbidity [determined by the absorbance of the suspensions at
350 nm as measured by a Beckman DU 7500i Spectrophotometer (Beckman Coulter Inc.,
Brea, CA)] (n=3). The remaining 30 μL were diluted to 1 mL using 0.2 μm filtered water,
and DLS particle size measurements were obtained as described above (n=3).

6.2.5.3. SEC of SLNs with HSA. A Shimadzu Prominence Ultra Fast Liquid
Chromatography (UFLC) system equipped with a gel filtration-HPLC column, TSK-GEL
G 3000 SW (7.5 mm i.d. x 30 cm) and coupled to a diode array detector was employed to
separate SLNs from HSA. SLNs were mixed 1:1 with a 10 mg/mL HSA solution in PBS
and incubated at 37°C for 2 h. The mixture at time 0 and 2 h, HSA solution (2x diluted
with PBS), and SLNs (2x diluted with PBS) were injected onto the column with an
injection volume of 20 μL. The elution was monitored at 280 nm (HSA λmax).

6.2.6. Stability of Dex-P Association with SLNs. All radioactivity measurements were
performed using a Tri-Carb liquid scintillation counter (LSC; PerkinElmer). For the
determination of the protein binding of Dex-P in human plasma, 0.5 mg Dex-P/3H-Dex-P
were mixed with 2 mL of human plasma and incubated at 37°C for 24 h (n=2). The
mixture was filtered through a 0.2 μm filter (referred to as MF filtrate), and 100 μL of
each MF filtrate was measured for radioactivity. An additional 300 μL of each MF filtrate
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were ultrafiltered, and 50 μL of the UF filtrate measured for radioactivity. Using this
data, the percentage of free drug in human plasma was calculated; this is referred to as
the protein unbound ratio. Binding of Dex-P to the ultrafiltration membrane under these
conditions was determined by collecting 200 μL of the UF filtrate and refiltering it
through a new membrane. One hundred microliters of the second filtrate were assayed for
radioactivity. The loss of radioactivity in the second UF filtrate as compared to the first
was considered due to the binding of the drug to the membrane.

3

H-Dex-P labeled SLNs were mixed with 50% human plasma (1:14 dilution, v/v) and

filtered through a 0.2 μm filter. The loss of radioactivity at this stage was assumed to be
due to the precipitation of any drug aggregates. Two hundred microliters of the MF
filtrate were then ultrafiltered as described above, and the UF filtrate was analyzed for
radioactivity. The percent Dex-P associated with the SLNs (% SLN associated) was
calculated using the equation:

This process was repeated following either a 2 or 24 h incubation at 37°C, and
comparisons were made with SLNs in PBS alone.

6.2.7. Statistical Analysis. All data is presented as the mean ± SD of three independent
measurements. For comparison of two samples, t-tests (paired two sample for means)
were used. Groups of 3 or more were compared using analysis of variance (ANOVA)
one-way test with SigmaStat 3.5 software (Systat Inc., San Jose, CA). Differences were
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considered statistically significant when P<0.05, and the Holm-Sidak method was used to
perform pairwise multiple comparisons on significant effects and interactions.

6.3.

RESULTS AND DISCUSSION**

6.3.1. SLN Stability – Physiological Temperature and pH. The initial studies in this
section were focused on evaluating the stability of the SLNs. Although the Dex-P release
study discussed in the previous chapter indicated that SLNs likely remained intact in the
presence of physiological temperature and pHs, further studies were conducted to
evaluate size and shape changes. SLNs prepared in PBS were initially monitored for
time- and temperature-dependent changes in size and shape. As determined by DLS,
SLNs incubated at 37°C were shown to increase in size by approximately 40 nm within a
24 h time period, whereas the particle size of SLNs stored at 4°C remained approximately
the same (Figure 6.4).
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Figure 6.4. Time- and temperature-dependent growth of SLNs (n=3)

108

30

SLNs stored at either 4°C or 37°C for 24 h were also analyzed by TEM. Visually, the
SLNs appeared to be similar in shape, and there was no significant difference (P>0.05) in
the calculated aspect ratios. Particle size results obtained using this method were
consistent with the DLS results, again showing a difference of approximately 40 nm
between SLNs at 4°C and 37°C (Figure 6.5, Table 6.1). As in the previous chapter, the
actual values obtained using TEM were slightly larger than those obtained with DLS.
This may be attributable to the assumption of spherical particles inherent in the DLS
calculations. Overall, no evidence for disassociation of the SLNs was observed, and the
particles remained within the size range (<200 nm) deemed suitable for tumor-targeting
via the EPR effect [29].

Figure 6.5. TEM images of SLNs stored for 24 h at either 4°C (left) or 37°C (right)
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Table 6.1. Particle size, PSD, and aspect ratio of SLNs stored at either 4°C or 37°C
for 24 h as calculated from analysis of TEM images (n=3)
Temperature (°C) Particle Size (nm) PSD (nm) Aspect Ratio
4
16.4
1.30±0.02
92.9±3.7
37
43.7
1.29±0.02
131.8±5.0
Additional studies were focused on elucidating the mechanism of particle size growth. As
an initial test, SLNs were returned to 4°C following a 24 h incubation at 37°C and
monitored for size changes. Over a seven day period, SLNs did not exhibit any size
recovery, indicating that growth was not attributable to any temperature-dependent
swelling process (Figure 6.6).
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Figure 6.6. Particle size of SLNs stored at 4°C following a 24 h incubation at 37°C
(n=3)
Further studies were focused on evaluating the particles for Ostwald ripening, a process
whereby larger particles grow at the expense of smaller ones and which has previously

110

been used to explain growth of SLNs [33]. The driving force is the higher surface energy
and correspondingly higher solubility of the smaller particles in comparison to larger
particles, as described by the Kelvin equation [211]. Small particles dissolve, generating
a supersaturated solution with respect to the large particles, and the dissolved species then
redeposit on the surfaces of larger particles. To test this theory, the data was fit using
appropriate equations describing Ostwald ripening. The process can be divided into two
steps: 1) diffusion of the solute molecules and 2) interface-controlled growth
(detachment/attachment of the solute molecules to and from the particle surface) [212].
Interface-controlled growth can occur through continuous growth, surface nucleation, or
spiral growth. The process can be rate-limited by either step. In the case of diffusioncontrolled growth or interface-controlled growth occurring through continuous or spinal
growth, the data can be fit using

where d is the average diameter at time t, d0 is the average diameter at time t=0, and k is
the growth rate. For diffusion- and spiral growth-controlled processes, the exponent n is
3, whereas for continous growth processes, the exponent n is 2 [213, 214]. In the case of
surface nucleation, growth can best be fit using a logarithmic dependence on time:

where τ is a time constant [213]. For our system, the data was non-linear when plotted
against the log time (Figure 6.7), confirming that, within this time range, growth is not
likely controlled by surface nucleation. Plots of the cube and square of the mean diameter
versus time were both, however, reasonably linear (Figure 6.7), preventing a conclusive
determination of the growth mechanism.
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Figure 6.7. SLN 37°C growth profiles plotted as the cube of the mean diameter
versus time (top left), the square of the mean diameter versus time (top right), and
the diameter plotted versus the log time (bottom)

To differentiate between the two, an additional study evaluating the effect of particle
concentration on growth was performed. Dilution of SLNs led to smaller particle size
increases when SLNs were incubated at 37°C (Figure 6.8), corresponding with
dissolution-mediated growth. However, it may be that both processes are involved or that
the mechanism changes over time. It is also notable that because the various components
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of the SLNs are characterized by different solubilities, they may also display different
rates of exchange. This may lead to particles having different compositions following
growth than they did initially, though it is difficult to prove this experimentally.
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Figure 6.8. Effect of concentration on particle size growth at 37°C (n=3)

6.3.2. SLN Stability – Human Plasma Proteins. SLNs were next evaluated for their
stability in the presence of human plasma proteins (excepting CE). Following incubation
with 10% human plasma in PBS, SLNs were analyzed by DLS and TEM. Unfortunately,
the presence of the plasma proteins obscured the SLN peak in the DLS data. SLNs
appeared to remain intact in the presence of the plasma as determined by TEM imaging
(Figure 6.9), but the background resulting from plasma components prevented a
conclusive analysis.
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Figure 6.9. TEM images of 10% human plasma with (left) and without (right) SLNs

For this reason, further studies were conducted with HSA as representative of human
plasma. The particle size growth profiles of SLNs incubated with and without 10% HSA
were similar across a 24 h study (Figure 6.10), indicating that particles were remaining
intact without aggregation in the presence of the protein. Only a slight increase in the
particle size of SLNs incubated with the protein over that of SLNs alone was observed at
the final time point, which may be attributable to some protein adsorption on the particle
surface.
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Figure 6.10. Particle size of SLNs incubated at 37°C with or without 10% HSA as a
function of time (n=3)

The turbidity of SLN suspensions was assessed as a second measure of stability. Large
turbidity increases would be expected with particle aggregation or disassociation (due to
the insolubility of the lipid phase). Instead, both SLNs incubated with and without 10%
HSA displayed only minor increases in turbidity over the time period of the study (Figure
6.11), which could be attributed to the normal particle size growth. Finally, SLNs of a
similar formulation were incubated with HSA and analyzed by SEC. SLNs were eluted at
11.2 min, while HSA came off the column later at 15.5 min (dimer) and 17.5 min
(monomer). Following the initial mixing of SLNs with HSA, the two components eluted
similarly to their individual SEC profiles (Figure 6.12). After a 2 h incubation at 37°C,
the SLN peak area was increased slightly from that observed before incubation (P<0.05).
This was likely a result of protein adsorption. However, the amount of HSA associated
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with SLNs was so low that no HSA loss was identified on the basis of the HSA peak size.
Overall, no evidence was seen for SLN instability in the presence of the representative
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plasma protein.
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Figure 6.11. Turbidity of SLNs (as measured by the absorbance at 350 nm)
incubated at 37°C with or without 10% HSA as a function of time (n=3)

Figure 6.12. SEC profiles for HSA, SLNs, and a mixture of SLNs with HSA before
and after a 2 h incubation at 37°C (left). Direct overlay of the mixture profiles at 0
and 2 h (right). Adapted from [197]**
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6.3.3. Stability of Dex-P Association with SLNs. The final studies in this section were
focused on confirming the stability of the association of Dex-P with SLNs in the presence
of human plasma proteins. The drug release studies discussed in the previous chapter
were conducted under sink conditions, and as such, should represent the drug release that
would occur in the circulation. However, in addition to this study, other methods were
considered to specifically evaluate drug partitioning onto plasma proteins. Centrifugation
at 40,000g for 4 h failed to sediment the SLNs due to the low average density of the
SLNs (1.05 g/cm3). While SEC can be effectively used with individual proteins or
possibly mixtures of a few proteins, it can be difficult to use with a complex plasma
sample. As an alternative, a stepwise filtration method was used to determine the stability
of Dex-P association with SLNs.

It was hypothesized that Dex-P would exist in three forms following incubation with
human plasma: 1) Dex-P associated with SLNs, 2) Dex-P solubilized in plasma
(including protein-bound drug), and 3) drug aggregates (unsolubilized drug). The SLNand protein-associated Dex-P would be expected to pass through a 0.2 μm filter, but
unsolubilized drug would not. Using ultrafiltration (MWCO 10 kD), free drug could then
be separated from that bound to proteins or associated with SLNs. As the ratio of bound
to unbound drug is constant when protein concentration is greater than drug
concentration, determination of the free drug will allow for the calculation of protein
bound and correspondingly SLN-associated Dex-P.
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Dex-P was shown to be highly protein-bound (64%) under the conditions used in this
study; sequential ultrafiltrations led to a loss of approximately 2% of the drug. Using
these corrections, it was shown that greater than 96% of Dex-P remained associated with
the SLNs in PBS following a 24 h incubation. When incubated in 50% human plasma,
this value was reduced to 85.5% due to an increased presence of drug aggregates as well
as free drug (Table 6.2). Thus, while drug release from the SLNs was slightly accelerated
in the presence of plasma proteins, Dex-P remained predominantly associated with the
nanoparticles.

Table 6.2. Association of Dex-P with SLNs during a 24 h incubation in PBS or 50%
human plasma (n=3). Adapted from [197]**

Sample
SLN in
PBS
SLN in
plasma

Incubation Unaggregated
time (h)
DEX-P(%) a
0
98.4 ± 0.5
2
97.8 ± 1.4
24
97.8 ± 1.5
0
98.1 ± 2.3
2
98.1 ± 3.0
24
93.2 ± 1.2

a

Released
DEX-P (%) b
0.8 ± 0.5
1.2 ± 0.2
1.6 ± 0.1
3.0 ± 0.2
4.2 ± 0.5
7.7 ± 0.6

SLN-associated
DEX-P (%) c
97.6 ± 0.6
96.6 ± 1.3
96.2 ± 1.6
95.2 ± 2.2
93.9 ± 2.7
85.5 ± 1.8*

calculated from the recovery of DEX-P after microfiltration using a 0.2 µm syringe filter
calculated from the percentage of DEX-P in the filtrate of ultrafiltration (MWCO: 10
kDa) and corrected based on 98% membrane recovery and 64% protein binding
c
calculated from the following equation, SLN-associated DEX-P (%) = a-b
*
Significantly different from 0 and 2 h time points of this sample
b
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6.4.

CONCLUSIONS

The studies described in this section were designed to confirm the stability of SLNs and
the retention of Dex-P with the SLNs under conditions mimicking those found in human
plasma (specifically the absence of CE activity). Although SLNs increased in size by
approximately 40 nm when incubated for 24 h at physiological temperature, they
appeared to retain their ellipsoidal shape. This growth may be attributable to Ostwald
ripening and is unlikely to affect the ability of SLNs to achieve tumor targeting. Analysis
of SLNs incubated with 10% HSA by DLS, UV/Visible spectroscopy, and SEC indicated
the possibility of minor protein adsorption on the particles, but no evidence of particle
disassociation or aggregation was observed. Further, using a multi-step filtration process,
Dex-P was shown to remain predominantly associated with the SLNs (85.5%) during a
24 h incubation in the presence of 50% human plasma.

*Portions of the introduction, Figure 6.1, and Figure 6.2 reprinted with kind permission
from Springer Science+Business Media: AAPS Journal, Nanoparticles Containing Antiinﬂammatory Agents as Chemotherapy Adjuvants II: Role of Plasma Esterases in Drug
Release, 11(1), 2009, 120-122, X. Lu, M.D. Howard, D.R. Talbert, J.J. Rinehart, P.M.
Potter, M. Jay, M. Leggas, Copyright © 2009 Springer Science+Business Media, LLC.
**Portions of the results and discussion section, Table 6.2, and Figure 6.12 containing
data from M.D. Howard reproduced with permission from Kim, J-K; Howard, M.D.;
Dziubla, T.D.; Rinehart, J.J.; Jay, M.; Lu, X., Uniformity of Drug Payload and Its Effect
on Stability of Solid Lipid Nanoparticles Containing an Ester Prodrug. ACS Nano 2010,
5, (1), 209-216. Copyright ©2011 American Chemical Society.
Copyright © Melissa Howard 2011
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Chapter 7
Carboxylesterase-Triggered Hydrolysis of Nanoparticle PEGylating Agents

7.1.

INTRODUCTION

The discovery that poly(ethylene glycol) (PEG) can be used as a surface coating to
increase the circulation lifetime of nanoparticles has unquestionably contributed to the
growth of research on nanocarrier drug delivery systems [215]. Today, PEG is considered
a primary component of nearly all nanoparticle drug delivery systems with surfaces being
coated through a variety of adsorption, grafting, or entrapment techniques [63]. This
hydrophilic, flexible polymer acts to reduce opsonin adsorption and macrophage uptake,
delaying removal of the nanoparticles by the RES [71, 85]. The extended circulation in
turn provides a greater opportunity for the nanoparticles to reach the site of action, most
notably tumors [216, 217].

Much research has been conducted on how to achieve optimum in vivo results, including
studying the ideal amount, packing density, molecular weight, and structure of PEG on
the surface of nanoparticles [63]. However, the other component of achieving optimal in
vivo results that has been considered less frequently is the stability of the PEG coating.
The nanoparticle drug delivery systems must not only be appropriately PEGylated upon
injection, but the PEG coating must remain stably attached to the nanoparticle while in
the circulation. The paucity of reports in this area may be due in part to the difficulty in
characterizing PEG itself. PEG lacks a chromophore for UV detection, limiting
quantitative measurements by traditional methods [218, 219]. Alternatively, as PEG is

120

used to provide stealthiness to nanocarriers, it may be assumed that the PEG cloud
surrounding the nanoparticle will sufficiently prevent interactions with proteins and
enzymes that may affect its own stability.

However, recent studies may refute this assumption. PEG has been shown to desorb from
nanoparticle surfaces in the presence of proteins [114, 220]. Further, the development of
bioresponsive systems based on sheddable PEG coatings has led to concern over the
stability of PEG derivatives against hydrolysis. These systems are designed such that
upon loss of the PEG coating, nanoparticles become destabilized, accelerating drug
release [221]. While hydrolysis has been triggered by stimuli such as an acidic pH [222]
and a reducing environment [223, 224], PEG derivatives have also been designed for
enzymatic cleavage [23, 225]. These are of the greatest concern because they indicate
that the PEG cloud may not be as impenetrable to proteins as expected, at least in some
cases, and warrant the study of PEG coatings previously assumed to be stable.

PEG coatings secured by ester linkages are one such example. Many PEGylating agents
are linked to a lipid moiety through an ester bond; the lipid moiety is inserted into the
core of the nanoparticle while PEG resides on the surface of the particle. Two of the
PEGylating agents used in the SLNs under consideration – PS60 and PEG6000MS – are
a case in point, and it is of interest to know if these SLN components are susceptible to
hydrolysis in the presence of CE for several reasons (Figure 7.1). On a system-specific
level, enzymatic degradation of these compounds may help explain the drug release
results previously obtained. Previous studies have shown that release of ester prodrugs
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incorporated into the SLNs was dependent on CE activity [37], and while this may be
attributable to the structure of the specific ester prodrug, hydrolysis of one or both of
these SLN components may have contributed to the accessibility, and subsequent release,
of the drug by CE. On a broader level, this knowledge may be used to design systems
capable of achieving tumor-targeted drug delivery in humans by taking advantage of the
negligible blood CE activity [208] in comparison to the higher tumor CE activity [37,
209]. Unfortunately, enzymatic degradation of PEGylating agents may also prevent the
use of normal animal models for in vivo testing. Mice and rats both have significantly
higher blood CE levels than humans [208, 226, 227], and studies performed in these
animals may fail to give results representative of what would be seen in humans.
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Figure 7.1. CE-catalyzed ester hydrolysis of PS60 (top) and PEG6000MS (bottom)

7.2.

MATERIALS AND METHODS

7.2.1. Materials. SA was obtained from Spectrum Chemicals and Laboratory Products
(Gardena, CA). PS60 and Brij® 78 were from Uniqema (Chicago, IL). PEG6000MS was
a gift from Stepan (Northfield, IL). PBS was purchased from Invitrogen (San Diego,
CA). NaOH was obtained from Fisher Scientific (Pittsburgh, PA). NaCl, BNPP, and CE
(porcine liver esterase, 3.2 M (NH4)2SO4 suspension, 36 mg/ml, 154 units/mg) were
obtained from Sigma-Aldrich (St. Louis, MO). Water was used from a Millipore Milli-Q
Synthesis ultrapure water system (Billerica, MA).

7.2.2. SLN Preparation. SLNs were prepared using NET as previously described [131].
In brief, the process consists of three steps: 1) melting an appropriate mixture of lipids
and surfactants, 2) adding an aqueous phase to generate an oil-in-water microemulsion,
and 3) cooling the microemulsion to form a suspension of SLNs. For this study, materials
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were melted at 70°C and cooled to room temperature. The aqueous phase consisted of
0.9% NaCl or PBS, as appropriate. The primary formulation (formulation 2 SLNs)
consisted of 1.6 mg/mL SA, 0.4 mg/mL PS60, 2.8 mg/mL Brij® 78, and 3.0 mg/mL
PEG6000MS; unless specifically noted otherwise, the term “SLN” refers to this
formulation. Formulation 1 SLNs comprised of 1.6 mg/mL SA, 0.4 mg/mL PS60, and 3.5
mg/mL Brij® 78 were also used in the pH-stat experiments. PS60 (0.4 mg/mL) and
PEG6000MS (3.0 mg/mL) micelles were prepared using the same process but without the
addition of a lipid phase.

7.2.3. Turbidity and DLS analysis. As a measure of turbidity, UV absorbance
measurements were taken at 380 nm using a Beckman DU 7500i Spectrophotometer
(Beckman Coulter Inc., Brea, CA). Five samples (n=3) were incubated at 37°C in PBS
with shaking at 100 rpm over a period of 48 h: SLNs, SLNs with CE, SLNs with CE and
BNPP, CE, and CE with BNPP. Concentrations of CE (1.86 Units/ml, equivalent of 10%
mouse plasma [208]) and BNPP (1mM, previously shown to inhibit CE [37]) were kept
constant for all samples. At each time point (0, 1, 3, 6, 24, and 48 h), 500 μL aliquots
were removed for turbidity measurements. PBS dilutions were performed as necessary to
achieve a signal in the range of 0.2-1.0 absorbance units. The background signal
associated with CE alone or the CE-BNPP combination was subtracted from the
respective SLN sample for ease of analysis. An additional 30 μL were removed at each
time point for measurement of the particle size and PI by DLS. These aliquots were
diluted to 1 mL using 0.2 μm filtered water. Measurements were performed at 25°C on a
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Delsa™ Nano Zeta Potential and Submicron Particle Size Analyzer (Beckman Coulter
Inc., Brea, CA).

7.2.4. TEM. SLNs in PBS were incubated with and without CE (1.86 units/ml) at 37°C
with shaking at 100 rpm. Samples were removed for TEM imaging at 1 and 24 h. Seven
microliters of each were incubated for 1.5 min on a carbon-coated TEM grid. The grid
was dried and stained with 0.2 μm filtered 2% uranyl acetate for an additional 1.5 min
followed by an additional 5 min of drying. Images were obtained using a Philips Tecnai
Biotwin 12 equipped with a Gatan ES 1000W CCD digital camera (FEI, Hillsboro, OR)
and analyzed using the ImageJ processing program [164]. For each sample, five images
were taken at different locations on the grid and twenty particles were measured per
image. For each particle, the lengths of both the major and minor axes were obtained
using the manual analytical tools. The volume of an ellipsoid with these dimensions was
calculated from these values using the equation for a prolate spheroid (the assumed
shape):

where r is the radius of the relevant axis. This value was used as the volume of an
equivalent sphere to allow for the calculation of an approximate particle diameter
according to the following equation:
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The calculated diameters for the 100 analyzed particles were averaged to provide a mean
and SD for the particle size.

7.2.5. SEC. Analysis was performed using a Shimadzu Prominence LC series equipped
with a RID-10A refractive index detector. The mobile phase was 5 mM PBS, run at a rate
of 0.5 mL/min. Twenty microliter samples were injected to a Shodex Asahipak GF-7M
HQ column (7.5 mm x 150 mm). Molecular weight calculations were made using a
calibration curve developed from PEG molecular weight standards. For concentration
calculations, a calibration curve was prepared using NaOH-treated PEG6000MS. SLNs
and PEG6000MS micelles were treated with 0.1 N NaOH for 3 days. Aliquots were
removed and neutralized with 0.1 N HCl. Samples were centrifuged to remove any
precipitate prior to analysis. To confirm complete release of free PEG, new aliquots were
removed and analyzed again 24 h later. For the CE hydrolysis study, SLNs and
PEG6000MS micelles (3 mg/ml) were prepared in PBS and aliquots immediately
removed for the 0 h time point measurements (n=3). Samples were then treated with CE
(1.86 units/mL final concentration) or a combination of CE and BNPP (5 mM) and
incubated at 37°C with shaking at 100 rpm. Five hundred microliter aliquots were
removed for analysis at 1, 5, 10, 15, 30, and 60 min. The CE-only aliquots were treated
with BNPP upon removal in order to stop the reaction. Prior to analysis, all samples were
centrifuged, and the supernatant was collected for injection onto the column. To
determine the origin of the peak present in the initial samples, PEG6000MS was prepared
in PBS at various concentrations (1-5 mg/mL) and analyzed without undergoing CE- or
NaOH-treatment.
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7.2.6. Measurement of Free Fatty Acid (FFA) Production. In addition to measuring
the production of free PEG, hydrolysis of ester-containing PEGylating agents can also be
analyzed by monitoring for production of FFAs. These experiments were performed
using a pH-stat apparatus (Metrohm Titrando 842, Metrohm USA Inc., Riverview, FL).
The pH meter was calibrated using pH 2.0, 7.0, and 10.0 standards, and all samples were
degassed prior to analysis. Twenty-five milliliters of formulation 1 SLNs, formulation 2
SLNs, or PS60 micelles in 0.9% NaCl were brought to 37°C with stirring. The pH was
adjusted to 7.4, and the enzyme solution was added (1.86 units/mL final concentration).
The pH was kept constant by titrating the produced FFAs with a 0.01 N NaOH solution
using an automated burette; the volume of NaOH added was recorded as a function of
time. Samples were monitored for 2 h. Control samples for each were pre-treated with
BNPP (5 mM) prior to CE exposure. Additionally, blank samples in which CE was added
to 0.9% NaCl alone were analyzed. All samples were analyzed in triplicate. For
comparison, the amount of NaOH added at 15 min intervals was averaged, and the
measurements for all three samples were corrected for the addition of enzyme alone using
their respective BNPP measurements. The SLN measurements were corrected for the
hydrolysis of PEG6000MS using information (molecular weight and purity) obtained
from the SEC studies. An additional study was performed in which, following the normal
study period, samples with and without BNPP were titrated to pH 9.0 in order to confirm
that all FFAs produced were in the detectable, ionized form. A spiking experiment was
run to determine if enzyme was being inactivated. PS60 micelles with and without BNPP
were run as normal; at 1 h, 1 mL of sample was removed and replaced with 1 mL of a 10
mg/mL PS60 solution. The samples were run for an additional hour.
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7.2.7. Statistical Analysis. All data is presented as the mean ± SD of three independent
measurements. Comparisons were made using a t-test (paired two sample for means).
Results are considered statistically significant at a level of p<0.05.

7.3.

RESULTS

7.3.1. Particle Size and Turbidity. It was assumed that hydrolysis of the SLN
PEGylating agents may lead to instability of the particles, either due to particle
disassociation or aggregation. If the concentration of surfactants is reduced due to
degradation of PEG6000MS or PS60, particles may disassociate, leading to the release of
the lipid phase. Due to the presence of Brij® 78, a non-ester-containing surfactant, and
other unhydrolyzed surfactant molecules, this insoluble material may remain dispersed at
least temporarily before precipitating. Alternatively, if SLNs remain intact, it is possible
that they may aggregate due to the lessened concentration of PEG on their surfaces.
Based on this assumption, we monitored the turbidity of the SLN suspensions; the
absorbance at 380 nm was chosen as a quantifiable marker of turbidity due to the low
absorbance of CE and BNPP at this wavelength. SLNs incubated with CE were compared
to SLNs alone and SLNs pre-treated with BNPP prior to the addition of CE over a 48 h
period (Figure 7.2). Following correction for the background signal of CE or CE and
BNPP in combination, the turbidity of SLNs incubated with CE was observed to be 35fold greater at the 0.5 h time point as compared to the two controls. Only a minimal
increase in turbidity was seen with SLNs alone or SLNs incubated with CE and BNPP;
no significant differences were observed between the two (p>0.05). Interestingly, the
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absorbance measurements of SLNs incubated with CE showed a decrease between 0.5
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and 6 h followed by a slight increase for the remaining time period.
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Figure 7.2. Turbidity of SLNs incubated at 37°C with CE, with BNPP-inhibited CE,
or alone. Turbidity is assessed by measuring the sample absorbance at 380 nm.
Samples were corrected for the background signal of CE or CE and BNPP in
combination (n=3).

Throughout the turbidity study, aliquots were removed from the samples for
measurement of the particle size. Control samples of CE alone or CE with BNPP failed to
give the intensity necessary for particle size measurement by DLS and, as such, it was
assumed that all size measurements reported were related to the SLNs themselves. The
particle sizes of SLNs and SLNs with inhibited CE are similar, while SLNs with CE
showed smaller sizes (Figure 7.3). This difference became especially noticeable at later
time points with SLNs incubated with CE showing an average size of nearly 40 nm
smaller than SLNs pre-treated with BNPP prior to exposure to CE at 48 h. SLNs with and
without exposure to CE exhibited similar morphologies and homogeneities based on
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TEM images taken at the 1 and 24 h time points (Figure 7.4) though analysis of the
particle size using the ImageJ processing program revealed a similar trend as was
observed by DLS (Table 7.1).
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Figure 7.3. Particle size of SLNs incubated at 37°C with CE, with BNPP-inhibited
CE, or alone as a function of time (n=3)

Figure 7.4. TEM images of SLNs incubated at 37°C with or without CE for 1 (left)
and 24 (right) h
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Table 7.1. Representative particle size distribution data obtained from SLNs
incubated at 37°C with and without CE for either 1 or 24 h. Both DLS and TEM
data is shown; analysis of the TEM images was performed using the ImageJ
processing program.
Sample
1h
24 h

-CE
+CE
-CE
+CE

DLS
Size (nm)
93.3
87.5
146.8
127.9

PI
0.017
0.017
0.035
0.101

TEM
Size (nm) SD (nm)
98.0
15.1
90.0
11.8
154.3
52.0
143.1
43.9

7.3.2. SEC. While the low molecular weight of PS60 prevented its analysis by SEC, this
method was deemed suitable for monitoring the hydrolysis of PEG6000MS. In analyzing
this material alone, identical peaks were observed for the degradation product of
PEG6000MS incubated with CE and PEG6000MS exposed to NaOH. Based on a PEG
molecular weight calibration curve (Figure 7.5), it was determined that this peak was
associated with a higher molecular weight than was expected (10,376 vs 6,000). As this
prevented the use of an external standard for quantification, a calibration curve was
developed using NaOH-treated PEG6000MS; peak height was shown to increase linearly
with concentration (Figure 7.6).

131

Retention time (min)

25
20
15
10
5

y = -2.6825x + 26.973
R² = 0.9953

0
2.9

3.4

3.9

4.4

4.9

5.4

Log MW

Peak Height

Figure 7.5. SEC molecular weight calibration curve (data from laboratory of Dr.
Younsoo Bae)
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Figure 7.6. SEC concentration calibration curve developed from NaOH-treated
PEG6000MS

In experiments designed to study the hydrolysis of PEG6000MS by CE, it was observed
that a peak was present at the expected retention time in the SEC eluent prior to CE
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exposure. To determine if this was associated with an impurity in the product (PEG6000)
or to free PEG6000MS, PEG6000MS was analyzed at concentrations ranging from 1-5
mg/mL. Peak height was again shown to increase linearly with concentration, indicating
that the initial peak was likely due to a product impurity (Figure 7.7). A peak associated
with free PEG6000MS would be expected to remain constant above the CMC (appendix
C). This impurity peak was subtracted from all subsequent analyses of SEC results.
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Figure 7.7. Untreated PEG6000MS peak height varies with concentration,
indicating the presence of an impurity.

Inclusion in SLNs appears to delay the hydrolysis of PEG6000MS as compared to when
it is in micellar form (Figure 7.8). However, almost 100% hydrolysis is still reached
within 15 minutes following exposure of the SLNs to CE. When samples were pre-treated
with BNPP prior to CE exposure, hydrolysis of PEG6000MS in both SLN and micellar
form was negligible.
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Figure 7.8. Hydrolysis of PEG6000MS as determined by SEC with RI detection.
SLNs (top) and PEG6000MS micelles (bottom) were incubated with CE in the
presence or absence of BNPP (n=3).
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7.3.3. Measurement of FFA Production. The pH-stat technique was used to measure
the change in pH induced by the formation of FFA following hydrolysis of PS60 and
PEG6000MS by CE. PEG6000MS could not be monitored in its micellar form using this
technique due to immediate precipitation following CE exposure. However, both SLNs
and PS60 micelles were monitored for the production of FFA following the introduction
of CE. To provide a direct comparison between SLNs and micelles, a second SLN
formulation (formulation 1 SLNs) was analyzed in which PS60 but not PEG6000MS was
included. Adjustment of pH was not required when BNPP was included in the mixture
except for that required to correct for the enzyme itself (determined by blank
measurements).

The average amount of NaOH added at 15 min intervals (n = 3) appears in Figure 7.9,
having corrected for the amount associated with the addition of enzyme alone by
subtracting out the amount added in the respective BNPP measurements at each time
point (n=3). Additionally, SLN measurements were corrected for the hydrolysis of
PEG6000MS, calculating the μmoles hydrolyzed using the SEC-determined molecular
weight and accounting for the free material present initially. In each case, a substantial
input of NaOH was required initially following CE exposure to return the pH to 7.4
followed by a slower addition over the long-term. During the initial phase, hydrolysis of
PS60 appeared slower in SLNs than micelles. The addition of PEG6000MS to the SLNs
appeared to retard hydrolysis even further. At later time points, the three curves become
linear. If only the second hour was plotted and fitted with a linear trend line, hydrolysis
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rates could be obtained: PS60 micelles, 0.0036 μmol/min; formulation 1 SLNs, 0.0087
μmol/min; formulation 2 SLNs, 0.0080 μmol/min.
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Figure 7.9. Hydrolysis of PS60 in SLNs and PS60 micelles as determined using the
pH-stat technique. All three samples were corrected for the addition of enzyme;
formulation 2 SLNs were also corrected for PEG6000MS hydrolysis (n=3).

To confirm that all FFAs produced were in the detectable ionized form, samples were
titrated to pH 9 following a 2 h incubation. There was no difference between samples
with and without BNPP (data not shown). To determine if enzyme was being inactivated
over time, PS60 micelle samples with and without BNPP were run as above but spiked
with additional PS60 at 1 h. Accounting for the general dilution effect using the BNPP
control, hydrolysis of the spiked PS60 was 75-95% of the initial addition.
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7.4.

DISCUSSION

Although many PEGylated nanoparticles have been described, relatively little research
has been conducted on the stability of PEG coatings [114, 220]. Most reports have
focused on the therapeutic outcome involved with the use of PEGylated nanocarriers
instead of the mechanism of degradation. However, loss of PEG from the surface of
nanoparticles may have profound implications for drug release and in vivo behavior.

Ester-containing PEGylating agents have long been used in nanoparticles, some of which
have achieved long circulation lifetimes and/or desirable therapeutic outcomes [228]. In
the cases where such results have not been achieved, it has typically been attributed to
suboptimal PEG surface coverage. However, as recent studies have described
nanoparticles designed to specifically release PEG in the presence of esterases [23], it is
possible that this may occur in other systems not specifically designed to do so. Loss of
surface PEG may explain the sub-optimal results observed for some nanoparticle drug
delivery systems.

As such, it was considered critical to evaluate the SLNs under study for their stability in
the presence of CE. Both PS60 and PEG6000MS contain potentially cleavable ester
bonds, and previous studies have shown that drug release from the SLNs was dependent
on the CE activity of the surrounding environment [37]. As it was anticipated that
cleavage of PEG from the surface of SLNs may result in particle instability (either from
particle breakdown or aggregation), preliminary studies were focused on observing
changes in particle stability due to the presence of CE. Turbidity studies clearly indicated
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a difference between SLNs incubated with and without CE. The addition of BNPPinhibited CE as a second control showed that the turbidity increase with CE was likely
due to hydrolysis of the ester bonds and not simply to a general protein effect. The
minimal increase in turbidity observed with the two control samples was likely a result of
the observed increase in particle size.

Interestingly, it was noted that the SLNs incubated with CE alone decreased in turbidity
following a major spike at 0.5 h. Although this could be due to precipitation, the samples
did not show visible signs of settling at this stage. This may instead be attributable to the
formation of other colloidal structures since the SLNs also have a non-ester-containing
surfactant, Brij® 78, which would not be hydrolyzed in the presence of CE.

As a second test of stability, the change in the particle size distributions of SLNs
incubated with and without CE and SLNs incubated with both CE and BNPP were
measured. SLNs remained detectable following exposure to CE, although the particle size
was smaller than the two controls. Based on this, it did not appear that aggregation was
occurring to a large extent. Instead, the produced FFAs may be released from the SLNs
or a portion of the SLNs may be disassociating completely. Again, due to the presence of
Brij® 78 and other unhydrolyzed surfactant, alternative colloidal structures may be
formed that allow for at least temporary solubilization of the free lipid material.
However, these would likely be dissolved during the dilution step necessary to achieve an
intensity reading within the instrument‟s range, leaving only intact SLNs. The SLNs may
then be smaller than the controls because a portion of the PEG has been cleaved from the
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surface or because the remaining SLNs had less of the ester-containing PEGylating
agents initially. Preparation of test batches containing SA with Brij® 78 only, SA with
Brij® 78 and PS60, and SA with Brij® 78, PS60, and free PEG6000 confirmed that
particles could be detected in all cases, with sizes ranging from 100-200 nm in diameter.

TEM analysis of the SLNs provided confirmation of the DLS results. While a similar
trend in size growth was seen between DLS and TEM images, the sizes obtained with
TEM were slightly larger than what was measured by DLS. This atypical result is
potentially a result of the non-spherical structure of the particles, which will give a
slightly larger hydrodynamic radius than a perfectly spherical particle [207].
Interestingly, the SLNs remaining following CE exposure appeared to have no major
morphological differences as compared to those without CE, although their image
backgrounds appeared slightly different. This may be attributed to the presence of the
free hydrolyzed materials in the SLN plus CE samples.

Based on these studies, it appeared that changes were occurring to SLNs incubated with
CE, and further study was warranted. Methods were developed to allow for the
measurement of the hydrolysis of each of the components separately. In each case,
hydrolysis of the material in SLNs was compared to hydrolysis of the material in micelle
form to determine if SLNs provided any protection against enzymatic cleavage.

The degradation of PEG6000MS was monitored using SEC. As no external standard was
available, a reference was prepared by hydrolyzing PEG6000MS with NaOH. Repeat
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measurements confirmed the complete hydrolysis of PEG6000MS, and chromatographic
peaks associated with the CE-hydrolyzed PEG6000MS were shown to appear with the
same retention time as NaOH-hydrolyzed PEG6000MS. Thus, all data obtained with CE
is expressed in reference to the NaOH-hydrolyzed PEG6000MS. A clear difference was
observed between SLNs pre-treated with BNPP prior to CE exposure and those not pretreated. Whereas untreated SLNs reached approximately 100% hydrolysis within 15 min,
the addition of BNPP appeared to completely inhibit hydrolysis of the PEG-ester bonds
in the SLNs.

In comparing degradation of PEG6000MS in SLNs and in micelles, we expected that
SLNs may offer some protection against hydrolysis. Previous NMR studies confirmed
that these nanoparticles exhibited the expected core-shell structure with the majority of
lipids (from stearyl alcohol as well as the hydrophobic portion of the surfactants and
PEGylating agents) solidified in the core [207]. Based on the solid nature of the particles,
it was assumed that CE would have limited access to the PEG6000MS ester bond, which
likely resides at the interface between the core of the nanoparticles and the PEGylated
surface. Interestingly, this was observed but only to a limited extent. The increase in free
PEG was more gradual with SLNs than micelles. For example, nearly 75% of
PEG6000MS in micellar form was hydrolyzed within 1 min of exposure to CE; this level
was not reached in SLNs until 10-15 min after exposure. However, the SLN advantage
was quickly negated, with both samples reaching nearly 100% hydrolysis within 15 min.
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Unfortunately, the low molecular weight of the PS60 degradation product prevented its
analysis using the available SEC system. The pH-stat technique, which relies upon the
analysis of FFAs produced instead of free PEG, was employed as an alternative method.
As FFAs were produced, a neutralizing basic solution was automatically added to the
solution in order to maintain a constant pH. The amount of NaOH added was reflective of
the amount of FFA formed by hydrolysis of PS60.

Again, a clear difference was observed between SLNs exposed to CE with and without
BNPP pre-treatment, with the NaOH addition being significantly greater in untreated
samples. There was no difference in the profiles obtained with pre-treated samples and
blank samples (CE added to 0.9% NaCl), providing a second confirmation that
PEGylating agents were susceptible to hydrolysis by CE. In order to better compare PS60
hydrolysis between SLNs and micelles, formulation 1 SLNs (containing PS60 but not
PEG6000MS) were also analyzed.

Interestingly, within 2 h, the hydrolysis for all samples was less than 40% of the total
predicted amount. This low amount could not be traced to a pKa issue or to enzyme
inactivation. Instead, it is assumed that this is attributable to the accessibility of the PS60
ester bond to attack. The rapid initial NaOH addition may be due to hydrolysis of free or
easily accessible PS60, of which there appears to be less in SLN samples than micellar
samples. The slower hydrolysis rates observed later may be associated with the
hydrolysis of PS60 in micelles or SLNs. During this stage, the hydrolysis of PS60 in the
SLN samples was more rapid than in micellar samples. This was unexpected and
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indicates that the PS60 micelles may pack such that the ester bond is protected from
enzymatic attack. However, the rate in SLNs was still quite slow.

These results were somewhat surprising based on the hydrolysis of PEG6000MS
discussed previously. Based on their structures, it was expected that PS60 and
PEG6000MS would align within SLNs in a similar manner, i.e., with the ester bonds of
both at the interface of the solid core of the SLNs and the PEGylated surface. If this
indeed were the case, they might be expected to display similar degradation patterns. Yet,
the hydrolysis of PEG6000MS occurred much more rapidly than the hydrolysis of PS60.
It is possible that the PS60 ester bond is integrated more extensively into the core of the
SLNs, providing it with greater protection against attack by CE. The addition of
PEG6000MS to the SLNs may thus provide another barrier against enzymatic attack,
explaining why hydrolysis in the SLN formulation containing PEG6000MS is even
slower than in the SLNs lacking PEG6000MS. CE may have to cleave PEG6000MS from
the surface of particles prior to attacking the PS60 ester bonds. Further, it was previously
proposed that the SLNs lacking PEG6000MS may be in a more fluid state at 37°C than
the SLNs containing PEG6000MS, thereby rendering enzymatic attack easier [207].
Alternatively, it may be the structure of PS60 itself that is less favorable to enzymatic
attack than PEG6000MS. As seen in Figure 7.1, PEG6000MS consists of a single linear
PEG chain, whereas PS60 is in effect a branched PEG chain. This structure may provide
more steric hindrance than the linear PEG chain in PEG6000MS.
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7.5.

CONCLUSIONS

SLNs were evaluated for their stability in the presence of CE, specifically in regard to
degradation of PS60 and PEG6000MS. Blank SLN suspensions were observed to become
extremely turbid within the first 30 min following exposure to CE indicating dissociation
or aggregation of at least a portion of the nanoparticles. The particle size of SLNs
incubated with CE was smaller than the size of controls at all time points studied, but
their morphologies appeared similar in TEM images taken following 1 and 24 h
incubations. Although SLNs offered some protection over micelles, PEG6000MS was
rapidly degraded within 15 min. In contrast, PS60 hydrolysis was much slower, reaching
only 36% in 2 h. Based on these results, it appears that the accelerated release of Dex
observed in the presence of CE may be partially attributable to increased accessibility of
the prodrug to enzymes following hydrolysis of the ester-containing materials PS60 and
PEG6000MS. On a broader scale, these studies reveal the importance of confirming the
stability of PEG surface coatings prior to undertaking in vivo experiments in small animal
models, which can have considerably higher plasma esterase activity than humans.

Copyright © Melissa Howard 2011
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Chapter 8
Optimization of the Lyophilization Process for Long-term Stability of Solid Lipid
Nanoparticles
8.1.

INTRODUCTION

Long-term storage stability can be considered as a final criterion for the development of a
nanoparticle drug delivery system. However, stability can be limited by a number of
factors when nanoparticles are stored as aqueous suspensions. Specifically with SLNs,
lipid crystallization and/or polymorphic transformations can lead to drug expulsion [136138]. Particles can grow via Ostwald ripening processes [34], and aggregation can lead to
gelation [142, 143]. Drug degradation can also occur [155, 229].

Lyophilization (freeze-drying) is one of the most effective means of improving both the
physical and chemical stability of SLNs. The process consists of three main steps:
freezing, primary drying, and secondary drying [230]. During the first step, water freezes
into ice crystals while excluding particles and any free material (the cryo-concentrated
phase). Both drying steps are conducted under vacuum. The primary drying step is
conducted at low temperatures, and it is during this phase that frozen water is removed
through sublimation. During the secondary drying phase, the temperature is raised to
remove any unfrozen water through desorption.

Unfortunately, both the freezing and drying steps can generate various stresses that may
destabilize nanoparticles. For example, the formation of ice crystals can induce
mechanical stress on the particles [231]. Freezing can lead to crystallization of PEG,
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reducing its ability to serve as a steric stabilizer and leading to particle fusion [230]. For
this reason, it is critically important to optimize the lyophilization process in order to
reduce these stresses. It can also be valuable to add excipients designed to protect the
nanoparticles from these stresses; such molecules are known as lyoprotectants (LPs).
Sugars are the most commonly used LPs, though various polymers have been used
successfully in some situations [230].

Several possible mechanisms have been proposed for the ability of LPs to prevent
destabilization of the nanoparticles. The particle isolation hypothesis is based on the
theory that particle aggregation is prevented simply by LPs spatially separating the
particles [230]. The water replacement hypothesis is based on the ability of LPs to
hydrogen bond with the components on the particle surface, effectively replacing water
as it freezes. This can maintain PEG in a pseudo-hydrated state and prevent chain
entanglement [230, 232]. The most popular theory, however, is the amorphous glass
theory. This theory states that the LPs partition into the cryo-concentrated phase during
the freezing process and then solidify into an amorphous glass around the particles. This
glassy matrix can subsequently protect the particles from fusion [231, 232].

This section was designed to develop an optimized lyophilization protocol for Dex-P
loaded SLNs, in terms of both the use of LPs and the lyophilization process itself.
Lyophilized SLNs will be tested for their redispersibility, which is defined as their ability
to be returned to their pre-dried state. Upon development of an optimized protocol, SLNs
will be evaluated for their long-term storage stability. Comparisons will be made between
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lyophilized SLNs and SLNs stored as aqueous suspensions and between storage at 4°C
and 25°C/60% RH.

8.2.

MATERIALS AND METHODS

8.2.1. Materials. SA, polyvinyl alcohol (PVA), and poly(vinylpyrrolidone) (Povidone
K-30, 40K average molecular weight; PVP) were obtained from Spectrum Chemicals and
Laboratory Products (Gardena, CA). PS60 and Brij® 78 were purchased from Uniqema
(Chicago, IL), and PEG6000MS was a gift from Stepan (Northfield, IL). Dex (USP) was
a gift from Pﬁzer (Kalamazoo, MI). ACN and MeOH were purchased from Fisher
Scientific (Pittsburgh, PA). HYDRANAL®-Coulomat AD, NaCl, fructose, glucose,
maltose, mannose, sucrose, and trehalose were from Sigma-Aldrich (St. Louis, MO).
Lactose was from Sheffield Bioscience (Norwich, NY, USA). PBS was from Invitrogen
(San Diego, CA). Water was obtained from a Milli-Q Synthesis ultrapure water system
(Millipore; Billerica, MA). Centrifugal ﬁlter devices (Amicon Ultra-0.5, Ultracel-10
Membrane, 10 kD) were purchased from Millipore (Billerica, MA).

8.2.2. Synthesis of Dex-P. The procedure to prepare Dex-P has previously been
reported [35]. Briefly, 300 mg Dex was dissolved in 12 mL pyridine to which 578 mg
palmitoyl chloride was added in a dropwise manner. The mixture was stirred in the dark
under nitrogen for 24 h. The solvent was evaporated using a stream of nitrogen, and the
dried product was dissolved in dichloromethane prior to loading onto a 30 mL silica gel
column.

The

purified

product

was

obtained

using

a

dichloromethane

to

dichloromethane:ethyl acetate (6:4 v/v) gradient elution. The reaction progress was
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monitored using silica gel TLC with a chloroform:ethyl acetate (7:3 v/v) mobile phase.
Retention factors for Dex and Dex-P were 0.10 and 0.69, respectively.

8.2.3. SLN Preparation. SLNs were prepared using NET as previously described [131].
The process consists of three steps: 1) melting an appropriate mixture of lipid,
surfactants, long-chain PEGylating agents, and drug; 2) adding a pre-heated aqueous
phase with stirring to generate an o/w microemulsion; and 3) cooling the microemulsion
to form a suspension of SLNs. For this study, microemulsions were prepared at 70°C in
order to ensure the melting of all components, and SLNs were cooled in a room
temperature water bath. The formulation composition was 1.6 mg/mL SA, 0.4 mg/mL
PS60, 2.8 mg/mL Brij® 78, and 3.0 mg/mL PEG6000MS. Where appropriate, Dex-P was
added at 0.16 mg/mL, or the equivalent of a 10% drug load (w/w comparison with SA).
SLNs designed for lyophilization were prepared in Milli-Q water, whereas SLNs
designed to be stored as aqueous suspensions were prepared in 0.9% NaCl. SLNs were
filtered using a 0.2 μm nylon membrane prior to lyophilization. SLNs were lyophilized
using an FTS Systems Dura-Dry MP/Dura-Stop MP lyophilizer System (SP Scientific,
Warminster, PA). Specific lyophilization protocols are described in detail below.

8.2.4. General SLN Characterization Techniques
8.2.4.1. DLS. Particle size and PI values were obtained using a Delsa™ Nano Zeta
Potential and Submicron Particle Size Analyzer (Beckman Coulter Inc., Brea, CA). All
measurements were performed at 25°C following a 1:30 dilution with Milli-Q water.
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8.2.4.2. Drug Loading and Encapsulation Efficiency. The following HPLC conditions
were used for determination of the Dex-P concentration: Alltech C18 column (5 μm, 250
mm×4.6 mm), 95:5 ACN:H2O mobile phase run at 2 mL/min, and UV detection at λ=240
nm. A standard curve was developed in the range of 10-200 μg/mL using three samples at
five concentrations (shown in chapter 5). Drug loading and encapsulation efficiency were
determined using a two-step process. Drug loaded SLNs were first filtered through a 0.2
μm nylon membrane to remove any unsolubilized drug. Filtered SLNs (termed MF) were
then ultrafiltered (Amicon YM-10, 10K MWCO) to remove free drug, and the retentate
was collected. One hundred microliters each of the initial, MF, and retentate samples
were diluted to 500 μL with MeOH, and 10 μL were injected onto the HPLC column.
Encapsulation efficiencies were calculated by comparing the amount of drug remaining
in the retentate to that in the initial sample.

8.2.5. Optimization of the Lyophilization Process
8.2.5.1. Effect of LP Type and Concentration: Freeze-thaw study. SLNs (1 mL) were
added to 7 mL vials containing potential LPs. Nine LPs (glucose, fructose, mannose,
trehalose, maltose, sucrose, lactose, PVA, and PVP) were tested at four concentrations:
0.5:1, 1:1, 2:1, and 5:1 (LP:SA weight ratio). An additional sample lacking any LP was
used as a control. Following an overnight freezing at -20°C, samples were thawed at
room temperature and evaluated for particle size/PI by DLS.

8.2.5.2. Effect of LP Type and Concentration: Lyophilization Study. SLNs (1 mL)
were added to 7 mL vials containing fructose, mannose, maltose, or sucrose. Four LP:SA
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ratios were used (5:1, 10:1, 15:1, and 20:1). Three samples were prepared per condition,
and an additional three control samples were prepared without LP. The following
lyophilization protocol was used: freezing at -40°C on a pre-cooled shelf for 2 h, primary
drying at -20°C for 24 h using a vacuum of 100 mTorr, and secondary drying at 20°C for
16 h using a vacuum of 100 mTorr. SLNs were reconstituted to their original volume
with Milli-Q water using manual shaking, and the particle size and PI were determined
by DLS.

8.2.5.3. Effect of SLN Concentration. SLNs were prepared at 1x, 5x, and 10x the
original concentration, i.e., the 1x, 5x, and 10x samples contain 1.6, 8, and 16 mg/mL
SA, respectively. Sucrose was added at either a 15:1 sucrose:SA weight ratio or at a fixed
2.4% w/v concentration (n=3 per condition). Lyophilization and reconstitution were
conducted as described above, and the particle size and PI were determined by DLS.

8.2.5.4. Effect of Secondary Drying Time. SLNs were lyophilized using a 15:1
sucrose:SA weight ratio. Lyophilized samples were reconstituted to the original volume
using Milli-Q water, and DLS was used for measurement of the particle size and PI
(n=3). The lyophilization protocol was as follows: freezing at -40°C for 2 h on a
precooled shelf, primary drying at -20°C for 24 h, and secondary drying at 20°C for
either 0, 8, or 16 h. A vacuum of 100 mTorr was used during both drying steps.

8.2.5.5. Effect of Freezing Temperature and Rate. SLNs were lyophilized using a 15:1
sucrose:SA weight ratio. Lyophilized samples were reconstituted to the original volume
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using Milli-Q water, and DLS was used for measurement of the particle size and PI
(n=3). For the evaluation of the temperature effect, temperatures of -20°C, -40°C, and 80°C were used in the 2 h freezing period; the rest of the lyophilization protocol was the
same as described above. In order to compare the rate effect, SLNs were either frozen at 20°C on a precooled shelf for 2 h (“fast” freeze) or placed on a room temperature shelf,
cooled to -20°C at a rate of 0.5°C/min, and then allowed to sit at -20°C for an additional
2 h (“slow” freeze). The primary and secondary drying conditions were the same as
described above.

8.2.5.6. Effect of Reconstitution Media. SLNs prepared in Milli-Q water were
lyophilized with a 15:1 sucrose:SA weight ratio. The lyophilization protocol was as
follows: freezing at -20°C on a precooled shelf for 2 h, primary drying at -20°C for 24 h
using a vacuum of 100 mTorr, secondary drying at 20°C for 16 h using a vacuum of 100
mTorr. SLNs were reconstituted to the original volume using either Milli-Q water, 0.9%
NaCl, or PBS. The effects on particle size and PI were determined by DLS (n=3).
Osmolality measurements (n=3) were performed using a Fiske 110 Osmometer
(Advanced Instruments, Inc., Norwood, MA, USA). The instrument was calibrated with
50, 290, and 850 mOsm/kg standards.

8.2.5.7. Effect of Drug Loading. SLNs loaded with 10% Dex-P and control blank SLNs
were lyophilized using a 15:1 sucrose:SA weight ratio. The lyophilization protocol was
as follows: cooling from room temperature to -20°C at 0.5°C/min, a 2 h hold at -20°C,
primary drying at -20°C for 24 h using a vacuum of 100 mTorr, secondary drying at 20°C
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for 16 h using a vacuum of 100 mTorr. SLNs were reconstituted to the original volume
using Milli-Q water, and the particle size and PI were determined using DLS (n=3).

8.2.5.8. Batch-to-Batch Variability. Three batches of SLNs with and without 10% DexP were lyophilized on separate days (n=3/batch). A sucrose:SA weight ratio of 15:1 was
used, and the lyophilization process was as follows: cooling from room temperature to 20°C at 0.5°C/min, a 2 h hold at -20°C, primary drying at -20°C for 24 h using a vacuum
of 100 mTorr, secondary drying at 20°C for 16 h using a vacuum of 100 mTorr. SLNs
were reconstituted to the original volume with Milli-Q water, and the particle size and PI
were measured by DLS.

8.2.5.9. Evaluation of the Optimized Lyophilized Product. Prior to reconstitution, the
lyophilizate was evaluated for water content using a Metrohm 684 Karl Fischer
coulometer equipped with a Metrohm 703 titration stand. Lyophilized SLNs (1-3 mg)
were dissolved in MeOH, and approximately 100 μL were added to the Karl Fischer
reagent (HYDRANAL®-Coulumat AD). Corrections were made for the presence of
water in the MeOH used to dissolve the samples. Following reconstitution, SLNs were
evaluated for the presence of large aggregates using a SALD-7101 Laser Diffraction
Particle Size Analyzer (Shimadzu Scientific Instruments, Columbia, MD, USA). To
achieve an appropriate signal intensity, SLNs were diluted 2x with Milli-Q H2O.
Reconstituted SLNs were also analyzed by TEM. Images were obtained using a Philips
Tecnai Biotwin 12 equipped with a Gatan ES 1000W CCD digital camera (FEI,
Hillsboro, OR). A drop of sample (7 µL) was incubated for 1.5 min on a carbon coated
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TEM grid. The grid was then dried and stained with 0.2 μm filtered 2% uranyl acetate for
an additional 1.5 min. Excess stain was removed, and the grid was allowed to dry for 5
min prior to imaging. Drug loaded SLNs were also evaluated for encapsulation efficiency
using the methods described above.

8.2.6. Stability Study. A 3 month stability study was conducted comparing 10% Dex-P
loaded SLNs lyophilized prior to storage with those stored as aqueous suspensions.
Lyophilization was conducted as follows: cooling from room temperature to -20°C at
0.5°C/min, a 2 h hold at -20°C, primary drying at -20°C for 24 h using a vacuum of 100
mTorr, secondary drying at 20°C for 16 h using a vacuum of 100 mTorr. A 15:1
sucrose:SA weight ratio was used. All vials were stoppered and crimped for storage.
SLNs were stored under two conditions: 4°C or 25°C/60% relative humidity (RH). A
saturated sodium bromide solution was used to control the RH [233]. At select time
points [days 0, 1, 3, 7, 14, 28 (1 mo), 59 (2 mo), and 89 (3 mo)], SLNs were removed
from storage for analysis (3 vials/condition). Lyophilized SLNs were reconstituted to
their original volume (1 mL) with 0.9% NaCl, and all samples were tested for changes in
the particle size/PI and encapsulation efficiency. These experiments were conducted as
described above, with the exception that for samples that showed a particle size > 200
nm, one of the three replicates was filtered with a 0.45 μm nylon filter instead of a 0.2 μm
nylon filter. This was done in an attempt to differentiate between drug loss due to the
filtration of large particles and drug loss due to removal of unsolubilized drug. However,
no differences were observed between the two filtration methods, and as such, data from
all three samples were used in calculating average values.
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8.2.7. Statistical Analysis. All data is presented as the mean ± SD of three independent
measurements. For comparison of only two data sets, a t-test (paired two sample for
means) was utilized. For comparison of 3 or more data sets, an analysis of variance
(ANOVA, single factor) was performed. Results are considered statistically significant at
a level of p<0.05.

8.3.

RESULTS AND DISCUSSION

8.3.1. Optimization of the Lyophilization Process
8.3.1.1. Effect of LP Type and Concentration. In order to avoid numerous timeconsuming lyophilization procedures, possible LPs were first evaluated by a freeze-thaw
study. If the tested excipients are unable to provide protection against aggregation during
the first step of the lyophilization protocol, i.e., freezing, they are unlikely to be suitable
LPs. Based on previous literature reports [230], nine excipients were chosen for study: 3
monosaccharides (glucose, fructose, and mannose), 4 disaccharides (trehalose, maltose,
sucrose, and lactose), and 2 polymers (PVA and PVP). Each excipient was tested at four
different concentrations, all expressed as LP:SA weight ratios: 0.5:1, 1:1, 2:1, and 5:1.
Following freezing at -20°C overnight, SLNs were thawed and evaluated for changes in
the particle size and PI (Figure 8.1). In general, higher concentrations of excipient led to
smaller increases in the particle size. It was observed that the two polymers were clearly
the least effective in maintaining the particle size. Even at the highest concentrations,
particles increased from approximately 95 nm to over 130 nm. Performance was better
with the sugars, although there was no clear difference between the mono- and
disaccharides. PI values followed a similar trend. As such, the two best performers from
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each sugar category were chosen for a full lyophilization study: fructose and mannose for
the monosaccharides and sucrose and maltose for the disaccharides. At the highest
concentrations, particle size increases were <10 nm and changes in the PI were negligible

Particle Size (nm)

with these excipients.
160.0
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2:1 LP:SA

5:1 LP:SA

0.200
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0.150
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Figure 8.1. The effect of various LPs on the change in particle size (top) and PI
(bottom) following an overnight freezing at -20°C and subsequent thawing.
Excipients include 3 monosaccharides (glucose, fructose, and mannose), 4
disaccharides (trehalose, maltose, sucrose, and lactose), and 2 polymers (PVA and
PVP). Each excipient was tested at four concentrations, all expressed in reference to
SA (LP:SA weight ratio): 0.5:1, 1:1, 2:1, and 5:1. The bottom dotted line represents
the original SLN condition: 95.5 nm and a PI of 0.047. The top dotted line
represents the condition of SLNs frozen without any LP: 142.1 nm and a PI of 0.167.
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Based on the trend of decreasing particle size with increasing LP concentration observed
in the freeze-thaw study, higher concentrations were chosen for the lyophilization study.
LP:SA ratios began at the 5:1 ratio used in the previous study and were raised to 10:1,
15:1, and 20:1. A basic lyophilization protocol was chosen for use: freezing at -40°C for
2 h on a precooled shelf, primary drying at -20°C/100 mTorr for 24 h, and secondary
drying at 20°C/100 mTorr for 16 h. In this study, disaccharides were shown to better
maintain the particle size and PI values of SLNs than monosaccharides (Figure 8.2).
Specifically with fructose, particle size increases were large and variable. PI values were
also higher (>0.2) than disaccharide samples (0.1-0.2). This is consistent with previous
studies in which the use of disaccharides has been shown to be advantageous [146, 234].
It is thought that this is due to the ability of the disaccharides to solidify in an amorphous
state while the monosaccharides crystallize upon freezing. Crystallization may decrease
the ability of the excipient to interact with the SLNs and limit its ability to prevent
aggregation.
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Figure 8.2. The effect of various LPs on the change in particle size (top) and PI
(bottom) following lyophilization. Excipients included 2 monosaccharides (mannose
and fructose) and 2 disaccharides (sucrose and maltose). Each excipient was tested
at four LP:SA weight ratios: 5:1, 10:1, 15:1, and 20:1 (n=3). The bottom dashed line
represents the initial SLN condition: 96.2 nm and a PI of 0.092. The top dashed line
represents the condition of SLNs lyophilized without LP: 207.0 nm and a PI of
0.212.
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Interestingly, increases in the LP concentration were not as clearly advantageous in the
lyophilization study as they were in the freeze-thaw study. Sucrose was the only LP that
showed a smaller particle size increase with higher concentration, and the reduction upon
going from the 15:1 ratio to the 20:1 ratio was minimal. With all other LPs, there
appeared to be a destabilization of the particles with higher LP concentrations (15:1 with
fructose and maltose and 20:1 with mannose). This was somewhat surprising as most
studies have reported that increasing the excipient concentration improves the
maintenance of particle size [216, 235, 236]. However, there have been at least some
reports of destabilization with higher LP concentrations [237, 238]. Unfortunately, there
is currently a lack of understanding regarding what controls this. As has been reported,
the most important parameter is the concentration of LP in the cryo-concentrated phase,
which is determined by a competition between the diffusion rate of LP molecules and the
freezing rate [231]. If diffusion of the LP molecules is limited (for example, because of
high viscosity), the LP may be retained in the bulk frozen state as opposed to entering the
cryo-concentrated phase. It may be that there is a certain critical LP concentration at
which the freezing rate becomes faster than the diffusion step, and particle aggregation
results. Alternatively, it has been proposed that the sugar molecules hydrogen bond with
the PEGylated surfaces of nanoparticles [230], and it is possible that at high
concentrations, this could lead to particle bridging.

Based on these studies, sucrose at a LP:SA ratio of 15:1 was chosen as the optimal LP
concentration. This equates to 2.4% w/v and is a considerably lower LP concentration
than has been used with numerous other nanoparticle systems [232, 239]. Under these
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conditions, particles increased in size by <17% and remained within a size range
appropriate to take advantage of the EPR effect [29]. Although the particle size
distribution broadened, it also remained within the range of PI values (PI<0.3) considered
acceptably monodisperse [240, 241]. Additional studies were aimed at optimizing the
lyophilization protocol in order to potentially limit changes to an even greater degree.

8.3.1.2. Effect of SLN Concentration. It has previously been observed with polymeric
nanoparticles that a higher nanoparticle concentration can lead to improved
redispersibility following reconstitution [242]. To determine whether this was the case
with the SLN system under consideration, nanoparticles were prepared at 1x, 5x, and 10x
the original concentration, lyophilized, and evaluated for particle size changes. Results
are shown in Table 8.1. Surprisingly, only the 1x SLN sample could be easily
reconstituted. All other samples remained cloudy, despite showing relatively small
particle sizes. This may be partially attributed to the dilution step required for particle
size measurement, during which large aggregates may dissolve. For comparison, the 5x
and 10x samples were diluted to the 1x concentration and re-analyzed, but the results
were not improved. Finally, to determine if it was the overall sucrose concentration and
not the LP:SA ratio that led to good redispersibility, SLNs prepared at 5x and 10x were
lyophilized in the presence of 2.4% w/v sucrose and evaluated for particle size changes.
In this case, the samples were very cloudy following reconstitution, and the particle size
increases were larger. The higher SLN concentrations may prevent the formation of the
protective amorphous shell around the nanoparticles, possibly for similar reasons to those
described earlier with higher LP concentrations. Results may be improved by using lower
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SLN concentrations, but this would be undesirable for achieving a sufficiently high drug
dose.

Table 8.1. Effect of SLN concentration on redispersibility
15:1 LP:SA Ratio +
Initial
15:1 LP:SA Ratio
2.4% LP
Dilution
SLN
Concentration Particle
Visual
Particle
Visual
Particle
Visual
Particle
Visual
size (nm) Appearance size (nm) Appearance size (nm) Appearance size (nm) Appearance
1x
97.8
clear
116.4±1.6
clear
N/A
N/A
N/A
N/A
5x
98.4
clear
125.6±2.7 cloudy 123.5±4.6 cloudy 180.1±17.0 very cloudy
10x
102.3
clear
154.5±10.3 cloudy 161.1±17.1 cloudy 424.7±108.1 very cloudy

8.3.1.3. Effect of Secondary Drying Time. The effects of the secondary drying time on
the particle size and PI of the SLNs are shown in Figure 8.3. No clear trend was evident,
with the 8 h drying time resulting in slightly higher (though not statistically significant,
P>0.05) particle size increases and PI values than that of either the 0 h or 16 h drying
time. The smallest average values were obtained for the 16 h drying time. Based on this
data and a desire to ensure the least residual moisture content, a 16 h secondary drying
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time was chosen for further studies.
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Figure 8.3. The effect of secondary drying time on the particle size and PI of SLNs
following lyophilization in the presence of a sucrose:SA 15:1 weight ratio (n=3)
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8.3.1.4. Effect of Freezing Temperature and Rate. The effects of freezing temperature
and rate were evaluated together because they are inherently related. Lower freezing
temperatures lead to faster freezing rates. However, to attempt to separate the two effects,
three different temperatures were tested initially, and then direct comparisons were made
between two different freezing methods at the “optimal” temperature. A clear trend in the
redispersibility of the SLNs was observed with freezing temperature when the fast freeze
method was employed (Figure 8.4). As the temperature decreased, both the particle size
and PI increases became larger. With a -20°C freeze, the particle size increased by only
12.4±2.0%, and the average PI was 0.177±0.025. For comparison, samples were then
frozen to -20°C using a slow freeze and evaluated for redispersibility (Figure 8.5).
Although the fast freeze samples trended toward a smaller particle size, the difference
was not statistically significant (p>0.05). On the other hand, the slow freeze samples
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exhibited a statistically significant smaller PI value (p<0.05).

-80

Freezing Temperature (°C)
Figure 8.4. The effect of freezing temperature on the particle size and PI of SLNs
following lyophilization in the presence of a sucrose:SA 15:1 weight ratio (n=3)

160

0.300
0.250
0.200
0.150

PI

Particle Size Increase (%)

20.0%
18.0%
16.0%
14.0%
12.0%
10.0%
8.0%
6.0%
4.0%
2.0%
0.0%

0.100
0.050
0.000
Fast

Slow
Freezing Rate

Figure 8.5. The effect of freezing rate (-20°C freeze) on the particle size and PI of
SLNs following lyophilization in the presence of a sucrose:SA 15:1 weight ratio
(n=3)
These results were again somewhat surprising in light of other literature reports. Most
studies have reported an improvement in redispersibility with lower temperatures and
faster freezing rates [231, 232, 242, 243]. This is primarily because a faster freezing rate
should result in smaller ice crystals that result in less mechanical stress on the particles.
However, if the freezing rate is too fast to allow partitioning of the LP molecules into the
cryo-concentrated phase, this benefit may be negated, as it apparently is with these SLNs.
Overall, it appeared clear that better redispersibility could be obtained with a -20°C
freezing temperature, and that although a slower freezing rate at that temperature did not
significantly affect the particle size change, it may reduce the change in the particle size
distribution (PI of 0.117±0.043 for slow freeze vs PI of 0.177±0.025 for fast freeze).

8.3.1.5. Effect of Reconstitution Media. Although SLNs could be reconstituted with
water, it may be preferable to use alternative solutions for reconstitution, either for
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certain lab situations or to satisfy clinical requirements. For example, a 2.4% w/v sucrose
solution would be considered hypo-osmotic and may be unsuitable for injection. For this
reason, SLNs reconstituted in H2O, 0.9% NaCl (used commonly for reconstitution in
clinical situations), and PBS (used commonly in lab situations to mimic physiological
conditions) were compared (Table 8.2). No difference was observed among the particle
size and PI values for the three solutions as determined by ANOVA, indicating that a
variety of solutions could be used for reconstitution without significantly impacting the
properties of the SLNs. Specifically, samples reconstituted with 0.9% NaCl were slightly
hyperosmotic but remained within a clinically relevant range [244].

Table 8.2. Effect of the reconstitution media on SLN properties
Reconstitution
Media
H2O
0.9% NaCl
PBS

Size (nm)

PI

101.6±1.8 0.177±0.025
104.2±4.3 0.171±0.027
102.0±2.3 0.223±0.020

Osmolality
(mOsm/kg)
74.8±1.1
350.9±2.2
382.8±4.0

8.3.1.6. Effect of Drug Loading. Drug loading has been shown to significantly impact
nanoparticle redispersibility in some situations [239] but not in others [245]. The
difference was primarily attributed to the presence of free drug in solution. As Dex-P
loaded SLNs typically display very high encapsulation efficiencies (only 1-2% free drug
following 0.2 μm filtration), this was not expected to be a limiting factor. However, in
experiments designed to test this, it was observed that SLNs loaded with 10% Dex-P w/w
SA showed slightly larger particle size increases and slightly higher PI values than blank
SLNS (Figure 8.6). This may be a result of the small amount of free drug present in
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solution or to a difference in the surface properties of the SLNs with drug loading. Either
way, the changes with drug loading are not expected to impair the ability of the SLNs to
function as a drug delivery system. With the 22.50% increase in particle size, the particle
size increased only to 123.2±0.8 nm, which is well within the 200 nm size limit
considered appropriate for taking advantage of the EPR effect [29]. The PI also remained
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within a range considered suitably monodisperse [240, 241].
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Figure 8.6. The effect of drug loading on the particle size and PI of SLNs following
lyophilization in the presence of a sucrose:SA 15:1 weight ratio (n=3)

8.3.1.7. Batch-to-Batch Variability. Although intra-batch variability was minimal as
evidenced by the standard deviations given above, it was important to evaluate batch-tobatch variability. As shown in Table 8.3, batches of both blank and 10% Dex-P loaded
SLNs prepared on different days using the same protocol appeared to be of similar
quality. ANOVA tests revealed no statistically significant differences in either the
particle size or PI of SLNs prepared on different days (p>0.05).

163

Table 8.3. Batch-to-Batch variability
Day
1
2
3

Particle Size Increase (%)
PI
Blank
10% Dex-P
Blank
10% Dex-P
15.22±1.61% 22.50±0.81% 0.133±0.012 0.181±0.023
15.16±4.18% 24.22±1.80% 0.117±0.043 0.161±0.009
14.91±1.39% 27.50±0.83% 0.171±0.027 0.152±0.046

8.3.1.8. Evaluation of the Optimized Lyophilized Product. Lyophilized products were
shown to have a low water content of 1.09±0.12%, a value considered acceptable for
lyophilized pharmaceuticals [246]. Following reconstitution, SLNs were evaluated for the
presence of large aggregates by laser diffractometry (LD) and for shape changes by TEM.
Although DLS is preferable for analyzing particles in the nanometer range, it has a
limited range of analysis for particles in the micrometer or millimeter range. For
example, the Delsa™ Nano instrument used in these studies has an analytical range of 0.6
nm-7 μm. LD can be used as a complementary technique for evaluation of larger
particles; the Shimadzu SALD-7101 instrument used in these studies was designed to
study particles in the range of 0.01-300 μm. Both blank and drug-loaded SLNs appeared
monodisperse with median diameters (D50%) of 247 and 257 nm, respectively.
Representative particle size distributions are shown in Figure 8.7. The different particle
sizes obtained from the two techniques can be explained by the different measurement
principles. Of relevance for this study is that large aggregates did not appear to be present
to any significant extent. Analysis of the reconstituted SLNs by TEM further indicated
that the particle shape was maintained throughout the lyophilization and reconstitution
process (Figure 8.8).
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Figure 8.7. Representative particle size distributions obtained by laser
diffractometry of SLNs following lyophilization and reconstitution (Blank SLNs,
top; 10% Dex-P loaded SLNs, bottom)
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Figure 8.8. Representative TEM images of blank (left) and 10% Dex-P loaded SLNs
(right) following lyophilization and reconstitution

Finally, drug loaded SLNs were evaluated for encapsulation efficiency. A number of
studies have shown drug loss upon lyophilization as a result of lipid crystallization or
phase transitions [235, 247]. However, this was not observed to any significant extent
with the Dex-P loaded SLNs. Drug was shown to remain predominately associated with
SLNs (97.98±1.83% retention), confirming that SLNs could be lyophilized using this
protocol with minimal changes to the physicochemical properties of the nanoparticles.

8.3.2. Stability Study. Once the lyophilization protocol was optimized to minimize
changes in the physicochemical properties of the SLNs, lyophilized SLNs were evaluated
for stability over a 3 month time period. Two possible storage conditions were tested
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(4°C and 25°C/60% RH), and comparisons were made with SLNs stored as aqueous
suspensions. Particle size and PI data are shown in Figures 8.9 and 8.10. The most
significant particle size growth was observed with the aqueous suspensions stored at
25°C/60% RH. With the particle size reaching nearly 500 nm within 3 months, the
system would be considered unacceptable for use as a tumor-targeted drug delivery
system in most cases. SLN suspensions stored at 4°C also showed growth, but it was
much less than that observed at 25°C/60% RH. The particle size increased <40 nm,
remaining well within the recommended 200 nm limit [29]. On the contrary, lyophilized
SLNs showed greater consistency in their particle size measurements. The particle size of
lyophilized SLNs stored at 4°C was maintained across the entire time period of the study.
Lyophilized SLNs stored at 25°C/60% RH were stable up to 1 month prior to showing a
slight increase in the particle size. In terms of PI values, all remained <0.3, generally
considered the acceptable limit of monodispersity [240, 241]. However, increases were
also observed over the 3 month time period with all conditions. Although the lowest
absolute values were obtained with the aqueous suspension stored at 4°C, the increase
over the time period of the study was smallest with the lyophilized SLNs stored at 4°C.

167

600.0

0.350

500.0

0.300
0.250

400.0

0.200

300.0

0.150

200.0

PI

Particle Size (nm)

Lyophilized 4°C

0.100

100.0

0.050

0.0

0.000
0

20

40

60

80

100

Time (d)

600.0

0.350

500.0

0.300
0.250

400.0

0.200

300.0

0.150

200.0

PI

Particle Size (nm)

Lyophilized 25°C/60% RH

0.100

100.0

0.050

0.0

0.000

0

20

40

60

80

100

Time (d)
Figure 8.9. Changes in the particle size and PI of lyophilized SLNs stored at either
4°C or 25°C/60% RH over a 3 month time period (n=3)
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Figure 8.10. Changes in the particle size and PI of SLNs stored as aqueous
suspensions at either 4°C or 25°C/60% RH over a 3 month time period (n=3)
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In analyzing the drug loading, the first step was to confirm that the drug concentration in
the samples remained stable across the time period of the study (Figure 8.11). Comparing
drug concentrations of each sample to the day 0 sample, it appeared that virtually 100%
of the drug remained in the Dex-P form with no noticeable hydrolysis. Following this
confirmation, it was then necessary to determine how much Dex-P remained associated
with the SLNs. A two-step process was used in which any unsolubilized drug is removed
by 0.2 μm (or 0.45 μm) filtration and free drug is removed by ultrafiltration. Figures 8.12
and 8.13 provide information regarding the drug retention following each step. The data
generally echoed that observed with the particle size changes. SLNs stored as aqueous
suspensions at 25°C/60% RH exhibited the most significant drug loss. This drug loss was
consistent across the entire time period, with the exception of the final time point.
Interestingly, the other three samples seemed to exhibit a “plateau” encapsulation
efficiency in the range of 75-80%. However, they differed in how long it took to achieve
this plateau, how long the plateau was maintained, and whether the drug loss was
primarily associated with the 0.2 μm filtration step or the ultrafiltration step. Aqueous
suspensions stored at 4°C showed decreasing encapsulation efficiency up to 2 weeks and
then remained approximately consistent at 75%. Lyophilized SLNs stored at 4°C showed
a drop in encapsulation efficiency at the 3 day mark but then remained at approximately
80% encapsulation efficiency. Results with the lyophilized SLNs stored at 25°C/60% RH
were similar but could not be maintained. As the particle size began to increase following
1 month of storage, drug loss was also accelerated. With both sets of lyophilized samples,
drug loss due to the 0.2 μm filtration step was fairly consistent and less than that lost
during the ultrafiltration step. The trend was opposite with the samples stored as aqueous
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suspensions with the drug loss being predominantly controlled by the 0.2 μm filtration
step. The difference may be associated with Dex-P exhibiting varying solubility in the

Drug Concentration (% of Day 0)

presence and absence of sucrose, as has been observed with other compounds [248].
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Figure 8.11. Stability of drug concentration in SLN samples over a 3 month time
period (n=3)
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Figure 8.12. Changes in the drug encapsulation efficiency of lyophilized SLNs stored
at either 4°C or 25°C/60% RH over a 3 month time period (n=3). Data is expressed
as % drug retention and is separated into the Dex-P concentration found in the 0.2
μm filtrate (MF) and the retentate collected following ultrafiltration.
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Figure 8.13. Changes in the drug encapsulation efficiency of SLNs stored as aqueous
suspensions at either 4°C or 25°C/60% RH over a 3 month time period (n=3). Data
is expressed as % drug retention and is separated into the Dex-P concentration
found in the 0.2 μm filtrate (MF) and the retentate collected following
ultrafiltration.
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Overall, lyophilized SLNs stored at 4°C seemed to exhibit the greatest stability. Based on
the slight decrease in encapsulation efficiency, there appeared to be some restructuring of
the particle. However, this did not affect the particle size, and once it was complete, the
encapsulation efficiency remained constant throughout the rest of the study. Further, with
a size of approximately 130 nm and an encapsulation efficiency of around 80%, SLNs
stored under these conditions could be considered suitable for use as tumor-targeted drug
delivery system.

8.4.

CONCLUSIONS

In this section, an optimized protocol for lyophilization of SLNs was developed, and
comparisons were made between the long-term stability of aqueous and lyophilized
SLNs. Of nine possible lyoprotectants tested, sucrose was shown to provide the best
particle redispersibility. Specifically, a 15:1 sucrose:SA weight ratio was chosen based on
the minimal increase in particle size and PI observed with this condition. A series of
experiments also showed that better redispersibility could be obtained using lower SLN
concentrations, higher freezing temperatures, slower freezing rates, and longer secondary
drying times. The choice of reconstitution media was shown to have a negligible effect
on the particle redispersibility. Larger particle size and PI increases following
lyophilization were observed with drug loaded SLNs, but both parameters remained
within an acceptable range for a tumor-targeted nanoparticle drug delivery system.
Encapsulation efficiency and particle shape were maintained following lyophilization,
and no large aggregates could be detected. Lyophilized SLNs stored at 4°C exhibited the
greatest stability during the 3 month study. Particle size was maintained across the entire
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time period. A slight reduction in encapsulation efficiency was observed within the first 3
days of storage but then remained consistent at approximately 80%.

Copyright © Melissa Howard 2011
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Chapter 9
Summary and Conclusions

The guiding hypothesis for this dissertation was that the interactions among the
components of SLNs decrease the crystallinity of nanoparticle lipids resulting in
enhanced drug loading and decreased nanoparticle stability. To this end, the following
specific aims were identified: 1) to fully characterize nanotemplate engineered SLNs for
their physicochemical properties including particle size, shape, structure, and changes in
the extent or type of crystallinity from the starting materials due to interactions among the
nanoparticle components, 2) to assess the degree of loading of Dex-P into nanotemplate
engineered SLNs compared to other compounds of similar structure or lipophilicity, 3) to
evaluate the stability of nanotemplate engineered SLNs in conditions mimicking those of
human plasma as a function of time, 4) to determine if the PEGylating agents
incorporated into SLNs are affected by the CE activity of the surrounding environment,
and 5) to determine if the storage stability of drug loaded SLNs is enhanced when using
lyophilization protocols that minimize changes in the physicochemical properties of the
nanoparticles.

Based on early work from this laboratory, two formulations were chosen for evaluation.
SA was used as the lipid phase with Brij® 78 and PS60 as surfactants in both
formulations; the second formulation differed by the inclusion of a long-chain
PEGylating agent, PEG6000MS. Both formulations exhibited a particle size of <100 nm,
an ellipsoidal shape, and low polydispersity. SLNs were shown to have the expected solid
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core structure and PEGylated surface based on 1H-NMR spectroscopy. Analysis of the
bulk materials indicated that a number of complex interactions are present among the
SLN components, including a eutectic between SA and Brij® 78. Unfortunately, the low
melting point of the eutectic was shown to limit the physiological stability of the SLNs,
specifically in the formulation lacking PEG6000MS. For this reason, formulation 2 SLNs
in which PEG6000MS was included, were chosen for further studies.

Following this choice of formulation, SLNs loaded with Dex-P were prepared and
evaluated for changes in their physicochemical properties. High drug loadings of up to
30% w/w SA could be obtained while maintaining drug encapsulation efficiencies >85%.
The core-shell structure of the particles was maintained at all drug loadings, and although
particle size was shown to increase with drug concentration, it remained within the size
range considered suitable for tumor-targeting by the EPR effect.

Interestingly, a

transition from ellipsoidal- to rod-shaped particles was observed at the 30% drug loading.
Analysis of the drug-matrix interactions by DSC indicated that Dex-P likely resided at
the core-shell interface with the palmitate chain serving to anchor the drug within the
solid SA and Dex interacting with the SA-Brij® 78 phase. A small burst release of Dex-P
(<20%) was observed within the first 3 h of incubation at 37°C followed by a slower
release over the remaining time period. For comparison, AP and curcumin were also
evaluated for their extent and mechanism of drug loading as well as for their effects on
SLN properties. AP interacted more favorably with the SA-PEG6000MS phase than with
the SA-Brij® 78 eutectic but seemed to adopt a similar conformation to Dex-P, allowing
for high drug loadings. The drug loading of curcumin was more limited, and its release
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from the SLNs was faster than Dex-P. This difference was attributed to the lack of
interaction between curcumin and the solid SA phase of the particle. From this data, it
appears that these SLNs have a great potential for high drug loading based on the
decreased crystallinity of SA described above. However, this potential is modulated by
the ability of the drug to interact with the SLN components, which may be correlated
with its structure.

Previous studies indicated that drug release from the SLNs was dependent on the CE
activity of the surrounding environment. However, additional studies were required to
evaluate the stability of the nanoparticles in both the presence and absence of CE activity.
When incubated at 37°C in the absence of protein, SLNs increased in diameter by
approximately 40 nm within a 24 h time period but appeared to retain their ellipsoidal
shape. Analysis of SLNs incubated with 10% HSA by DLS, UV/Visible spectroscopy,
and SEC indicated the possibility of minor protein adsorption on the particles, but no
evidence of particle disassociation or aggregation was observed. Although Dex-P
association with SLNs was slightly lower in the presence of 50% human plasma than in
PBS alone (85.5%<96.2% at 24 h), it appeared that the majority of enzymatic drug
release was taking place at the surface of the SLNs.

Interestingly, even in the absence of Dex-P, SLNs demonstrated some instability in the
presence of CE that could be attributed to hydrolysis of the PEG-ester compounds. Blank
SLN suspensions became extremely turbid within the first 30 min following exposure to
CE indicating dissociation or aggregation of at least a portion of the nanoparticles. The
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particle size of SLNs incubated with CE was smaller than the size of controls at all time
points studied, although particle shape appeared similar as determined by TEM images
taken following 1 and 24 h incubations. Although SLNs offered some protection over
micelles, PEG6000MS was rapidly degraded within 15 min. PS60 hydrolysis was much
slower, reaching only 36% in 2 h. These results indicated that the accelerated release of
Dex observed in the presence of CE may be partially attributable to increased
accessibility of the prodrug to enzymes following hydrolysis of the ester-containing
materials PS60 and PEG6000MS.

During the last stage of this project, a lyophilization protocol designed to minimize
changes in the physicochemical properties of the SLNs was developed, and the long-term
storage stability of SLNs was evaluated. Sucrose was shown to provide the best particle
redispersibility among the nine lyoprotectants that were evaluated. Specifically, a 15:1
weight ration of sucrose:SA was chosen based on the minimal increase in particle size
and PI observed with this condition. Lower SLN concentrations, higher freezing
temperatures, slower freezing rates, and longer secondary drying times were also shown
to contribute to better redispersibility. A variety of both lab and clinically relevant
solutions could be used to reconstitute the SLNs with negligible effects on the
physicochemical properties of the particles. Larger particle size and PI increases
following lyophilization were observed with drug loading, but both parameters remained
within an acceptable range for a tumor-targeted nanoparticle drug delivery system.
Changes in the encapsulation efficiency and particle shape following lyophilization were
minimal. Also, no large aggregates were produced during the process. During the 3
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month stability study, comparisons were made between lyophilized SLNs and SLNs
stored as aqueous suspensions and between SLNs stored at either 4°C or 25°C/60% RH.
The greatest stability was observed with lyophilized SLNs stored at 4°C. Particle size
was maintained across the entire time period, and encapsulation efficiency was shown to
be consistent at 80% following a reduction to this value within the first 3 days of storage.

The results of these studies support the proposed hypothesis. The interactions among the
SLN components were shown to result in decreased crystallinity of the lipid phase. This
was advantageous in terms of achieving a high drug load but did have negative
ramifications in terms of the stability of the particles. However, for practical
considerations, the stability of the SLNs could be improved by adjustments to the
formulation (e.g., the addition of PEG6000MS and the reduction in the Brij® 78
concentration) and storage conditions (e.g., lyophilization). Further, instability in the
presence of CE likely contributed to the accelerated drug release observed in CEcontaining media and may be used as a trigger for achieving bioresponsive drug release.

In conclusion, this work yielded valuable information in regard to both the drug delivery
system under study and nanoparticles in general. Several observations were reported with
the nanotemplate engineered SLNs that may be of relevance to other nanoparticle
systems. For instance, the in-depth crystallinity analysis led to the discovery of complex
interactions among the SLN components that have a major effect on the particle behavior.
This points to the importance of analyzing bulk materials in order to identify potential
issues that may arise with the nanoparticles (e.g., physiological stability) prior to
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performing expensive and time-consuming in vitro or in vivo studies. It is also possible
that these interactions may be utilized advantageously in other systems. The drug loading
analysis provided information regarding the mechanism of drug packing within SLNs and
outlined some tools that may be utilized to predict how and to what extent drugs can be
loaded into SLNs. As another example, evidence of instability of the ester-containing
PEG compounds in the presence of CE may provide an explanation for the poor in vivo
results observed with other PEG-coated nanoparticle systems. It also provides
justification for evaluating such stability prior to undertaking animal studies.

In terms of the drug delivery system itself, SLNs could be prepared using formulation 2
with desirable physicochemical properties and sufficient stability to warrant further
development. Future studies must be aimed at determining the biodistribution and
therapeutic efficacy of these SLNs in vivo. Due to the hydrolysis of Dex-P as well as the
ester-containing PEGylating agents in the presence of CE, alternative animal models
must be employed for these studies. Currently, the most feasible option seems to be the
carboxylesterase-deficient Es1e(-/-)/SCID mouse model. Although drug was still released
to a greater extent in the plasma from these animals than from human plasma, it is likely
to be the most closely representative situation of the small animal models. Further, if
results could be shown to be improved using this animal model as compared to normal
mice or rats, it would provide validation for the CE-triggered drug release and give
confidence that results in humans would be improved to an even greater extent.

Copyright © Melissa Howard 2011
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Appendices

This section contains the following additional information:

Appendix A: Abbreviations
Appendix B: Analytical Techniques
Appendix C: Surfactant Micelle Evaluation
Appendix D: Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable
Release of Dexamethasone

182

Appendix A
Abbreviations

Throughout this dissertation, abbreviations are given following the first use of a word or
phrase. However, for convenience, Table A.1 includes an alphabetical list of the
commonly used abbreviations.

Table A.1. Abbreviations
AA
Ascorbic acid
ACN
Acetonitrile
AP
Ascorbyl palmitate
BNPP
Bis(4-nitrophenyl) phosphate
CE
Carboxylesterase
CHCl3/CDCl3
Chloroform/Deuterated chloroform
Dex
Dexamethasone
Dex-P
Dexamethasone palmitate
DLS
Dynamic light scattering
DSC
Differential scanning calorimetry
EPR
Enhanced permeability and retention
FFA
Free fatty acid
H2O/D2O
Water/Deuterated water
HPH
High pressure homogenization
HPLC
High performance liquid chromatography
HSA
Human serum albumin
IFP
Interstitial fluid pressure
LD
Laser diffractometry
LP
Lyoprotectant
MDR
Multidrug resistance
MeOH
Methanol
NaCl
Sodium chloride
NaOH
Sodium hydroxide
NET
Nanotemplate engineering technology
NF-κB
Nuclear factor kappa B
NMR
Nuclear magnetic resonance
P-gp
P-glycoprotein
PBS
Phosphate buffered saline
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Table A.1. Abbreviations (continued)
PEG
Poly(ethylene glycol)
PEG6000MS
PEG6000 monostearate
PI
Polydispersity index
PS60
Polysorbate 60
PSD
Pooled standard deviation
PVA
Polyvinyl alcohol
PVP
Poly(vinylpyrrolidone)
RES
Reticuloendothelial system
RH
Relative humidity
RI
Refractive index
SA
Stearyl alcohol
SD
Standard deviation
SEC
Size exclusion chromatography
SLN
Solid lipid nanoparticle
TEM
Transmission electron microscopy
TLC
Thin layer chromatography
UV
Ultraviolet
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Appendix B
Analytical Techniques

This section is intended to provide an explanation of the analytical techniques used
throughout this dissertation as well as to provide information regarding their application
as appropriate.

B.1.

PARTICLE SIZING TECHNIQUES

B.1.1. Dynamic Light Scattering (DLS)
Both DLS and laser diffractometry (LD, described in detail below) make use of the light
scattering property of particles in determining the particle size distribution. As light
waves strike the particle, the electron orbits of the included molecules are perturbed with
the same frequency as the electric field of the incident wave. This generates an induced
dipole within the molecule, which manifests itself as a source of electromagnetic
radiation, resulting in scattered light. Basically, the end result is that the direction and
intensity of the light appears changed though its wavelength/energy remain the same
[249]. This scattering primarily results from diffraction, refraction, and reflection of the
light (Figure B.1).

185

Diffraction
Refraction

Reflection

Figure B.1. Mechanisms of light scattering

DLS is a technique primarily used to determine the size of sub-micron particles
suspended in a liquid [250]. It is based on the measurement of the Brownian motion of
the particles, which is their random movement due to the bombardment by solvent
molecules that surround them. By accounting for the viscous forces and thermal energy
that affect particle movement, the particle size can be inversely correlated with particle
velocity. This relationship is known as the Stokes-Einstein equation:

where d is the diameter of the particle, k is the Boltzmann‟s constant (1.38 x 10-23 J/K), T
is the temperature in kelvins,

is the viscosity, and D is the translational diffusion

coefficient. It is important to recognize that the diameter measured by this technique is
the hydrodynamic diameter of the particle and can be affected by the particle‟s surface
properties as well as the concentration and type of ions in the surrounding environment
(Figure B.2).
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Hydrodynamic Diameter

Figure B.2. The measured hydrodynamic diameter of a particle

The instrument is set up so that a laser is focused on the sample of interest. As the light
passes through the dispersion, it is scattered by the particles, and the scattered light is
detected. Because the particles are in motion, the intensity of the scattered light
fluctuates; the rate at which these intensity fluctuations occur will depend on the size of
the particles. A representative diagram of a DLS instrument set-up is shown in Figure
B.3.
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Figure B.3. Schematic diagram of a dynamic light scattering instrument

Following detection, intensity signals are compared using a correlator with the goal of
generating an autocorrelation function (Figure B.4) [251]. Basically, the correlator
compares the intensity, I, at time t with that at time t + τ. Similar intensities are said to
exhibit high correlation. Normalization of the intensity function by average intensities
allows the correlation to be expressed within a range of 0-1:
τ

τ
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where g(2)(t) is the normalized intensity autocorrelation function, I(t) is the intensity
detected at time t, τ is the delay time,

is the normalization factor, and brackets

(<>) indicate a time average. For small particles, in which intensity fluctuations are rapid,
there is little similarity between the signals at different time points and the correlation
decays quickly. For larger particles with slower intensity fluctuations, the correlation may
persist for a long time.

Figure B.4. Representative intensity versus time graphs (left) for small (top) and
large (bottom) particles with their corresponding autocorrelation functions (right)

For particles that exhibit Brownian motion, the normalized intensity autocorrelation
function will be an exponential function or a sum of exponentials. Using the Siegert
relationship, the intensity autocorrelation function can be converted to the autocorrelation
function of the electric field of the scattered light,
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τ:

τ
If the particles are monodisperse,

τ

+1

τ will be a single exponential:
τ

τ

where B is a constant dependent on instrument parameters and

is a decay constant

proportional to the diffusion coefficient:
= Dq2
In this equation, D is the diffusion coefficient and q is the magnitude of the scattering
vector:
θ
λ
where n is the refractive index of the media, λ is the wavelength of the incident light, and
θ is the scattering angle. In the case of polydisperse particles,

τ will be the sum of

exponentials with differing decay constants:
τ

τ

where Ai is the relative intensity of light scattered by a particle with decay constant

i

and

is related to the amount of such particles.

As the final step in the analysis, the correlation function is fit using various algorithms to
determine the particle size. The most commonly applied analysis is the cumulants
analysis. However, it is most appropriately applied only when samples are monodisperse.
In this analysis, the logarithm of

τ is fit to a polynomial in τ to determine the

coefficients, Km:
τ

τ
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The first order coefficient [or the slope of

τ

is the average decay constant < >

from which the diffusion coefficient and particle size (z-average diameter) can be
determined. The second order coefficient (< -< >)2 divided by < >2 is the PI, which is
an estimate of the width of the particle size distribution.

In the case of multiple particle populations, a multiple exponential can be fit to the
correlation function using algorithms, such as CONTIN, Marquardt, and non-negative
least squares (NNLS). The NNLS technique is the simplest, solving the matrix so that
only positive values for Ai are obtained. The CONTIN method also uses an NNLS
technique but in combination with an eigenfunction analysis. The Marquardt method uses
repeated iterations from an initial guess to fit the data.

B.1.2. Laser Diffractometry (LD)
LD is the second light scattering technique used in these studies to determine the particle
size. However, it relies on different principles than DLS and is most commonly used for
particle populations in the micron range (though the exact range depends on the
properties of the instrument chosen). This technique is based on the fact that particles
scatter light at angles that are related to their size [252]. There is a logarithmic increase in
the scattering angle with a decrease in the particle size as well as a decrease in the
scattering intensity. Basically, larger particles scatter light at narrow angles with high
intensity while smaller particles scatter at wider angles but with less intensity. A
representative instrument set-up is shown in Figure B.5.
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Figure B.5. Representative set-up of a laser diffractometer

Two models are used in analyzing LD data: the Fraunhofer Approximation and the Mie
Theory [252]. Though the Fraunhofer Approximation was used with early LD
instruments, it has since been shown to be in error when measuring particles <50 μm in
size. For this reason, the Mie theory was introduced. It is based on Maxwell‟s
electromagnetic field equations and can predict the particle size of a much wider range of
particles. The calculations involved with Mie Theory are complex and will not be
discussed here, but the premise is that the particle size can be calculated based on the
scattering response of the particles.

B.1.3. Transmission Electron Microscopy (TEM)
TEM is a microscopic technique commonly used for the analysis of materials on the
nanoscale. Because it uses electrons, which have a shorter wavelength than light, it is
capable of achieving resolution a thousand times better than can be achieved with a light
microscope [253]. Instruments consist of three main parts: 1) the electron gun that
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produces the electron beam (usually a tungsten filament coupled to a high voltage source)
and the electromagnetic condenser lens that focuses it on the sample, 2) the imageproducing system (consisting of the sample stage along with the electromagnetic
objective, intermediate, and projector lenses that focus the electrons passing through the
sample to form a highly magnified image), and 3) the image-recording system (consisting
of a fluorescent screen for viewing the image and a digital camera for recording the
image). A representative instrument set-up is shown in Figure B.6. Although not shown,
all instruments are also equipped with a vacuum system. Samples must be analyzed under
vacuum in order to minimize the collision frequency of electrons with gas atoms.

Figure B.6. Schematic diagram of a transmission electron microscope. Adapted
from [253]. Reproduced with permission from Transmission Electron Microscope
(TEM). Encyclopedia Britannica. Encyclopedia Britannica Online. Encyclopedia
Britannica, 2011.
<http://www.britannica.com/EBchecked/topic/602949/transmission-electronmicroscope>. Copyright © 2008 Encyclopedia Britannica, Inc.
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Sample preparation for nanoparticles typically consists of applying the suspended
nanoparticles to a grid formed from a conductive metal and coated with carbon and
allowing them to dry. The use of the conductive metal disperses the electron beam and
prevents damage to the sample, while the carbon coating improves interactions with the
samples. Depending on the thickness of the sample in comparison to the wavelength of
the electrons, some electrons pass through the specimen while others are scattered,
generating the specimen image. However, due to the insufficient contrast for most
samples, stains are commonly required. In order to not obscure details of the samples,
negative staining is used more frequently than positive staining. This results in staining of
the background while the samples are left unstained. The most popular negative stains are
salts of heavy metals known to be good electron scatterers. Their application results in
the images having a dark background while the samples appear lighter.

B.2.

NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY

B.2.1. 1H-NMR Spectroscopy
1

H-NMR spectroscopy is the most commonly used analytical technique for the evaluation

of molecular structures [254]. It is based on the proton having a nuclear spin of ½, which
causes it to behave as a magnet. When this small “magnet” is placed within a larger
magnetic field, the proton can align either with (α, lower energy state) or against (β,
higher energy state) the magnetic field (Figure B.7). The energy difference between the
two spin states is proportional to the strength of the magnetic field:
,
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where ΔE is the energy difference between the two spin states, h is Planck‟s constant
(6.626 × 10-34 J∙s), B0 is the strength of the external magnetic field, and γ is the
gyromagnetic ratio (26,753 sec-1 gauss-1 for a proton). Following treatment with
electromagnetic radiation in the radiofrequency (RF) range, nuclei may absorb the
necessary photon of energy for promotion from the lower energy state to the higher
energy state. It is this absorption of energy that is detected by the NMR spectrometer.
Differences in the nuclei arise from the shielding of surrounding electrons, which allows
for the determination of chemical structures.

b)

a)

Figure B.7. (a) Nuclear spins align either with (α) or against (β) the applied
magnetic field, (b) leading to an energy difference that is dependent on the strength
of the external magnetic field, B0.

B.2.2. Relaxation Time Measurements
Following the promotion of a nucleus to a higher energy state, the energy must
subsequently be given off in order for the nucleus to return to the lower energy state. This
is referred to as relaxation. Nuclear relaxation can be broken into two components:
longitudinal or spin-lattice (T1) and transverse or spin-spin (T2). This is based on the fact
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that when a magnetic field (B1) is applied perpendicularly to the static magnetic field
(B0), the nuclear spin experiences a different effective magnetic field (Beff) (Figure B.8)
[255]. The magnetization vector is correspondingly tipped from the longitudinal plane
into the transverse plane, and relaxation must take place in both directions. Obtaining
information on the time necessary for the relaxation process can provide valuable
information regarding the environment of the molecule in question. Specifically, T1/T2
ratios much greater than 1 are indicative that a molecule (or portion of a molecule) is
highly constrained with little flexibility, whereas T1/T2 ratios close to 1 indicate that a
molecule (or portion of a molecule) is free in solution.

a)

b)

Figure B.8. Nuclei precess around the longitudinal magnetic field, B0, with a
magnetization vector, M (a). Application of a transverse magnetic field, B1, causes
the nuclear spin to experience a different effective magnetic field, Beff, and a
corresponding change in M (b).
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Longitudinal relaxation involves an exchange of energy between the excited spins and the
surrounding molecules (the lattice) as thermal motion or heat. A number of processes can
be involved, including dipolar coupling, quadrapolar coupling, paramagnetic interactions,
scalar coupling, chemical shift anisotropy, and spin rotation [256]. The most commonly
applied experiment used for the determination of T1 values is an inversion recovery
sequence (Figure B.9). A 180° pulse is applied to invert the longitudinal magnetization
(while not applying any transverse magnetization). This is followed by a delay (t) and a
90° pulse prior to detection. The sample undergoes longitudinal relaxation during the
delay but does not necessarily reach equilibrium, giving a signal that is only a fraction of
that obtained with the sample in its original state. The experiment is repeated numerous
times with various delay periods, allowing for the generation of a curve comparing the
signal intensity with the time delay. Fitting of this curve allows for the calculation of the
longitudinal relaxation time (T1), which is considered the time necessary to reduce the
difference between the longitudinal magnetization and its equilibrium value by a factor of
e (Figure B.10).

Figure B.9. Inversion recovery experiment used for the determination of T1
relaxation times
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Figure B.10. The spin-lattice relaxation time, T1, is defined as the time necessary to
reduce the difference between the longitudinal magnetization (MZ) and its
equilibrium value by a factor of e.

Transverse relaxation involves excited spins exchanging energy with each other and is a
shorter process than longitudinal relaxation. Relaxation mechanisms may be similar to
those seen with longitudinal relaxation but may also involve spins interacting through J
coupling [256]. Although in theory, T2 values could be determined from the linewidths
obtained following a 90° pulse, these can be skewed based on magnetic field
inhomogeneity (resulting values are given the term T2*). To account for this, the Carr
Purcell Meiboom Gill sequence is typically employed for determination of T2 values
(Figure B.11). This sequence begins with a 90° pulse to shift the magnetization vector
out of the longitudinal plane into the transverse plane. Following a delay (t), a 180° pulse
is applied to flip the magnetization in the y direction. A delay of “2t” is allotted, followed
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by a second 180° pulse and a final delay of “t” time. The signal is then detected, and
again, a curve can be prepared comparing the delay time with the signal. The time needed
to reduce the transverse magnetization by a factor of e is then considered the actual T 2
relaxation time (Figure B.12).

Figure B.11. The Carr Purcell Meiboom Gill sequence applied for the determination
of T2 relaxation times

Figure B.12. The spin-spin relaxation time (T2) is defined as the time necessary to
reduce the transverse magnetization by a factor of e.
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B.3.

DIFFERENTIAL SCANNING CALORIMETRY (DSC)

DSC is an analytical technique based on comparing the difference in the amount of heat
required to increase the temperature of a sample in comparison with a reference at the
same rate [257]. A representative instrument set-up is shown in Figure B.13. Larger
amounts of heat are required to keep the sample increasing in temperature at the same
rate as the reference. First, the sample will have a higher heat capacity than the reference.
Secondly, the sample may undergo thermal transitions (melting, recrystallization, glass
transition, etc) that require large inputs of heat at certain temperatures. By plotting the
heat input required versus temperature, information regarding both heat capacity and
phase transitions can be obtained.

Figure B.13. Schematic of a differential scanning calorimeter
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B.4.

POWDER X-RAY DIFFRACTION (PXRD)

PXRD is an analytical technique primarily used for phase identification of crystalline
materials; additional information may be gained on crystal structure as well [258]. It is
based on the fact that as X-rays hit atoms, they are diffracted. In the absence of atomic
order, the diffracted waves will be random and will interfere destructively. However, in
the presence of crystalline material, there will be constructive interference in some
directions (Figure B.14). This can be described by Bragg‟s law:

where λ is the X-ray wavelength, d is the distance between crystalline planes, and θ is the
angle between the incident ray and the scattering planes. Because the wavelength is fixed
by the instrument, the X-ray tube and/or the detector must move in order to achieve the
necessary θ angles for constructive interference (Figure B.15). The result is that each
type of crystal generates a distinctive diffraction pattern.

Figure B.14. Schematic depicting Bragg’s Law
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Figure B.15. Schematic of a powder X-ray diffractometer

B.5.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

As with all chromatography techniques, HPLC is an analytical technique designed to
separate mixtures [259]. It involves the flow of solvent (mobile phase) through a column
(stationary phase) at high pressures. Samples are injected onto the column, and molecules
within the sample are separated based on their properties. In this dissertation, reversed
phase HPLC is employed in which the stationary phase is non-polar and the mobile phase
is more polar. Separation is based on the hydrophobicity of the molecules with more
polar compounds coming off the column more quickly. Detection techniques can be
chosen as appropriate.
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B.6.

SIZE EXCLUSION CHROMATOGRAPHY (SEC)

SEC is a chromatographic technique designed to separate materials (molecules,
macromolecules, colloids) based on their size [260]. Similarly to HPLC, samples are
added to a column through which mobile phase is flowing. Mobile phase can be pumped
through the column or run through using gravity flow. Larger materials fail to enter the
pores of the column and pass through the column quickly, whereas smaller materials
enter the pores of the column and are retained for a longer period of time. When an
aqueous solution is used as the mobile phase, SEC is referred to as gel filtration
chromatography (GFC). When an organic solvent is employed, SEC is termed gel
permeation chromatography (GPC). Detection techniques can be chosen as appropriate.

B.7.

KARL FISCHER COULOMETRIC TITRATION

The Karl Fischer titration is a commonly used titrimetric method for the determination of
trace amounts of water in a sample [261]. The titration is based on two reactions. In the
first, an alcohol (ROH), sulfur dioxide (SO2), and a base (R‟N) react to form an
alkylsulfite intermediate:
ROH + SO2 + R‟N ↔ [R‟NH]SO3R
During the second reaction, this intermediate reacts with iodine (I2) and water from the
sample:
[R‟NH]SO3R + I2 + H2O + 2R‟N ↔ [R‟NH]SO4R + 2[R‟NH]I
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Because water and iodine are consumed in equimolar amounts during the second
reaction, the consumption of iodine can be monitored to provide information on the
presence of water in the sample. In the volumetric method, iodine is included with the
reagents. However, with the coulometric method, which is used in this study, iodine is
generated at an electrode.

The extent of reaction is monitored bipotentiometrically, meaning that electrical
conductivity changes of the reaction solution are measured. As sulfur is oxidized in the
second reaction, two electrons are produced that react with iodine:
I2 + 2e- → 2IThis changes the electrical potential of the system, and the change is detected by an
electrode.

Practically speaking, the alcohol generally used for the reaction solution is methanol.
Substitutions have been made in the case of sample insolubility in methanol or side
reactions with methanol. Pyridine was originally used as the base but has been replaced
by imidazole (Figure B.16). As a stronger base, imidazole serves to shift the balance of
reaction 1 to the right. Further, it lacks the unpleasant odor and toxicity associated with
pyridine.
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Figure B.16. Structures of bases used in Karl Fischer Titration: Pyridine (left) and
Imidazole (right)

Copyright © Melissa Howard 2011
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Appendix C
Surfactant Micelle Evaluation

C.1.

INTRODUCTION

A careful evaluation of the uniformity of any drug delivery system is important,
specifically in the case of SLNs where the low molecular weight surfactants used for
stabilization are known to form other structures, such as micelles [34]. As such, it was
deemed important to gain background information on the potential self-assembly of all
components used in the formation of the SLNs under study.

C.2.

PYRENE CMC ASSAY

C.2.1. Background
Pyrene is a polynuclear aromatic compound with a strong fluorescence spectrum (Figure
C.1). Due to its different, non-planar structure in its excited state as compared to its
ground state, certain emission bands in its fluorescence emission spectrum are very
sensitive to the solvent‟s polarity [262]. This makes it a valuable probe molecule for
CMC determination because, as micelles form, they entrap pyrene, causing it to
experience a more hydrophobic environment than when it is free in the aqueous solution.
This results in a corresponding change in its emission spectrum [263].

Figure C.1. Structure of pyrene
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C.2.2. Experimental Method
The assay consisted of adding pyrene (67.6 μL of a 0.1 mg/mL acetone solution) to clean
7 mL vials and allowing it to evaporate. Five milliliter surfactant samples prepared in
Milli-Q water at relevant concentrations were then added to the vials and allowed to
shake overnight at 100 rpm in the dark. Two milliliters of each sample were then added
to a quartz cuvette and analyzed by a Varian Cary Eclipse Fluorescence
Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). The following
conditions were used: excitation wavelength, 335 nm; emission spectra, 350-500 nm;
excitation slit width, 5 nm; emission slit width, 1.5 nm; slow setting. Before the first
sample was loaded into the quartz cuvette and between every sample, the cuvette was
washed with acetone to eliminate any pyrene residue and then subsequently washed with
deionized water to remove any remaining acetone. Samples were analyzed to retrieve the
peak intensities using the Cary Eclipse software. The ratio of the first (I1 ~ 372 nm) and
third (I3 ~ 383nm) peak intensities was plotted against the surfactant concentration.
Concentration is expressed in mM values for comparison with the literature.
Manufacturer reported molecular weight values were used for Brij® 78 (1151.56 g/mol)
and PS60 (1311.67 g/mol). A value of 10,643 g/mol was used for PEG6000MS based on
the SEC-determined molecular weight of free PEG (chapter 7). Two different methods
were used for computing the CMC [264]. For the tangent method, the curve was fit using
two linear equations (one for the rapidly varying part and one for the nearly horizontal
part), and the point of intersection was defined as the CMC. For the inflection method,
the OriginPro8.5 program was used to fit the curve using a Boltzmann-type sigmoid, and
the inflection point was used as the CMC. Each experiment was repeated twice to provide
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an average and standard deviation. Experimentally determined values were compared to
literature values where available.

C.2.3. Results and Discussion
Representative curves for Brij® 78, PS60, and PEG6000MS are shown in Figure C.2.
Experimentally determined CMC values are given in Table C.1. The results from the
inflection and tangent methods are shown. Both have been used in the literature, though
the inflection method is more commonly applied for nonionic surfactants with low CMC
values (<1 mM) [264]. In this case, the PS60 literature values agreed better with the
CMCtangent value, whereas the Brij® 78 literature value agreed more closely with the
CMCinflection method. No literature data was available for PEG6000MS. Of greatest
importance for this study was the observation that the three surfactants can all form
micelles at the concentrations used in SLN preparation [PS60, 0.4 mg/ml≈0.3050 mM (>
12 times the CMC); Brij® 78, 2.8 mg/ml≈2.4315 mM (> 180 times the CMC);
PEG6000MS, 3.0 mg/ml≈0.2819 mM (>10 times the CMC)]. Preparations of SA and
Dex-P were also analyzed, but I1/I3 ratios were consistent across the entire concentration
range.
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Figure C.2. Representative plots of the variation in the I1/I3 ratio of pyrene peak
intensities (I1 ~ 372 nm, I3 ~ 383nm) with concentration for Brij ® 78, PS60, and
PEG6000MS
Table C.1. CMC values of Brij® 78, PS60, and PEG6000MS
Experimental Values
Sample
Brij® 78

CMCinflection
(mM)
0.0092±0.0023

CMCtangent
(mM)
0.0135 ± 0.0006

PS60

0.0135±0.0006

0.0240 ± 0.0005

PEG6000MS

0.0178±0.0007

0.0271 ± 0.0001

C.3.

Literature
CMC (mM)

Method

0.0050 [265]
0.0206 [266]

Surface tension
Surface tension
Iodine
0.0209 [266]
absorbance
Previously unreported

TEM

DLS is one technique that can be used in analyzing nanoparticle suspensions for the
presence of micelles. The SLNs under study appear monodisperse (Figure C.3) and are
characterized by low PI values (<0.1). Representative formulation 1 SLNs were
characterized by a D10% of 45.4 nm, a D50% of 58.4 nm, and a D90% of 75.3 nm.
Representative formulation 2 SLNs exhibited a D10% of 67.8 nm, a D50% of 85.6 nm,
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and a D90% of 109.9 nm. However, in this case, a dilution step was required to bring the
SLN sample intensity within the range appropriate for the instrument, which would dilute
PS60 and PEG6000MS micelles below their CMC values. This makes it difficult to
conclude the absence of micelles from the DLS analysis.

Figure C.3. Representative DLS intensity distributions for formulation 1 (left) and
formulation 2 (right) SLNs

TEM was chosen as an alternative technique for analysis. Brij® 78, PS60, and
PEG6000MS were prepared at the concentrations used in SLN preparation and imaged
using the same protocol as described in chapter 4 (Figure C.4). Brij® 78 and PS60 had a
dense population of small dots. When analyzed using ImageJ, the sizes were determined
to be 13.3±4.2 nm and 23.1±3.4 nm (mean ± SD of 10 micelles), respectively.
PEG6000MS micelles appeared larger at a size of 37.7±8.8 nm. In the majority of SLN
images (e.g., those in chapter 4), particles in this size range cannot be observed,
indicating the absence of micelles. In some SLN images, there were some dots
intermediate within this size range (17.3±2.1 nm), but these could be traced to the
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background associated with the stain itself (18.5±4.4 nm). Overall, it appeared likely that
micelles were not present to any great extent within SLN suspensions.

Figure C.4. TEM images of formulation 2 SLNs without background dots (a),
formulation 2 SLNs with background dots (b), uranyl acetate stain (c), Brij® 78
micelles (d), PS60 micelles (e), and PEG6000MS micelles (f)

Copyright © Melissa Howard 2011
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Appendix D
Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable Release of
Dexamethasone*

D.1.

INTRODUCTION

Polymer micelles are polymer nanoassemblies with a distinctive core-shell structure.
They have been touted as promising drug carriers because they can protect drug payloads
from the in vivo environment by entrapping drugs in a hydrophobic core enveloped by a
hydrophilic shell [267]. Several preclinical and clinical studies have shown that polymer
micelles improve the bioavailability and tumor-targeted delivery of various therapeutic
agents while allowing chemical modifications to the core and shell for multifunctional
applications [268].

Furthermore, these systems can be designed so that drugs are released in tumors in
response to a biological stimulus [269-271]. For example, in a process known as the
Warburg effect, cancer cells consume glucose inefficiently and produce a large amount of
lactic acid that acidifies tumor tissues [272]. Drug conjugation through acid-sensitive
hydrazone bonds may then lead to accelerated drug release at the tumor site [273]. In
addition to providing a second method for tumor-targeting, this technique also provides
opportunities for tuning drug release to achieve an appropriate profile. By modifying the
chemistry surrounding the drug linker, drug release can be modulated so that tumors are
treated with the appropriate drug concentration and schedule [274].
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For these reasons, pH-sensitive polymer micelles were investigated as an alternative
delivery system for Dex. Poly(ethylene glycol)-poly(amino acid) block copolymers were
chosen because they have been shown to be a versatile drug delivery platform to design
multifunctional drug carriers [275]. Dex was entrapped using hydrazone-ester dual
linkers to achieve pH-controlled drug release in a tunable manner (Figure D.1A). The
dual linkers consist of acid-labile hydrazone (a) and enzymatically degradable ester (b)
linkages while spacers (X) modulate Dex release patterns and stability of the micelles.
The dual linker micelles can achieve tunable release of Dex in tumors (Figure D.1B),
reducing the IFP that limits tumor accumulation of other drugs (Figure D.1C). Micelles
with single hydrazone or ester linkers were also tested for acid-sensitive Dex release. The
physicochemical properties of the micelles, including particle size and Dex release
patterns, were characterized at different pH values corresponding to the normal
physiological condition (pH 7.4) and the acidic tumor tissues (pH 5.0). Stability of Dex
loaded micelles was also tested in the presence of CE. In addition to providing
information on a possible Dex delivery system, our characterization of these polymer
micelles provides valuable insight into the design of drug-binding linkers and drug
carriers for tunable release.
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Figure D.1. Mechanism of tumor-preferential tunable release of Dex from polymer
micelles. Polymer micelles entrap Dex through hydrazone-ester dual linkers (A).
The dual linkers consist of acid-labile hydrazone linkages (a) and enzymatically
degradable ester linkages (b) while spacers (X) modulate Dex release patterns and
stability of the micelles. The dual linker micelles can achieve tunable release of Dex
in tumors (B), reducing the IFP that limits tumor accumulation of other drugs (C).

D.2.

MATERIALS AND METHODS

D.2.1. Materials. α-Methoxy-ω-amino poly(ethylene glycol) (PEG-NH2, MW=12,266)
was purchased from NOF Corporation (Shibuya-ku, Tokyo, Japan). L-aspartic acid βbenzyl

ester,

triphosgene,

4,4-diphenyl-cyclohexa-2,5-dienone,

2-hydroxy-1-(1-

hydroxycyclohexyl)ethanone, 4-acetylbutyric acid (ABA), 6-oxoheptanoic acid (OHA),
7-oxooctanoic acid (OOA), Dex, prednisolone, N,N‟-diisopropylcarbodiimide (DIC), 4(dimethylamino)pyridine (DMAP), ACN, benzene, N,N-dimethylformamide, anhydrous
N,N-dimethylformamide (DMF), anhydrous dimethyl sulfoxide (DMSO), DMSO-d6,
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D2O, anhydrous ethyl ether, anhydrous hexane, anhydrous hydrazine, anhydrous
tetrahydrofuran (THF), acetate buffer solution, and phosphate buffer solution were
purchased from Sigma-Aldrich (St. Louis, MO). Regenerated cellulose dialysis bags with
molecular weight cut off (MWCO 6-8,000 Da) and Slide-A-Lyzer G2 dialysis cassettes
with MWCO 10,000 were purchased from Fisher Scientific (Pittsburgh, PA). AmiconUltra centrifugal ultrafiltration devices with MWCO 10,000 were purchased from
Millipore (Billerica, MA).

D.2.2. PEG-PBLA Block Copolymer Synthesis. Our synthesis protocol is shown in
Figure D.2. β-Benzyl-L-aspartate N-carboxy anhydride (BLA-NCA, 2) was prepared
using the Fuchs-Farthing method as described elsewhere [276]. Triphosgene (2.88 g, 9.7
mmol) and β-benzyl-L-aspartate (5.0 g, 22.4 mmol) were mixed in dry THF (100 mL).
The reaction was conducted in N2 at 45°C until the solution turned clear. Anhydrous
hexane was slowly added to the reaction solution for recrystallization of BLA-NCA in 20C. Purified BLA-NCA was polymerized in anhydrous DMSO at 45C for 2 days by
using amino-terminated PEG as a macroinitiator. The amount of BLA-NCA was adjusted
with respect to PEG to prepare PEG-PBLA block copolymers with 35 units of aspartic
acid, 3. The reaction solution was precipitated in anhydrous ethyl ether. White PEGPBLA was collected by freeze-drying from benzene.
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Figure D.2. (A) Synthesis of block copolymers. PEG-PBLA, 3, was prepared from 12
kDa PEG, 1, and 35 units of BLA-NCA, 2. PEG-pAsp, 4, was produced by complete
deprotection of 3 in 0.1 N NaOH. Dex was conjugated to 4 through an ester linkage
by an esterification reaction between the hydroxyl group at the C21 moiety of DEX
and carboxyl groups of 4 to give 7. Dex was conjugated at its C3 and C20 positions
to PEG-p(Asp-Hyd), 5, through ketone linkages to produce 8 and 9, respectively.
Reactions between 5 and various ketonic acids (ABA, OHA, and OOA) produced 6
in which the ketonic acids served as spacers. Dex was conjugated to 6 through an
esterification reaction to give three polymer compositions with hydrazone-ester dual
linkers (10, 11, and 12). (B) Structure of Dex with relevant conjugate sites numbered

D.2.3. PEG-p(Asp-Est-Dex) Synthesis. PEG-PBLA was dissolved in 0.1 N NaOH to
deprotect benzyl ester groups. The solution was dialyzed against deionized water using
MWCO 6-8,000 Da until NaOH was removed completely. PEG-poly(aspartate) [PEGp(Asp), 4] was collected by freeze drying. Dex was conjugated to PEG-p(Asp) through
an ester bond in DMSO at room temperature. DIC and DMAP were used for the
esterification reaction. The reaction solution was precipitated in anhydrous ethyl ether.
The product was freeze dried from benzene to collect PEG-poly(aspartate ester
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Dexamethasone) [PEG-p(Asp-Est-Dex), 7]. Sample aliquots were filled with nitrogen to
minimize hydrolytic degradation.

D.2.4. PEG-p(Asp-Hyd-Dex) Synthesis. Hydrazide groups were introduced to PEGPBLA through aminolysis reactions as previously reported [273]. PEG-PBLA and
anhydrous hydrazine were reacted in DMSO at 45C for 1 h (50-100 mg polymer/mL
DMSO) to prepare PEG-poly(aspartate hydrazide) [PEG-p(Asp-Hyd), 5]. PEG-p(AspHyd) was precipitated in anhydrous ethyl ether and freeze dried from benzene. Dex and
PEG-p(Asp-Hyd) were mixed in DMSO at 40C for 72 h. The reaction solution was
precipitated in anhydrous ethyl ether repeatedly. The precipitates were collected from
benzene to provide PEG-poly(aspartate hydrazone Dexamethasone) [PEG-p(Asp-HydDex), 8 and 9].

D.2.5. PEG-p(Asp-Hyd-X-Est-Dex) Synthesis (‘X’ indicates ketonic acids as
spacers). PEG-p(Asp-Hyd) block copolymers were reacted with three ketonic acids
(ABA, OHA and OOA) separately in DMSO at 40C for 3 days. Reaction solutions were
precipitated in anhydrous ethyl ether, followed by freeze drying from benzene. Each
PEG-p(Asp-Hyd) modified with ketonic acids, 6, was reacted with Dex in DMSO at
room temperature by adding DIC and DMAP. The reactions were conducted for 24 h,
followed by precipitation in anhydrous ethyl ether and freeze drying from benzene. The
ketonic acids provided spacers of 3, 4 and 5 methylene groups („X‟) between PEGp(Asp-Hyd) and Dex in the final products [PEG-p(Asp-Hyd-X-Est-Dex), 10, 11 and 12].
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D.2.6. Polymer Micelle Preparation. Polymer micelles were prepared from 7, 8, 9, 10,
11 and 12. Either reconstitution or freeze drying methods were used to prepare the
micelles. The reconstitution method was conducted by dissolving drug-conjugated
polymer powders directly in aqueous solutions and sonicating the solution. For the freeze
drying method, block copolymers were dissolved in ACN first and diluted with deionized
water, adjusting the final ACN content to 20%. The block copolymer solutions were
freeze dried, following dry ice freezing. Freeze-dried micelle powders were reconstituted
in aqueous solutions. All micelles were filtered through 0.2 m filters prior to further
experiments. Polymer micelles from Dex-conjugated block copolymers are abbreviated
according to the drug-binding linkers used, which include hydrazone (HYD-M), ester
(EST-M), hydrazone-ABA-ester (ABA-M), hydrazone-OHA-ester (OHA-M) and
hydrazone-OOA-ester (OOA-M).

D.2.7. Analytical Methods. Particle size of polymer micelles in water was determined
by DLS measurements using a Zetasizer Nano-ZS (Malvern; Worcestershire, UK). The
instrument was equipped with a He-Ne laser (4 mW, 633 nm) and set up to collect 173°
angle scattered light. Number distributions are presented as the mean particle size. 1HNMR experiments were performed on a Varian 500 MHz NMR (Varian Inc., Palo Alto,
CA) at 25°C. Products were dissolved in DMSO-d6 and analyzed following each step in
the synthetic pathway. NMR spectra were also obtained for freeze-dried micelles
reconstituted in D2O. Where appropriate, SEC was additionally used to confirm the
success of reactions. The system was a Shimadzu Prominence HPLC series equipped
with a Shodex Asahipack GF-7M HQ column and an RID-10A refractive index detector.
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The mobile phase was 5 mM PBS run at 0.5 mL/min; the column temperature was held at
35°C. Molecular weight was calculated through comparison with a calibration curve
based on PEG standards. The PI was calculated by dividing the weight average molecular
weight by the number average molecular weight. Dex loading was confirmed by 1HNMR spectroscopy and quantified by HPLC. Ester-containing micelles were prepared at
2 mg/mL in either acetate buffer (10 mm pH 5.0, n=3) or phosphate buffer (10 mM pH
7.4, n=3).

One hundred microliters of each sample were combined with 100 µL

prednisolone (0.1 mg/mL) as an internal standard and 10 µL NaOH (0.1 N). The mixed
solutions were incubated at 37°C overnight with shaking at 100 rpm. Samples were
neutralized with 10 µL HCl (0.1 N). One hundred microliters of the neutralized samples
were mixed with ACN (45% ACN/55% H2O) and ultrafiltered. Filtrates were analyzed
by HPLC according to the following conditions. The system was a Shimadzu Prominence
HPLC series equipped with a SPD-M20A Photodiode Array Detector. Five microliter
samples were injected to an Eclipse XDB-C18 (4.6 mm×150 mm, 5 micron, Agilent
Technologies) column at 40°C. The mobile phase (45% ACN/55% H2O) was run at a
flow rate of 1 mL/min. Concentrations were calculated based on peak area calibration
curves prepared for Dex and Prednisolone at 254 nm from 1 to 500 μg/mL.

D.2.8. pH-Dependent Drug Release Study. Drug release studies were conducted in
acetate (10 mM, pH 5.0) and phosphate (10 mM, pH 7.4) buffers under sink conditions.
Samples were removed at 0 h from initial preparations. Dialysis cassettes were loaded
with 400 μL of 2 mg/mL micelle solutions and placed into 5 L of buffer solutions at
37°C. At each time point (1, 3, 6, and 24 h), the entire internal solution was collected
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from three dialysis cassettes and stored at room temperature until all samples had been
collected. Samples were treated as described above to determine drug loading by HPLC
analysis. Data are presented as percent drug remaining, using 0 hr concentrations as the
standard. The area under the curve (AUC0-t: where „t‟ represents a time point) was
determined by using the trapezoidal rule for % Dex released (% Dex released = 100 - %
DEX remaining) with respect to time. AUC values were compared for the early (0-3 h)
and late (3-24 h) periods.

D.2.9. CE-Dependent Drug Release Study. Polymer micelles (2 mg/mL) were
incubated under non-sink conditions at 37°C/pH 7.4 in media with varying levels of CE
activity: 1) RPMI cell culture medium; 2) RPMI with 10% fetal serum bovine (FBS); 3)
RPMI with 10% mouse plasma (MP); 4) RPMI with 10% human plasma (HP); 5) RPMI
with 10% FBS and 10% MP; and 6) RPMI with 10% FBS and 10% HP. Mouse plasma is
known to have higher levels of CE activity than human plasma (46). RPMI was used as a
control to determine the effects of ions and small molecules (vitamins and amino acids)
on micelle stability. FBS was used as a control for general protein effects on micelle
stability. All combinations were prepared on a volume basis. Plasma samples contained
sodium heparin as the anti-coagulant. One hundred microliter aliquots (n=3) were
collected at 0 and 24 h, followed by ultrafiltration and HPLC analysis as described above.
Drug release patterns were determined by quantifying cleaved Dex and Dex-ketonic acid
conjugates.
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D.2.10. Statistical Analysis. Statistical analyses were performed using ANOVA (single
factor) at the 5% significance level. Data were recorded as mean ± SD. All experiments
were done in triplicate as specified in the results section. Data analyses were performed
using Microsoft Excel (2007).

D.3.

RESULTS

D.3.1. Block Copolymer Synthesis. Figure D.2 summarizes the synthetic pathways for
all materials used in the research. Using the PEG peak as a reference, 1H-NMR indicated
that the polymerization reaction between 12 kDa PEG, 1, and BLA-NCA, 2, had
proceeded to give PEG-PBLA, 3, with 35 units of aspartic acid. GPC further showed
neither unreacted PEG nor PBLA homopolymers after purification. Molecular weight
distribution of the block copolymers was homogeneous with a polydispersity index
smaller than 1.3. The results were consistent with what we observed previously. PEGp(Asp), 4, was produced by complete deprotection of 3 in 0.1 N NaOH. Dex was
conjugated to 4 through an ester linkage by an esterification reaction between the
hydroxyl group at the C21 moiety of Dex and carboxyl groups of 4 to give 7. Dex loading
was 8.67±0.86 wt% (n=6). Dex was conjugated at its C3 and C20 positions to PEGp(Asp-Hyd), 5, through ketone linkages to produce 8 and 9, respectively. Drug loading
for these two products together appeared low by 1H-NMR and could not be quantified by
HPLC due to difficulties in cleaving the drug from the polymer. Reactions between 5 and
various ketonic acids (ABA, OHA, and OOA) produced 6 in which the ketonic acids
served as spacers containing 3, 4 and 5 methylene groups. Dex was subsequently
conjugated to 6 through esterification to give three polymer compositions with
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hydrazone-ester dual linkers, 10, 11, and 12. Dex loadings were 4.63±0.75, 5.57±0.61,
and 4.50±0.28 wt% for 10, 11, and 12, respectively (n=6).

D.3.2. Polymer Micelle Preparation. All Dex-conjugated block copolymers formed
polymer micelles irrespective of the composition. Freeze-dried micelles were readily
reconstituted in aqueous solutions at concentrations >2 mg/mL; no precipitate was
observed. Prepared micelles were smaller than 100 nm: EST-M (85.74 nm), ABA-M
(61.50 nm), OHA-M (43.82 nm), and OOA-M (37.84 nm). 1H-NMR spectra of the
micelles in DMSO-d6 (Figure D.3) showed the characteristic peaks of Dex [dienone (7.3,
6.2 and 6.0 ppm) and hydroxyethanone (5.2 ppm)] and PEG (3.6 ppm). A complete
reduction of Dex peaks was seen in the micellar spectra in D2O while the PEG peak
remained, indicating that Dex is primarily entrapped within the micelles.
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Figure D.3. 1H-NMR spectra of polymer micelles in DMSO-d6 and D2O. 1H-NMR
spectra of the micelles in DMSO-d6 showed the characteristics peaks of Dex
[dieneone (7.3, 6.2 and 6.0 ppm) and hydroxyethanone (5.2 ppm)] and PEG (3.6
ppm). A complete reduction of Dex peaks was seen in the micellar spectra in D2O
while the PEG peak remained, indicating that Dex was entrapped within the
micelles.
HYD-M, a mixture of 8 and 9, did not form homogeneous polymer micelles. We were
unable to determine the particle size of HYD-M because it varied between batches (4.50 2187.20 nm). Our preliminary experiments showed that drug release from HYD-M (8
and 9) was negligible even under strongly acidic conditions (pH<2) and at elevated
temperatures (>60C). To elucidate the mechanism, PEG-p(Asp-Hyd) was reacted with
two model ketone compounds, 4,4-diphenyl-cyclohexa-2,5-dienone and 2-hydroxy-1-(1-
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hydroxycyclohexyl)ethanone, which represent the C3 and C20 moieties of Dex,
respectively. HPLC analysis revealed that hydrazone formation at the C3 ketone of Dex
is favorable and highly stable compared to the hydrazone at the C20 ketone of Dex.
Based on these results, we concluded that direct conjugation of Dex to PEG-p(Asp)
through the hydrazone would be inappropriate to design our polymer micelles for the
delivery and pH-sensitive release of Dex in tumors. We did not pursue further
experiments with HYD-M accordingly.

D.3.3. pH-Dependent Dex Release from the Micelles. Drug release patterns showed
that EST-M was unstable at pH 7.4 while it was more stable at pH 5.0 (Figure D.4).
51.39% and 32.37% of Dex were released from EST-M in 6 h at pH 7.4 and pH 5.0,
respectively. Polymer micelles with hydrazone-ester dual linkers showed the opposite
drug release patterns. In all cases (ABA-M, OHA-M, and OOA-M), Dex release from the
micelles was suppressed at pH 7.4 and accelerated at pH 5.0. The results suggest that
polymer micelles with hydrazone-ester dual linkers may remain stable in blood and
release more Dex in acidic tumor tissues. Dex release was reduced at pH 5.0 as the chain
length of the spacer increased. Interestingly, Dex release was less dependent on the
spacer at pH 7.4. To suppress Dex release at pH 7.4, we also attempted to test ketonic
acids longer than OOA, but the block copolymers precipitated forming no micelles (data
not shown).
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Figure D.4. Time- and pH-dependent release of Dex from polymer micelles at 37°C.
EST-M was unstable at pH 7.4 while it was more stable at pH 5.0. Polymer micelles
with hydrazone-ester dual linkers showed the opposite drug release patterns with
drug release being accelerated at pH 5.0 and suppressed at pH 7.4. Dex release was
reduced at pH 5.0 as the chain length of the spacer increased but was less dependent
on the spacer at pH 7.4.

Dex release profiles were compared by calculating the AUC values of Dex released at
different pH conditions. Data were analyzed by separating the AUC values for the early
(0-3 hr) and late (3-24 hr) time periods (Table D.1). The AUC0-3 showed that ABA-M
suppressed drug release at pH 7.4 effectively with respect to EST-M. OHA-M and OOAM released slightly more drugs than EST-M in the same time period. At pH 5.0 (0-3 h),
all micelles released Dex in a pH-dependent manner. At later time periods (AUC3-24),
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Dex release at pH 7.4 was slower and more sustained in all micelles with dual linkers
compared to EST-M. The AUC3-24 at pH 5.0 showed that ABA-M released more Dex
than either OHA-M or OOA-M. It is intriguing that OOA-M, containing longer and more
hydrophobic spacers, released more Dex than OHA-M. Among the micelles with dual
linkers, ABA-M released the least amount of Dex at pH 7.4 and the greatest amount of
drug at pH 5.0 during the early time period (0-3 h). In the later time period (3-24 h), all
micelles showed similar Dex release patterns at pH 7.4. However, ABA-M still released
more Dex than OHA-M and OOA-M at pH 5.0. Based on the pH-dependent drug release
studies, ABA-M was chosen as the lead composition for further studies.

Table D.1. Accumulated Dex release from polymer micelles
AUC a
pH

7.4

5.0

Micelles

% Dex released  hour b

Micelles/EST-M c

Micelles/ABA-M c

0-3 hr

3-24 hr

0-3 hr

3-24 hr

0-3 hr

3-24 hr

EST-M

59.62

1162.83

1

1

-

-

ABA-M

45.20

893.03

0.76

0.77

1

1

OHA-M

70.02

893.24

1.17

0.77

1.55

1.00

OOA-M

83.86

983.39

1.41

0.85

1.86

1.10

EST-M

30.29

540.59

1

1

-

-

ABA-M

105.38

1536.74

3.48

2.84

1

1

OHA-M

76.27

1106.28

2.52

2.05

0.72

0.72

OOA-M

97.17

1254.63

3.21

2.32

0.92

0.82

a

AUC denotes the area under the curve of Dex released from the micelles.
The unit for AUC is defined as % Dex released  hour.
c
The ratios show Dex released from each micelle with respect to either EST-M or ABAM.
b
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D.3.4. CE-Dependent Drug Release. In addition to pH, we tested stability of ABA-M
in the presence of CE to confirm that polymer micelles can protect Dex and the ester
linkers from enzymatic degradation. The micelles were incubated at 37°C under six
different conditions as described in the Materials and Methods section. Total Dex
released from ABA-M is summarized in Figure D.5. No dissociation of micelles was seen
in all incubation conditions at 0 h. Dex release was minimal (<5%) at the initial time
point. An ANOVA analysis indicated no significant differences among the six samples at
0 h (p>0.05). It is noticeable that ABA-M remained stable in RPMI, FBS, MP and HP
alone or in combination, suggesting that the micelles protected Dex and the dual linkers
in the solutions that contain various additives such as ions, small molecules, amino acids,
proteins and digestive enzymes. Following 24 h incubations, Dex release was slightly
higher (10 - 15%) in samples containing mouse plasma compared to the samples lacking
CE activity (p<0.05). A slight difference in release was also observed between drug
release in this study and the pH-dependent study described above, which may be
attributable to the non-sink versus sink conditions employed.
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Figure D.5. Stability of polymer micelles (ABA-M) in cell culture medium (RPMI),
10% fetal bovine serum (FBS), 10% mouse plasma (MP), 10% human plasma (HP),
and in combinations of these. Drug release was low at the initial time point,
indicating that polymer micelles are stable in the presence of biological media. Drug
release was slightly elevated in media containing CE at 24 h as compared to media
lacking CE.
D.4.

DISCUSSION

D.4.1. Polymer Synthesis and Dex Conjugation. Dex was conjugated to PEG-p(Asp)
block copolymers through hydrazone-ester dual linkers to prepare polymer micelles that
can release the drug preferentially in acidic tumor tissues (pH<7.0). We initially tested
Dex conjugation to PEG-pAsp block copolymers using single hydrazone and ester
linkers. While Dex could be conjugated to block copolymers directly through a
hydrazone linker, the drug loading was low and the hydrazone bond appeared too stable
to release the drug in a physiologically relevant time period. Further, micelles from this
composition were not homogenous in size, which may result from both 8 and 9 being
present or from the polymers having an insufficiently hydrophobic section due to the low
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drug load. The results also indicated that Dex conjugation through ester linkers had
limited stability. Polymer micelles entrapping Dex through an ester linkage would be
unsuitable for drug delivery to tumors because more drug would be released in blood (pH
7.4) than in acidic tumor tissues (<pH 6.5). In spite of these apparent failures at achieving
pH-dependent Dex release, each linkage still showed successful reaction yields
(hydrazone formation) and high drug conjugation (ester formation) between Dex and
block copolymers. To take advantage of these possibilities, Dex was conjugated to the
block copolymers using a hydrazone-ester dual linker with ketonic acids of varying
carbon chain lengths introduced as spacers. Dex loading (4.50 - 5.57 wt%) was high
enough to prepare polymer micelles that can carry the drug at concentrations even greater
than the effective dose (<1 mg/kg) [277] for future in vivo applications.

D.4.2. Preparation of Dex Loaded Micelles. Block copolymers with hydrazone-ester
dual linkers formed polymer micelles smaller than 100 nm, which is clinically relevant
for tumor-preferential drug delivery by the EPR effect [278]. Interestingly, particle size
of the micelles with dual linkers decreased as hydrophobicity of ketonic acids increased
in comparison to EST-M. This may be attributable to how the different polymer
compositions assemble into micelles with differences in hydrophobicity leading to a
change in the micellar aggregation number. 1H-NMR analysis in DMSO-d6 confirmed
Dex conjugation to polymers (Figure D.3). The NMR spectra of the micelles in D2O
showed a complete reduction of peaks from free Dex and the core-forming segment of
PEG-p(Asp) block copolymers. Only the PEG peak was observed in all micelle
compositions. These results indicate that micelles exhibited the expected core-shell
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structures with PEG on the surface and the hydrophobic portion of the polymers forming
the core to which Dex was entrapped with limited molecular mobility. It is noted that
polymer micelles were readily prepared by reconstituting freeze-dried powders, which
would facilitate the pharmaceutical development of Dex loaded polymer micelles.

D.4.3. pH-Dependent Dex Release from the Micelles. Polymer micelles with
hydrazone or ester single linkers were unsuitable to achieve Dex release in the acidic
environment of tumors. The hydrazone linker was too stable to release Dex in both pH
7.4 and 5.0 solutions likely as a result of the multiple double bonds present around the
hydrolytic site when Dex is conjugated at the C3 position. Dex release from HYD-M was
negligible in 72 h. Ester linkers caused undesirable Dex release from the micelles at pH
7.4 while suppressing drug release at pH 5.0. In vivo applications of our polymer micelles
with single linkers appeared unlikely for parenteral delivery of Dex. Ester linker micelles
may alternatively be suitable for oral delivery of Dex as they may remain stable in acidic
gastric fluids until they reach the small intestine.

Polymer micelles with hydrazone-ester dual linkers achieved Dex release suitable for
tumor-preferential delivery of Dex. As Dex is conjugated to these polymers following the
insertion of a spacer, the hydrazone linker regains its susceptibility to pH-dependent
hydrolysis that was lost in the HYD-M composition. In comparison to EST-M, the dual
linker micelles suppressed Dex release at pH 7.4 while accelerating Dex release at pH
5.0. Similarly to the hydrazone linker, the difference in ester stability between the single
and dual linkers can be attributed to the surrounding chemical structure. Importantly, the

230

results suggest that polymer micelles with dual linkers will remain stable in blood and
release more Dex in acidic tumor tissues. Dex release at pH 5.0 was dependent on the
chain length of ketonic acid spacers for the dual linker micelles. Dex remaining in OHAM and OOA-M at 24 h were greater than ABA-M. The suppressed drug release at pH 5.0
with longer ketonic acids may be attributed to the increased hydrophobicity stabilizing
the micelle core. The difference in Dex release between OHA-M and OOA-M was not
significant. There was no difference in Dex release at pH 7.4, irrespective of the spacer
length. These results suggest that the hydrazone is responsible for drug release at pH 5.0
while ester hydrolysis contributes to Dex release at pH 7.4.

It is unknown why polymer micelles did not prevent linkers from hydrolysis at pH 7.4.
Our initial expectation was that more hydrophobic spacers would make the micelle cores
more stable, and thus suppress drug release further. However, even though Dex
molecules are tightly entrapped in the micelle core (as seen in the 1H-NMR analysis), the
polymer micelle cores may be porous enough to allow water molecules to penetrate and
attack both bonds. Previous results have shown that hydrolysis of small molecule
prodrugs with ester linkages can be suppressed as the chain length of tail groups is
extended [279]. In contrast, our results showed that the chain length of spacers did not
seem to affect the stability of ester linkages in the micelle core. The difference may be
attributable to the fact that the mobility of spacers is restricted in the micelle core,
offsetting the effects of chain extension, whereas tail groups of prodrugs can move freely
in solutions, leading to extended degradation half-lives of ester bonds. It is also possible
that the surrounding micelle environment, including the hydrophilic PEG shell, might
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have attracted water molecules close to the ester linkages in polymer cores, and therefore,
hydrolysis reactions took place.

D.4.4. Tunable Dex Release from the Micelles. We analyzed the AUC of Dex release
patterns to confirm tunable drug release from the micelles. Tunable drug release is
important to control Dex distribution in tumors at different time points after the injection
of polymer micelles. Tumor accumulation of polymer micelles was previously shown to
reach its maximum level after 3 hours post-injection [280]. For this reason, the AUC
values were analyzed both in the early (0-3 h) and late (3-24 h) stages of the drug release
study (Figure D.4). Table D.1 summarizes the results.

The AUC0-3 showed that ABA-M (45.20) effectively suppressed drug release at pH 7.4
with respect to EST-M (59.62). OHA-M (70.02) and OOA-M (83.86) released slightly
more Dex than EST-M in the same period. At pH 5.0 (0-3 h), all micelles released Dex in
a pH-dependent manner [ABA-M (105.38), OHA-M (76.27) and OOA-M (97.17)]
compared to EST-M (30.29). At later time periods (AUC3-24), Dex release at pH 7.4 was
slower and more sustained in all dual linker micelles compared to EST-M (1162.83):
ABA-M (893.03), OHA-M (893.24), and OOA-M (983.39). The AUC3-24 at pH 5.0
showed that ABA-M (1536.74) released more Dex than either OHA-M (1106.28) or
OOA-M (1254.63). It is interesting that OOA-M, containing longer and more
hydrophobic spacers, released more DEX than OHA-M. Among the dual linker micelles,
ABA-M released the least drugs at pH 7.4 and the most drugs at pH 5.0 during the early
time period (0-3 h). Using Dex release from ABA-M (100%) as the reference, release
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from OHA-M (155%) and OOA-M (186%) was greater at pH 7.4 between 0-3 h. OHA-M
(72%) and OOA-M (92%) suppressed DEX release at pH 5.0 in the early period
compared to ABA-M (100%). In the later time period (3-24 h), Dex release patterns at
pH 7.4 were similar in all micelles [ABA-M (100%), OHA-M (100.0%) and OOA-M
(110%)]. At pH 5.0, however, ABA-M (100%) still released more Dex than OHA-M
(72%) and OOA-M (82%).

These multi-step drug release profiles are desirable for achieving the necessary Dex
concentrations at the tumor site. In the early stages following micelle accumulation in
tumors, micelles are expected to exhibit a prompt drug release, bringing Dex
concentrations up to the required level rapidly. The slower drug release at later time
points will allow for Dex concentration levels to be maintained over an extended period
of time, reducing the need for multiple doses. It remains challenging for OHA-M and
OOA-M to suppress Dex release at pH 7.4 while achieving tunable DEX release in acidic
tumor environment. Based on these results, we considered ABA-M the optimal
composition that would remain stable in blood and release Dex quickly in tumor tissues.

D.4.5. Enzymatic Stability of Dex Loaded Micelles. Ester linkers can undergo
enzymatic degradation in addition to hydrolysis. We tested stability of ABA-M in the
presence of CE, a digestive enzyme of esters. We also investigated the influence of ions,
small molecules (glucose, vitamins and amino acids), and proteins by testing stability of
micelles in cell culture medium (RPMI) and FBS. Such investigation is of importance
because the micelles will be exposed to various materials in the blood following
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injection. Instability in the presence of CE is critically important to be aware of because
the CE activity of mouse plasma is significantly higher than human plasma, and studies
performed in these animals may not give results representative of what would be
observed in humans. Total drug release patterns (free Dex plus Dex-ABA) were
compared at 0 and 24 h (Figure D.5). We observed no significant differences among the
samples at the initial time point (p>0.05). However, the micelles in mouse plasma
containing CE showed a slight increase in Dex release at 24 h as compared to the RPMI
control. Human plasma lacking CE activity caused no increase in Dex release. As 1HNMR of the micelles indicated that Dex was entrapped in the micelle core, it seemed
unlikely that a 60-70 kDa CE enzyme could penetrate the micelle to this extent. However,
this possibility cannot be excluded completely because no general protein destabilization
effects on our polymer micelles were observed. Despite this, it is still reasonable to
surmise that this minimal increase in Dex release (10 - 15% at 24 h) may not significantly
impact the outcome of future in vivo studies using ABA-M. This apparent stability of
polymer micelles in the presence of CE indicates that Dex-ABA should be primarily
released in a pH-dependent manner at the tumor site followed by CE-associated
regeneration of free Dex.

D.5.

CONCLUSIONS

In exploring polymer micelles as a second possible tumor-targeted drug delivery system,
Dex was conjugated to poly(ethylene glycol)-poly(aspartate) block copolymers using
hydrazone, ester, or hydrazone-ester dual linkers. Ketonic acids containing 3, 4, and 5
methylene groups were used as spacers to separate the dual linkers. DLS measurements
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and 1H-NMR analysis confirmed that all Dex loaded micelles were <100 nm with a coreshell structure. Single linker micelles appeared unsuitable to release Dex preferentially in
acidic tumor tissues. Hydrazone linkages between Dex and polymers were nondegradable at both pH 7.4 and 5.0. Ester linkages that were stable at pH 5.0 were unstable
at pH 7.4. Hydrazone-ester dual linkers suppressed Dex release at pH 7.4, while
accelerating drug release at pH 5.0. Dex release decreased at pH 5.0 as the length of the
ketonic acid increased but was independent of spacer length at pH 7.4. The dual linker
micelles were also stable in the presence of CEs, suggesting that Dex release was
primarily due to pH-dependent hydrolysis. Overall, it appears that PEG-poly(aspartate)
block copolymer micelles with hydrazone-ester dual linkers are a promising drug
delivery platform for tunable release of Dex in tumors. In comparison to single hydrazone
or ester linkers, hydrazone-ester dual linkers using ketonic acid spacers are convenient
and effective in changing the hydrophobicity of the micelle cores, chemical stability of
drug conjugation linkages, and drug release patterns. Such dual linkers may also be
useful for other drug delivery platforms to achieve pH-dependent tunable drug release,
especially for prodrugs that have been developed based only on ester chemistry. Tunable
drug release using hydrazone-ester dual linkers may bring a variety of options for
combination chemotherapy and mixed drug delivery using polymer drug carriers in the
pharmaceutical research area.
*Reproduced with kind permission from Springer Science+Business Media:
Pharmaceutical Research, Polymer Micelles with Hydrazone-Ester Dual Linkers for
Tunable Release of Dexamethasone, DOI 10.1007/s11095-011-0470-1, M.D. Howard, A.
Ponta, A. Eckman, M. Jay, Y. Bae, Copyright © 2011 Springer Science+Business Media,
LLC.
Copyright © Melissa Howard 2011
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